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Abstract 
AMP-activated protein kinase (AMPK) has long been known to play a critical role in the 
maintenance of energy homeostasis through direct interaction with or altering gene and 
protein expression of key players in diverse metabolic pathways. AMPK has been implicated 
in a number of diseases with roots in metabolic dysregulation, including obesity, type 2 
diabetes and cancer. Elucidating the regulation of AMPK is an important part in 
understanding the progression of these diseases, and for developing small molecule 
modulators of AMPK activity which could have therapeutic applications.  
AMPK activity is determined by the phosphorylation status of T172 in the activation loop of 
the α subunit kinase domain. Binding of AMP to the γ subunit also increases its activity, 
primarily by preventing dephosphorylation of T172 but also by direct allosteric activation of 
the complex. The overall aim of this study was to investigate nucleotide regulation of AMPK. 
Site-directed mutagenesis studies showed that loss of highly conserved residues in γ1 disrupts 
regulation of both dephosphorylation and allosteric activation of AMPK by AMP. However, 
my studies revealed that these mutations do not have site-specific effects. The role of ADP in 
AMPK regulation was also investigated following the observation that this nucleotide also 
prevented dephosphorylation and inactivation of AMPK. The action of ADP on AMPK 
activity was characterised in wild-type complexes and insights from new structures of the 
active AMPK complex has provided insight into the molecular mechanism underlying 
AMP/ADP protection and dephosphorylation of T172.  
The yeast homologue of AMPK, SNF1, plays a central role in responding to glucose 
limitation and adaption to alternative carbon sources. Recombinant SNF1 complexes were 
used to show that ADP is the long-sought metabolite responsible for transmitting this low 
glucose signal and activates SNF1 by a similar mechanism to that seen in AMPK, preventing 
dephosphorylation and inactivation.  
Together these studies identify an important activator of both AMPK and SNF1, drawing 
parallels between these two systems and characterising a highly conserved regulatory 
mechanism, suggesting that ADP may represent a unifying trigger for activation of AMPK 
homologues in diverse species. Finally a potential link between AMPK and redox 
metabolism was identified in the form of NADH, opening new avenues of research in this 
field. 
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  Chapter 1 - Introduction 
1 Introduction 
 
1.1  AMP-activated Protein Kinase 
Maintenance of energy homeostasis, both at the cellular and whole body level, is critical to 
survival and a component that has been found to be increasingly important in the control of 
energy balance is AMP-activated protein kinase (AMPK). AMPK is a protein kinase capable 
of acting as an energy sensor, responding to changes in the cellular AMP:ATP ratio as well as 
a number of hormonal signals in order to maintain a constant level of ATP within the cell 
(Carling, 2004). By rapidly altering the balance of anabolic and catabolic pathways as well as 
gene and protein expression AMPK contributes to modulation of feeding behaviour and 
energy metabolism on a whole-body level (see Figure 1.1) (Kahn et al., 2005; Kim and Lee, 
2005; Leff, 2003).   
The kinase activity present in liver cytosol associated with regulating both acetyl-CoA 
carboxylase (ACC) and HMG-CoA reductase (HMGR), the rate limiting enzymes for fatty 
acid and cholesterol synthesis respectively, was first observed over 30 years ago (Beg et al., 
1973; Carlson and Kim, 1973). This kinase activity was subsequently found to be increased 
by AMP but it wasn’t until several years later that these activities were attributed to a single 
kinase and given the name AMP-activated protein kinase (Carling et al., 1989; Carling et al., 
1987). It was subsequently found that AMPK played a central role in monitoring cellular 
energy levels, detecting a reduction in ATP and the subsequent increase in ADP and AMP 
due to the adenylate kinase reaction (Hardie, 2003). Acting to combat decreased energy 
levels, AMPK down regulates ATP-consuming anabolic pathways including protein 
transcription and synthesis in addition to the originally identified fatty acid and cholesterol 
synthesis pathways, and up-regulates ATP-generating catabolic pathways such as glycolysis 
and fatty acid oxidation. 
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CaMKKβ 
LKB1 
Ca2+ 
Phosphatases 
↑AMP:ATP 
Cellular Stress 
↑ATP producing pathways 
e.g. fatty acid oxidation 
glucose uptake 
↓ATP consuming pathways 
e.g. fatty acid synthesis 
protein synthesis 
Long-term effects 
e.g. altered gene expression 
AMPK is activated by phosphorylation on T172 as well as by an increase in the AMP:ATP
ratio which occurs when ATP is limiting. AMPK responds by down regulating energy
consuming anabolic pathways (left branch) and activating energy producing catabolic
pathways (right branch). This is achieved in the short-term by directly phosphorylating or
indirectly regulating substrates and in the long-term by altering gene expression.  
Figure 1.1 The role of AMPK in regulating energy homeostasis 
 
17 
 
Chapter 1 - Introduction 
1.1.1   AMPK Structure 
 Initially only the catalytic domain of AMPK was identified but it was subsequently found to 
exist as a heterotrimer consisting of the catalytic α subunit (~63kDa) and two regulatory 
subunits termed β (~30kDa) and γ (~36kDa) in a 1:1:1 molar ratio (Davies et al., 1994). 
Multiple isoforms exist for each of these subunits and they are encoded by distinct genes 
distributed across five chromosomes. Together they contribute to the 12 potential AMPK 
complexes which have been identified (Carling, 2004; Kahn et al., 2005). Alternative splicing 
of the AMPK subunit isoforms has also been reported in databases, increasing the range of 
possible heterotrimer combinations. Some of the γ subunit splice variants have been 
investigated (see γ subunit section) but little is known about the roles of these variants in 
vivo.  
The α subunit 
The α subunit was initially identified by its protein kinase activity and it has a highly 
conserved serine/threonine kinase domain in the N-terminal region. As with many other 
protein kinases, AMPK requires phosphorylation within the T-loop region of this domain 
which plays a central role in activating the kinase and this critical residue was identified as 
Threonine 172 (Thr174 in human α1) (Hawley et al., 1996). The α subunit is further 
phosphorylated at several other sites which are also thought to play an important part in the 
regulation of AMPK (see section 1.1.2). Following identification of a second α isoform that 
was more ubiquitously expressed, the initial isoform identified in liver was termed α2 and the 
new isoform α1 (Stapleton et al., 1997). These two isoforms are encoded by separate genes 
and share a highly conserved N-terminal kinase domain (α1 residues 1-312) and a more 
divergent C-terminus including the region where the α subunit interacts with the β and γ 
subunits (α1 residues 313-473) (see Figure 1.2) (Dyck et al., 1996; Iseli et al., 2005; 
Stapleton et al., 1997).  
In addition to these domains, another regulatory region has been identified termed the auto-
inhibitory domain (AID). The AID was initially identified as a conserved region of the α 
subunit (α1 residues 313-335) which, upon truncation, resulted in a highly active kinase 
domain that did not require the regulatory subunits for activity (Crute et al., 1998; Pang et al., 
2007). As such it was thought to play a role in increasing the turnover of the subunit when 
18 
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A. 
B. 
Figure 1.2 Sequence alignment and structure of the α subunits 
A. The alignment of human α1 and α2 amino acids is shown with the critical Thr residues
highlighted. Sequences were aligned using the Bioedit program (v7.0.9) with the clusterW
multiple alignment application. Identical residues to the α1 sequence are denoted with (.) and
any gaps in the sequence are denoted by (-). The numbers on the right refer to the amino acid
residues within the full-length peptide. 
B. The N-terminal region of the α subunit contains the catalytic domain, which includes the
critical threonine (T174 in human α1) residue essential for AMPK activation. The C-terminal
region contains the β/γ binding region and there is a short auto-inhibitory domain (AID) in
the centre of the subunit. Domains that are functionally similar are displayed in the same
colour. Percentages in the α2 subunit indicate the sequence identity (and the sequence
conservation of physico-chemical amino acid properties in brackets) of the indicated
domains. 
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not in complex with the regulatory β and γ subunits as well as potentially interfering with 
substrate binding and catalytic function. A similar method of auto-regulation exists in other 
protein kinases, such as the Ca2+/calmodulin-dependent protein kinases which have a C-
terminal domain that binds to the catalytic cleft (Goldberg et al., 1996; Rosenberg et al., 
2005). 
Recently the structure of the kinase domain and AID of the Schizosaccharomyces pombe 
AMPK α subunit homologue was elucidated, indicating that the AID might play a role in 
constraining the mobility of the kinase domain (Chen et al., 2009). Mutations in this region of 
the α subunit were also found to disrupt the regulation of AMPK by nucleotides as well as 
reducing the susceptibility of T172 to dephosphorylation, indicating that it may also play a 
role in AMP regulation of the holoenzyme in addition to the isolated subunit (discussed in 
section 1.1.2). 
While α1 and α2 share high levels of sequence conservation the two isoforms appear to have 
subtle differences in both localisation and substrate specificity, hinting at different roles 
within the cell. While α1 is widely expressed, α2 is predominantly found in both skeletal and 
cardiac muscle and both subunits have been shown to contribute equally in the liver 
(Stapleton et al., 1996; Woods et al., 1996b). Studies using immunofluoresence and Western 
blotting of subcellular fractions have shown that the two isoforms have different subcellular 
localisation patterns; α1 is located in the cytoplasm whereas α2 is resent in both the nucleus 
and cytoplasm (da Silva Xavier et al., 2000; Salt et al., 1998a). This difference is due to a 
nuclear localisation signal present only in α2 and suggests that while α1 is likely to 
phosphorylate cytosolic and membrane-bound targets, α2 may be primarily involved in 
regulation of transcription (Suzuki et al., 2007). This hypothesis is supported by a study 
indicating that AMPK α2, but not α1, plays an important role in the regulation of gene 
expression in response to glucose in pancreatic beta cells although interestingly this effect 
was only abolished by inhibition of α2 in both the nucleus and cytoplasm and not the nucleus 
alone (da Silva Xavier et al., 2000). Other studies have investigated this nuclear shuttling and 
in response to heat, energy depletion, oxidative stress or muscle contraction the levels of 
AMPK in the nuclei increase (Kodiha et al., 2007; McGee et al., 2003). Further work in this 
field will be required to fully understand the impact of this redistribution on both AMPK 
activity and its downstream targets. 
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Both isoforms have similar specific activities but complexes with α2 appear to be more 
sensitive to allosteric activation by AMP and inactivation by dephosphorylation of T172 
(Stapleton et al., 1996). The α1 and α2 isoforms also have subtle preferences for substrates; 
although they both recognise similar motifs the identity of the hydrophobic residues at P-5 
and P+4 positions appears to influence the rate of substrate phosphorylation (Michell et al., 
1996; Woods et al., 1996b). Taken together these data indicate that the two isoforms play 
different roles in AMPK regulation with varying tissue distribution, cellular localisation as 
well as activity of the complex, conferring a greater level of flexibility to AMPK responses 
within the cascade. 
The β subunit 
The 30 kDa regulatory β subunit was first identified as one of the two additional subunits that 
co-purified with the catalytic subunit and subsequently two isoforms have been identified 
(Thornton et al., 1998; Woods et al., 1996a). The β1 and β2 isoforms are ~70% identical in 
amino acid sequence and consist of a highly conserved C-terminal domain required for 
formation of the heterotrimeric complex and a second conserved regulatory domain. The C- 
terminal region (β1 residues 186-246) has been shown to be sufficient for the formation of an 
active complex and within this region the α and γ subunits associate with different residues; 
the presence of only the terminal 25 residues is sufficient for γ association but not α1 or α2 
(see Figure 1.3) (Iseli et al., 2008; Iseli et al., 2005).  
Sequence searches of the β subunits identified a region closely related to ‘N-iso-amylase’ 
domains that are found in a variety of enzymes, including glycogen and starch branching 
enzymes, suggesting that this regulatory region may represent a carbohydrate or glycogen 
binding domain (GBD) (Hudson et al., 2003). Subsequent studies showed that the β-GBD (β1 
residues 72-150) can bind to glycogen in vitro, a finding which was confirmed by elucidation 
of its structure bound to β-cyclodextrin (Figure 1.4) (Hudson et al., 2003; Polekhina et al., 
2003; Polekhina et al., 2005). These studies also showed AMPK co-localisation with 
glycogen, glycogen synthase (a known substrate of AMPK) and glycogen phosphorylase in 
vivo. The role of glycogen binding in AMPK regulation is discussed in section 1.1.2.  
The N-terminus of the β subunits also contain a consensus sequence for myristoylation and 
β1 complexes isolated from liver or skeletal muscle β2 complexes are fully myristoylated 
(Mitchelhill et al., 1997; Oakhill et al., 2010; Warden et al., 2001). N-myristoylation of target 
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A. 
B. 
 
β1 MGNTSSERAA LERHAGHKTP RRDSSGGTKD GDRPKILMDS PEDADLFHSE EIKAPEKEEF LAWQHDLEVN DKAPAQARPT 80  
β2 MGNTTSDRVS GERHG~AKAA RSEGAGGHAP GKEHKIMVGS TDDPSVFSLP DSKLPGDKEF VSWQQDLEDS VKPTQQARPT 79  
β1 VFRWTGGGKE VYLSGSFNNW S~KLPLTRSH NNFVAILDLP EGEHQYKFFV DGQWTHDPSE PIVTSQLGTV NNIIQVKKTD 159
β2 VIRWSEGGKE VFISGSFNNW STKIPLIKSH NDFVAILDLP EGEHQYKFFV DGQWVHDPSE PVVTSQLGTI NNLIHVKKSD 159
β1 FEVFDALMVD SQKCSDVS~~ ELSSSPPGPY HQEPYVCKPE ERFRAPPILP PHLLQVILNK DTGISCDPAL LPEPNHVMLN 237
β2 FEVFDALKLD SMESSETSCR DLSSSPPGPY GQEMYAFRSE ERFKSPPILP PHLLQVILNK DTNISCDPAL LPEPNHVMLN 239 
β1 HLYALSIKDG VMVLSATHRY KKKYVTTLLY KPI 270                                                  
β2 HLYALSIKDS VMVLSATHRY KKKYVTTLLY KPI 272  
B. The N-terminal region of the β subunit contains the glycogen binding domain (GBD) and
the regions required for α/γ interaction are in the C-terminus. Domains that are functionally
similar are displayed in the same colour. Percentages in the β2 domains indicate the sequence
identity (and sequence conservation of physico-chemical amino acid properties is shown in
brackets) of the indicated region. 
Figure 1.3 Sequence alignment and structure of the β subunits 
A. The alignment of human β1 and β2 amino acid sequences is shown. Sequences were
aligned using the Bioedit program (see Figure 1.2). Any gaps in the sequence are denoted by
(~). The numbers on the right refer to the amino acid residues within the full-length protein. 
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proteins can play a number of different roles including complex stabilisation as well as 
targeting and binding proteins to membranes (Resh, 1999). Studies on β1 have shown that 
loss of myristoylation results in increased recovery of AMPK in the soluble cell fraction as 
well as a 4-fold increase in AMPK activity (Hudson et al., 2003; Mitchelhill et al., 1997; 
Warden et al., 2001). This suggests that subcellular targeting and/or conformation changes of 
the heterotrimeric complex could be mediated by the β subunit. Contrary to these data a 
recent in vitro study has suggested a role for myristoylation in up-regulation of T172 
phosphorylation by AMPKKs in response to AMP, as well as suggesting that membrane 
partitioning of myristoylated AMPK may also be dependent on AMP levels (Oakhill et al., 
2010).  
A number of other post-translational modifications are present on the β subunits. Several 
autophosphorylation sites have been identified and these sites could confer another level of 
regulation to the β subunits, influencing factors including activity, activation by AMP, and 
subcellular localisation (discussed in section 1.1.2). Recent data also indicates that the β 
subunit may be involved in modulating complex stability by ubiquitin-mediated degradation. 
Qi et al. have proposed that cell death-inducing DNA fragmentation factor α-like effector A 
(Cidea) directly interacts with β1 (residues 232-248) and acts as an E3 ubiquitin ligase, 
ubiquitinating this subunit and promoting degradation of heterotrimeric AMPK (Qi et al., 
2008). Conversely another study has shown that K63-linked ubiquitination of different lysine 
residues in the β subunit by the laforin-malin E3-ubiquitin ligase promotes the formation of 
inclusion bodies containing the AMPK complex rather than promoting degradation, 
potentially altering the subcellular distribution of AMPKβ subunits (Moreno et al., 2010). 
AMPK complexes with β1 or β2 have been shown to have similar activities and similar levels 
of association with the other subunits (Thornton et al., 1998). Interestingly some differences 
have been observed in subcellular localisation of different complexes; in mouse myoblasts 
α2β1 complexes have been reported to be anchored to the mitochondrial membrane in the 
cytoplasm, whereas α2β2 translocate to the nucleus (Suzuki et al., 2007). The β subunits also 
have significant variation in their expression; whereas β1 is expressed very highly in the 
liver, accounting for almost all of the activity detected in this tissue, β2 is predominantly 
expressed in skeletal muscle, contributing about 50% of the activity in this tissue (Thornton 
et al., 1998). Furthermore, β2-containing complexes have been identified as an important 
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Orthogonal views of rat β1 GBD in ribbon style (residues 68-163) bound to the sugar β-
cyclodextrin (shown in ball-and-stick style). Key residues involved in binding to the β-
cyclodextrin are indicated (Polekhina et al., 2005). 
Figure 1.4 Structure of the β1 glycogen binding domain 
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factor in exercise-stimulated AMPK activity in skeletal muscle (Birk and Wojtaszewski, 
2006). These diverse expression and activation patterns indicate that there may be some 
preferences for AMPK subunit isoform in response to different stimuli. 
 
The γ subunit 
Since its initial identification as part of the heterotrimeric complex, three isoforms of the γ 
subunit have been identified, termed γ1 (36kDa), γ2 (63kDa) and γ3 (58kDa) (Cheung et al., 
2000). These isoforms differ significantly in the length of their N-terminal sequences but 
share a highly conserved C-terminal domain consisting of four cystathionine β-synthase 
(CBS) motifs. These domains were first described by Bateman and were found to 
predominantly occur in tandem repeats which associate to form CBS pairs termed Bateman 
domains (see Figure 1.5) (Bateman, 1997).  
These domains are found in a wide variety of proteins, acting as building blocks for 
regulation of activity by binding molecules with adenosyl groups, and as such pointed to the γ 
subunit as the major site of AMP interaction (Kemp, 2004).  Subsequent studies showed that 
AMP did bind to the γ subunit and that each Bateman domain appeared to contribute a single 
binding site (Cheung et al., 2000; Kemp, 2004; Scott et al., 2004). With the recent 
determination of the structure of the γ subunit of mammalian AMPK it is now known that the 
γ subunit actually binds three AMP molecules; one of which is non-exchangeable (in CBS4) 
and two which compete for binding with ADP and ATP in CBS1 and CBS3 (Figure 1.6) 
(Xiao et al., 2007). The symmetry of the CBS domains means that there are four potential 
adenyl-binding sites and it is yet to be elucidated why the γ subunit only binds three AMP 
molecules with very different affinities, as well as the mechanisms through which nucleotide 
binding to this subunit translates to increased catalytic activity in the α subunit. Regulation of 
AMPK by nucleotides is discussed in section 1.1.2.  
A conserved sequence immediately N-terminal to the Bateman domains was reported to be 
required for binding to the β subunit and the formation of the functional heterotrimeric 
complex (Viana et al., 2007). Elucidation of the crystal structure of the mammalian γ subunit 
showed that a β-sheet N-terminal to CBS1 does indeed interact with the β subunit but the role 
of the rest of this sequence was not clear from this structure (Figure 1.6) (Xiao et al., 2007). 
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A. 
γ1  ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~  1   
γ2  MGSAVMDTKK KKDVSSPGGS GGKKNASQKR RSLRVHIPDL SSFAMPLLDG DLEGSGKHSS RKVDSPFGPG SPSKGFFSRG  80  
γ3  MEPGLEHALR RTPSWSSLGG SEHQEMSFLE QE~~~~~~NS SSWPSPAVTS SSERIRGKRR AKALR~~~~~ ~~~~~~WTRQ  63  
γ1  ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~  1   
γ2  PQPRPSSPMS APVRPKTSPG SPKTVFPFSY QESPPRSPRR MSFSGIFRSS SKESSPNSNP ATSPGGIRFF SRSRKTSGLS  160 
γ3  KSVEEGEPPG QGEGPRSRPA AESTGLEATF PKTTPLAQAD PAGVG~~~~~ ~~~~~~~~~~ ~TPPTGWDCL PSDCTASAAG  127 
γ1  ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~MET VISSDSSPAV ENE~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~  16  
γ2  SSPSTPTQVT KQHTFPLESY KHEPE~RLEN RIYASSSPPD TGQRFCPSSF QSPTRPPLAS PTHYAPSKAA ALAAALGPAE  239 
γ3  SSTDDVELAT EFP~~ATEAW ECELEGLLEE RPALCLSPQA PFPKLG~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~  171 
γ1  ~~~~~~~~~H PQETPESNNS VYTSFMKSHR CYDLIPTSSK LVVFDTSLQV KKAFFALVTN GVRAAPLWDS KKQSFVGMLT  87  
γ2  AGMLEKLEFE DEAVEDSESG VYMRFMRSHK CYDIVPTSSK LVVFDTTLQV KKAFFALVAN GVRAAPLWES KKQSFVGMLT  319 
γ3  ~~~~~~~~~W DDELRKPGAQ IYMRFMQEHT CYDAMATSSK LVIFDTMLEI KKAFFALVAN GVRAAPLWDS KKQSFVGMLT  242 
γ1  ITDFINILHR YYKSALVQIY ELEEHKIETW REVYLQDSFK PLVCISPNAS LFDAVSSLIR NKIHRLPVID PESGNTLYIL  167 
γ2  ITDFINILHR YYKSPMVQIY ELEEHKIETW RELYLQETFK PLVNISPDAS LFDAVYSLIK NKIHRLPVID PISGNALYIL  399 
γ3  ITDFILVLHR YYRSPLVQIY EIEQHKIETW REIYLQGCFK PLVSISPNDS LFEAVYTLIK NRIHRLPVLD PVSGNVLHIL  322 
γ1  THKRILKFLK LFITEFPKPE FMSKSLEELQ IGTYANIAMV RTTTPVYVAL GIFVQHRVSA LPVVDEKGRV VDIYSKFDVI  247 
γ2  THKRILKFLQ LFMSDMPKPA FMKQNLDELG IGTYHNIAFI HPDTPIIKAL NIFVERRISA LPVVDESGKV VDIYSKFDVI  479 
γ3  THKRLLKFLH IFGSLLPRPS FLYRTIQDLG IGTFRDLAVV LETAPILTAL DIFVDRRVSA LPVVNECGQV VGLYSRFDVI  402 
γ1  NLAAEKTYNN LDVSVTKALQ HRSHYFEGVL KCYLHETLET IINRLVEAEV HRLVVVDEND VVKGIVSLSD ILQALVLT~~  325 
γ2  NLAAEKTYNN LDITVTQALQ HRSQYFEGVV KCNKLEILET IVDRIVRAEV HRLVVVNEAD SIVGIISLSD ILQALILTPA  559
γ3  HLAAQQTYNH LDMSVGEALR QRTLCLEGVL SCQPHESLGE VIDRIAREQV HRLVLVDETQ HLLGVVSLSD ILQALVLSPA  482 
γ1  GGEKKP~~~~  331                                                                            
γ2  GAKQKETETE  569                                                                            
γ3  GIDALGA~~~  489  
B. 
A. The alignment of human γ1, γ2 and γ2 amino acids is shown. Sequences were aligned
using the Bioedit program (see Figure 1.2). Any gaps in the sequence are denoted by (~). The
numbers on the right refer to the amino acid residues within the full-length peptide. 
B. The γ subunits contain four tandem Cystathionine β-synthase (CBS) domains. A region N-
terminal to the CBS domains is responsible for interaction with the β subunit. γ2 and γ3 also
have N-terminal extensions, the role of which is unclear. Functionally similar domains are
displayed in the same colour and percentages in these domains indicate the sequence identity
(sequence conservation of physico-chemical amino acid properties indicated in brackets). 
Figure 1.5 Sequence alignment and structure of the γ subunits 
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Interestingly the α subunit appears to require intact Bateman domains to interact with the γ as 
opposed to an isolated sequence and there appears to be interaction between all three subunits 
through the base of CBS1 and CBS2 (Viana et al., 2007; Wong and Lodish, 2006; Xiao et al., 
2007). Comparison of the three γ isoforms revealed, as with the β subunit, that all interacted 
with α1 and α2 equally, indicating that all 12 potential AMPK complexes could occur in vivo 
(Cheung et al., 2000). Furthermore, splice variants of γ2 and γ3 have been identified and one 
of these, originating from alternative promoter sequences in the γ2 gene, results in a protein 
approximately equal to γ1 in size, termed γ2short, although the effect of this truncation and 
the role of this isoform is yet to be elucidated (Lang et al., 2000).  
As with the other subunits, the γ isoforms exhibit differences in their subcellular localisation 
and expression patterns. While γ1 and γ2 are widely transcribed γ3 is only detected in skeletal 
muscle (Cheung et al., 2000). However, comparison of complex activities shows that γ1 is the 
predominant isoform, accounting for 80-90% of the activity in most tissues, with γ2 
contributing 10-20% and γ3 accounting for any remaining activity, with the exception of the 
brain and testis where contribution of the three isoforms is approximately equal. Interestingly 
the different splice variants of γ2 show mutually exclusive expression patterns (Lang et al., 
2000). Differences in subcellular localisation have also been observed in the central nervous 
system where γ1 exhibits a predominantly nuclear localisation relative to γ2 subunits 
(Turnley et al., 1999). These cellular and subcellular specific expression patterns may be 
indicative of functional differences between the isoforms, potentially due to the differences in 
the N-terminal regions. 
The importance of the γ subunit in AMPK function was emphasised by the finding that 
mutations in this subunit lead to glycogen accumulation and in the heart this leads to cardiac 
dysfunction. Numerous mutations have been identified in human γ2 that result in glycogen 
storage in the heart resulting in cardiac hypertrophy and a pre-excitation disorder called 
Wolff-Parkinson-White (WPW) syndrome (discussed in section 1.1.4).  
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A. 
B. 
Figure 1.6 Structure of mammalian AMPK γ subunit 
A. A diagram of AMPK with the regions crystallised indicated as hatched. 
B. Ribbon representation of the crystallised complex in two orthogonal views with three
AMP bound. The three subunits are coloured as in (A) and the AMP are represented as ball-
and-stick (Xiao et al., 2007). 
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1.1.2   AMPK Regulation 
When AMPK was initially characterised it was evident that it was subject to different levels 
of regulation including phosphorylation of the catalytic subunit, allosteric activation by AMP 
as well as the presence of autophosphorylation sites in the then-identified α subunit, outlined 
in Figure 1.7 (Carling et al., 1989). Since these initial observations over 20 years ago our 
understanding of the regulation of AMPK has broadened within these initial observations.  
As with many other protein kinases AMPK is activated by phosphorylation in the conserved 
T-loop region of the kinase domain and threonine 172 (T172) was identified as the target for 
the upstream AMPK kinase (Hawley et al., 1996). A series of mutagenesis studies went on to 
show that mutation of T172 to an aspartic acid was capable of mimicking phosphorylation at 
this site, generating a constitutively active complex whereas mutation to an alanine abolished 
kinase activity (Stein et al., 2000). These studies also identified other phosphorylation sites 
on both the α and β subunits and the importance of these sites, subject to both auto-
phosphorylation and phosphorylation by other kinases, is still under investigation. Central to 
the role of AMPK is its ability to detect changes to the AMP:ATP ratio and the fact that AMP 
acts to increase the activity of the complex by an allosteric mechanism. Furthermore, AMPK 
has been found to play a central role in the regulation of energy balance at a whole body 
level, itself being regulated by a variety of hormones. Finally, given the central role of 
AMPK in energy homeostasis AMPK has become a vital target for pharmacological 
manipulation. These aspects of AMPK regulation are discussed in this section. 
 
T172 phosphorylation 
For many years the identity of the AMPK kinase remained elusive and the breakthrough 
came with the identification of the upstream kinases responsible for activating the yeast 
orthologue of AMPK, SNF1. Large-scale screening methods were used to identify three, 
functionally redundant, kinases of SNF1: Sak1, Tos3 and Elm1 (discussed in section 1.2.2). 
Liver kinase B1 (LKB1) was the first physiological AMPK kinase to be identified based on 
its homology to these yeast kinases (Hong et al., 2003a). LKB1 was initially identified as a 
tumour suppressor kinase and mutations in it are responsible for the development of benign 
and malignant tumours in Peutz-Jeghers syndrome (PJS) (Jenne et al., 1998).  
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Studies identified LKB1 as the AMPK kinase activity purified from rat liver, demonstrating 
that it acts by directly phosphorylating AMPK at T172 (Hawley et al., 2003; Woods et al., 
2003a). LKB1 is activated by interaction with two other proteins, STE20-related adaptor 
(STRAD), a pseudokinase, and mouse protein 25 (MO25) and the ability of LKB1 to 
phosphorylate AMPK is enhanced over 100-fold in the presence of these proteins (Boudeau 
et al., 2004; Hawley et al., 2003). Furthermore, it was shown that AMPK in cells lacking 
LKB1 was unresponsive to a variety of agonists/stresses, and expression of a dominant 
negative form of LKB1 also blocked AMPK activation (Hawley et al., 2003; Woods et al., 
2003a). Various animal models have also been used to reinforce the role of LKB1 as the key 
regulator of AMPK in mammalian tissues (reviewed in Alessi et al., 2006). Interestingly 
LKB1 appears to be constitutively active and its activity remains unchanged regardless of the 
activation state of AMPK or its cellular environment (Hamilton et al., 2002; Sakamoto et al., 
2004; Woods et al., 2003a).  
Like AMPK, LKB1 is subject to a number of post-translational modifications and studies 
have shown that it is phosphorylated on at least nine residues as well as being subject to 
acetylation and farnestylation (summarised in Table 1). Despite the cross-species 
conservation of many of these sites their roles in its regulation remain unclear and studies 
have shown that the activity of LKB1 is unaffected by mutation of many of these residues or 
treatment with protein phosphatases (reviewed in Alessi et al., 2006; Woods et al., 2003a). 
Shortly after its discovery as an AMPK kinase, LKB1 was shown to regulate 12 other kinases 
within cells (Lizcano et al., 2004). Analysis of the human kinome showed that these 12 
kinases are closely related in sequence to AMPK and are thus referred to as the AMPK-
related kinases. These related-kinases may all contribute to the physiological effects of LKB1 
and its role as a tumour suppressor and this is a significant area of research (reviewed in 
Bright et al., 2009). Several of these related-kinases share homology with yeast proteins 
which are involved in cell polarity and cell cycle (Bouquin et al., 2000; Breeding et al., 
1998). Although several of these have proved useful when studying the BRSK and MARK 
families little is known about the majority of these homologues (Bright et al., 2009; Tassan 
and Le Goff, 2004). 
The majority of evidence indicated that LKB1 was the primary regulator of AMPK, but a 
number of findings suggested that there were alternative upstream kinases (Shaw et al., 
2004). A particularly intriguing example was the finding that in skeletal or cardiac muscle 
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lacking LKB1 only the activity of α2 complexes was significantly reduced, suggesting not 
only that there were other AMPK kinases but that they may exhibit isoform specificity in 
their regulation of AMPK (Sakamoto et al., 2005; Sakamoto et al., 2006).  
Table 1 Post-translational modifications of LKB1 
Modification Residues Detail 
Autophosphorylation 
sites 
T185, T189 
T335, S403 
In the kinase domain 
In the C-terminal domain 
Phosphorylation 
sites 
S31 
S307 
S325 
T363 
S428 
AMPK? MAPKAP-K2? CHK1? 
PKCζ (in the kinase domain) 
Proline-directed kinase 
ATM 
PKA, RSK, PKCζ 
Acetylation sites K44, K48, K96, 
K97, K296 
K311, K416, 
K423, K431 
In the kinase domain                      
In the C-terminal domain 
Farnestylation site C430 In the C-terminal domain 
Detail from Alessi et al. 2006. 
The Ca2+/calmodulin-dependent protein kinase kinase (CaMKK) family had previously been 
shown to activate AMPK in vitro but it was initially discounted as a potential upstream 
kinase due to the fact that it was not the AMPK kinase present in rat liver, now known to be 
LKB1 (Hawley et al., 1995). Following the discovery of the SNF1 orthologues of the 
AMPKK the β isoform of CaMKK was again highlighted as one of the nearest relatives. 
Furthermore, a study in pancreatic beta cells had indicated that AMPK activity may be 
regulated in a calcuim-dependent (and nucleotide independent) manner (Leclerc and Rutter, 
2004). Consequently, the role of CaMKKβ in the activation of AMPK was revisited and it 
was found that increases in intracellular Ca2+ lead to activation of AMPK (Hawley et al., 
2005; Hong et al., 2005; Woods et al., 2005). Many of the previously identified conditions 
that activate AMPK by altering the AMP:ATP ratio also increase intracellular Ca2+, e.g. 
exercise in muscle, mitochondrial uncoupling and oxidative stress (Patel et al., 2001). 
Furthermore, it was shown that increased expression of CaMKKβ or treatment with Ca2+ 
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Figure 1.7 Regulation of AMPK by phosphorylation and by nucleotides 
A. Regulation of AMPK activity by phosphorylation and dephosphorylation of Thr172.
AMPK is activated by phosphorylation of LKB1 and CaMKKβ (and possibly TAK1) and is
inactivated by dephosphorylation by an unknown phosphatase(s).  
B. AMP-dependent activation of AMPK. Under conditions that lead to a decrease in ATP and
an increase in AMP, AMPK is allosterically activated by AMP (mechanism 1) and
dephosphorylation is inhibited (mechanism 2). Since LKB1 is constitutively active, inhibition
of dephosphorylation leads to an increase in T172 phosphorylation and AMPK activity
(adapted from Sanders et al., 2007b). 
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ionophores increase AMPK activity whereas pharmacological inhibition of CaMKKβ with 
STO-609 or siRNA resulted in decreased AMPK phosphorylation and activity (Hawley et al., 
2005; Woods et al., 2005). These data also showed that CaMKKα is a very poor AMPK 
kinase relative to CaMKKβ or LKB1. 
Given these findings it is likely that in the majority of instances when AMPK is activated it 
will be a consequence of phosphorylation by both CaMKKβ and LKB1 but that LKB1 is the 
predominant AMPK kinase in most tissues. However, CaMKKβ is highly expressed in 
neuronal tissue and K+-induced depolarisation of rat cerebro-cortical slices has been shown to 
activate AMPK in an AMP independent manner, highlighting an important tissue-specific 
role for this kinase (Hawley et al., 2005). 
More recently a third protein kinase, transforming growth factor-β-activated kinase (Tak1), 
has been shown to be capable of phosphorylating AMPK in vitro (Momcilovic et al., 2006). 
Expression of a dominant-negative form of Tak1 in mouse heart elicits a similar phenotype to 
that seen in Wolff-Parkinson-White syndrome (see section 1.1.4) and Tak1 deficient MEFs 
were subsequently shown to have reduced T172 phosphorylation in response to a number of 
stimuli due to disruption of LKB1 activity (Xie et al., 2006). These results suggest that Tak1 
could function upstream of LKB1 in the AMPK cascade although this is contrary to the initial 
finding that Tak1 could phosphorylate AMPK directly. Furthermore, data from our group 
does not support the theory that AMPK is phosphorylated by Tak1 (N. Bright, personal 
communication). As such the physiological role of this kinase in the AMPK cascade remains 
unclear.  
A recent paper has highlighted a potential role for the tumor-suppressor ATM in the AMPK 
pathway (Zhou et al., 2011). Previous studies have identified a role for ATM in this pathway 
(Fu et al., 2008; Sun et al., 2007) but this genome-wide study identified a variant in the ATM 
gene as potentially mediating the ability of metformin (a popular antidiabetic, discussed in 
section 1.1.2) to activate AMPK. Cell-based studies went on to reveal that inhibition of ATM 
limited metformin-induced activation of AMPK and several studies have shown that ATM 
phosphorylates LKB1 the importance of this modification on activity is not clear (Table 1) 
(Sapkota et al., 2002). Furthermore, ATM does not appear to directly modulate AMPK 
activity (A. Woods, personal communication). As yet the mechanism through which ATM 
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could regulate AMPK activity in response to metformin is unclear and it will be important to 
investigate the potential interplay of these pathways. 
 
Multi-site phosphorylation 
Phosphorylation plays another important role in AMPK regulation; a number of additional 
sites have been identified within the α and β subunits that are subject to intra-molecular auto-
phosphorylation and phosphorylation by other protein kinases (Mitchelhill et al., 1997; 
Woods et al., 2003b). Initial studies conducted on rat liver AMPK identified S485 on α1 as 
well as S24/25, S108 and S182 on β1 and studies using recombinant AMPK identified 
additional sites within both the α and β subunits (Mitchelhill et al., 1997; Woods et al., 
2003b). However, the physiological role of many of these sites is still poorly understood  
A large number of the putative phosphorylation sites that have been identified in the α 
subunit are localised around the C-terminal domain interacting with the other subunits and it 
is possible that some of these could play a role in complex formation. Site-directed 
mutagenesis carried out on phosphorylation sites in the β subunit found that some of these 
sites appeared to play a role in regulation of activity, e.g. S108, while others played a role in 
the sub-cellular localisation of AMPK, e.g. S182 (Warden et al., 2001). Another study has 
shown that increasing autophosphorylation over a time course is concomitant with a decrease 
in the allosteric activation by AMP, although the reason for this was not investigated (Suter et 
al., 2006). 
One site that has been more thoroughly characterised is α1S485/α2S491. Insulin has long 
been known to control glucose utilisation and one of the signalling cascades that is down-
regulated is the AMPK pathway (Witters and Kemp, 1992).  Studies in the heart revealed that 
insulin treatment resulted in activation of Akt (PKB) coupled with a decrease in AMPK 
activation, which correlated with increased α1S485/α2S491 phosphorylation (Horman et al., 
2006; Kovacic et al., 2003). Akt was subsequently shown to directly phosphorylate S485 in 
vitro and in cell based studies PKA was found to phosphorylate the same residue in response 
to elevated cellular cAMP (Hurley et al., 2006). However, the mechanism that translates 
phosphorylation at this site, either by other kinases or by autophosphorylation, to reduce 
activity remains unclear. More recently PKA was also linked to the phosphorylation of 
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α1S173, and the authors proposed that this prevented T172 phosphorylation due to steric 
hindrance (Djouder et al., 2010). 
 
Dephosphorylation 
As with any kinase regulated by phosphorylation, the proportion of the phosphorylated form 
depends on the balance of kinase and phosphatase activity. This is also the case with AMPK. 
The finding that LKB1 is constitutively active indicates that the protein phosphatase(s) 
responsible for dephosphorylating T172 play a central role in AMPK regulation. Moreover, 
AMP has been shown to protect AMPK against dephosphorylation (Sanders et al., 2007b). 
Members of both the PPP family of phosphatases (PP1 and PP2A) and PPM family (PP2C) 
have been shown to dephosphorylate T172 in vitro but the physiological PP is yet to be 
identified (Davies et al., 1995; Haystead et al., 1989). Importantly these data showed that the 
effect of AMP on dephosphorylation is substrate mediated, indicating that AMP functions 
independently of the phosphatase acting on AMPK.  
A strong correlation between low AMPK activity and metabolic disorders is well established. 
Recent work has reported that decreased AMPK activity in these disorders may be due to 
increased expression of both PP2A and PP2C. Studies have shown that nutrients such as 
glucose or palmitate appear to regulate AMPK activity via increased PP2A activation 
(Ravnskjaer et al., 2006; Wu et al., 2007). Furthermore, cardiac lipid accumulation has been 
linked to increased expression of PP2C, and TNFα was identified as one of the upstream 
signals responsible for transcriptional up-regulation of this phosphatase using cell culture and 
in vivo techniques (Steinberg et al., 2006b; Wang and Unger, 2005). Another study suggested 
that the AMPK phosphatase may play a role not only in T172 activation but potentially 
through a mechanism mediating AMPK subunit interaction, identifying a weak interaction 
between a regulatory subunit of PP2A and isolated α2 subunits, although the physiological 
relevance of this regulation is unclear (Gimeno-Alcaniz and Sanz, 2003). 
Further recent studies have implicated other phosphatases involved in AMPK regulation. 
Cell-based studies from the Cohen group identified two phosphatases that weakly interact 
with AMPKα, PPM1E and PPM1F, highlighting a potential role for these phosphatases in the 
regulation of AMPK activity by the anti-diabetic drugs metformin and phenformin (Voss et 
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al., 2011). Another study has focussed on AMPK regulation in pancreatic β cells, identifying 
a role for PP1 and the regulatory subunit R6 in glucose-induced AMPK dephosphorylation 
(Garcia-Haro et al., 2010). Interestingly this study identified a direct interaction between the 
regulatory subunit R6 and the glycogen binding domain of the AMPKβ subunit. This mirrors 
the interaction seen between the yeast ortholog of AMPK (SNF1) and the regulatory subunit 
of its phosphatase (Reg1) (see section 1.2.2), illustrating potential parallels in glucose-
induced dephosphorylation between yeast and mammals. 
All these studies offer plausible candidates for the AMPK phosphatase and they highlight the 
complexity of this regulatory step in vivo. Indeed it is possible that multiple phosphatases or 
interaction with multiple regulatory subunits could be responsible for dephosphorylation in a 
tissue-specific or stimulant-specific manner.   
 
Nucleotide 
In addition to activation by phosphorylation, AMPK is also activated by AMP binding to the 
γ subunit (see section 1.1.1). Although initially identified for its ability to allosterically 
activate AMPK, AMP also plays a role in regulating the levels of T172 phosphorylation 
(Hardie et al., 1999). Initially several mechanisms for the actions of AMP on T172 
phosphorylation were proposed: direct activation of the upstream kinases by AMP; making 
AMPK a better substrate for phosphorylation by the upstream kinases; protecting T172 from 
dephosphorylation; and allosteric activation (Davies et al., 1995; Sanders et al., 2007b; Suter 
et al., 2006).  
With the development of recombinant expression of AMPK complexes detailed molecular 
studies could be conducted on the regulation of AMPK by AMP. Although the idea that the 
upstream kinases were directly stimulated by AMP had previously been disproven, data at the 
time still indicated that phosphorylation of AMPK by AMPKK isolated from tissue was 
augmented by AMP (Baron et al., 2005; Fogarty and Hardie, 2009; Hawley et al., 2003). 
Using this isolated recombinant system it was shown that phosphorylation by upstream 
kinases was not stimulated by AMP and the discrepancy between this and previous findings 
was attributed to contamination of the AMPKK preparation with PP2Cα (Sanders et al., 
2007b). Prevention of dephosphorylation of T172 was one of the roles proposed initially for 
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AMP and these studies showed that this was the predominant mechanism by which AMP 
exerts its effects on AMPK activity (outlined in Figure 1.7B). However, a recent paper has 
challenged this conclusion, showing that complexes in which the β subunit is myristoylated 
have increased rates of CaMKKβ- and LKB1-mediated T172 phosphorylation in the presence 
of AMP (Oakhill et al., 2010). Previous studies using bacterially expressed complexes will 
not have contained myristoylated β subunits, potentially accounting for these apparent 
discrepancies. 
These effects of AMP combine to activate AMPK; the allosteric effect contributes on average 
a 2-fold activation whereas the combined activation with T172 phosphorylation is over 1000-
fold. This indicates that AMP exerts the bulk of its effects via inhibition of 
dephosphorylation. Furthermore, given that LKB1 appears to be constitutively active, in 
tissues where LKB1 is the predominant kinase regulation of AMPK activity occurs at this 
stage of the cycle. Unlike LKB1, CaMKKβ is regulated by raised intracellular Ca2+ levels and 
under these conditions AMPK would be activated by increased T172 phosphorylation. 
Activation by AMP is dependent on the balance of AMP:ATP and it is known that the γ 
subunit is capable of binding both AMP and ATP in a mutually exclusive manner, competing 
for regulation of activity (Corton et al., 1995; Hardie et al., 1999). Under conditions when 
ATP is bound to AMPK the complex would become rapidly dephosphorylated and 
inactivated. Although previous data suggested that the affinity of the γ subunit for AMP was 
much higher than that of Mg-ATP (under physiological conditions nearly all ATP will be 
complexed with Mg2+), more recent studies suggest that the affinities may be very similar 
(Scott et al., 2004; Suter et al., 2006; Xiao et al., 2007). Under physiological conditions, 
when the ratio of AMP: ATP is roughly 1:100~1000,  the majority of AMPK will be bound to 
Mg-ATP and unphosphorylated and inactive. Upon increases in cellular AMP the pool of 
AMP-bound AMPK will increase resulting in increased activity, even though only a small 
proportion of AMPK is active at any one time.  
Crystal structures of truncated AMPK complexes are now available for both mammalian and 
yeast complexes showing the different nucleotides bound to the γ subunit (Amodeo et al., 
2007; Townley and Shapiro, 2007; Xiao et al., 2007). However, none have shown significant 
structural differences in the γ subunit between the bound and unbound forms or between 
AMP and ATP. The Saccharomyces cerevisiae structure did reveal novel interactions 
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between the γ subunit and the regulatory region of the α subunit and the glycogen binding 
domain of the β subunit. A more recent study has shown that upon AMP binding, AMPK 
takes on a more compact structure, potentially exerting its effects by stabilisation of the 
complex (Riek et al., 2008). However, the definitive mechanism/s by which AMP activates 
AMPK remains elusive.  
Previous studies have shown that disease causing mutations within the CBS domains of γ2 
and γ3 disrupt both allosteric activation by AMP and its effects on dephosphorylation, 
altering the basal activities of the complexes as well as regulation (see section 1.1.4). 
Structural mapping of these residues onto the γ1 structure shows that the majority of these 
mutations occur around the AMP binding sites, with six out of the ten characterised 
mutations disrupting direct contacts with the phosphate groups of AMP or ATP (Figure 1.10) 
(Xiao et al., 2007). Studies on one of these mutations, the R298G, show that it equally 
eliminates both the AMP allosteric and dephosphorylation effects, suggesting that the same 
mechanism may account for both modes of AMP activation (Sanders et al., 2007b). 
 
Glycogen 
As described in section 1.1.1, the AMPK β subunit contains a glycogen binding domain, 
potentially linking AMPK directly to glycogen metabolism. The importance of the AMPK 
cascade in the regulation of glycogen was emphasised by the observation that disease-causing 
mutations in the γ subunit of AMPK caused glycogen storage diseases in the skeletal muscle 
and heart (see section 1.1.4). A number of studies have implicated a role for AMPK in 
glycogen sensing in addition to detecting nucleotide levels. AMPK activation is enhanced in 
skeletal muscle containing low levels of glycogen at the onset of exercise relative to 
glycogen-loaded  muscle (Derave et al., 2000). High levels of skeletal muscle glycogen have 
also been shown to inhibit AMPK activation by either pharmacological treatment or exercise 
(Wojtaszewski et al., 2002; Wojtaszewski et al., 2003). Taken together these data suggest a 
role for glycogen in inhibiting AMPK activity. 
A recent study has shown that although AMPK binds glycogen at both free ends and branch 
points, it is only binding at the branch points within the structure that results in both allosteric 
inhibition and reduced T172 phosphorylation (McBride et al., 2009). The proposed model is  
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Figure 1.8 Modulators of AMPK activity 
Schematic diagram of cellular regulators of AMPK activity. Green arrows indicate activation where as red arrows indicate inhibitory effects on 
activity. Adapted from ScienceSlides online (http://www.scienceslides.com/). 
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that under conditions where glycogen levels are high AMPK will be bound to the surface of 
the glycogen, partially sequestering (but not actively inhibiting) AMPK away from other 
downstream targets but allowing phosphorylation of targets also localised to glycogen, i.e. 
glycogen synthase. Under conditions when phosphorylase is activated, such as muscle 
contraction, branch points of the glycogen would be exposed directly inhibiting AMPK, 
allowing rapid re-synthesis of glycogen. 
 
Endocrine regulation of AMPK 
 Regulation of whole-body energy metabolism is coordinated by a wide variety of hormones 
and cytokines including leptin, adiponectin, interleukin-6 (IL-6), TNFα and ghrelin. These 
signals are secreted from adipose tissue, skeletal muscle, pancreas and the gut and were 
originally identified as playing roles in several aspects of obesity and the metabolic syndrome 
(reviewed in Dzamko and Steinberg, 2009; Lage et al., 2008). Many have since been found to 
regulate AMPK activity.  
Leptin was first identified as the gene product responsible for the severe obese and diabetic 
phenotype of the ob/ob mouse (Ingalls et al., 1950; Zhang et al., 1994). It has since been 
found to activate AMPK in muscle and adipocytes, but not liver, increasing fatty acid 
oxidation and decreasing intramuscular lipid storage (Minokoshi et al., 2002; Steinberg et al., 
2003; Wang et al., 2005). In skeletal muscle this has been shown to be due to an α2-
dependent biphasic effect, while early activation is due to increases in the AMP:ATP ratio 
this wasn’t observed with chronic treatment which required intact sympathetic innervations 
(Minokoshi et al., 2002). Chronic leptin treatment was also shown to increase expression of 
α2 and β2 protein. Conversely, in the hypothalamus leptin reduces AMPK activity and 
thereby reduces food intake, an effect that is blocked by use of dominant-negative (DN) 
AMPK (Minokoshi et al., 2004). How leptin exerts these opposing effects remains unknown, 
although the AMPK isoform specificity observed in skeletal muscle suggests that it could be 
due to differential expression profiles of components of the pathway. Interestingly in some 
tissues the role of leptin remains controversial, and in the pancreatic β-cell it has been shown 
to have divergent effects on insulin secretion and furthermore leptin may not activate AMPK 
in this cell type (Kieffer and Habener, 2000; Leclerc et al., 2004). 
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Adiponectin levels are decreased in obese and type 2 diabetic humans and it was found to 
increase insulin sensitivity, glucose uptake and fatty acid oxidation while decreasing 
gluconeogenesis in a number of tissues (Wang et al., 2007; Yamauchi et al., 2002). The use 
of DN-AMPK blocked these functions and adiponectin is now thought to activate both α1 
and α2 complexes in skeletal muscle (Tomas et al., 2002). Unlike leptin, adiponectin also 
activates AMPK in the hypothalamus, stimulating food intake (Kubota et al., 2007). Recent 
studies by the Kadowaki and Dong groups suggest that adiponectin treatment can increase 
both intracellular AMP and calcium, potentially activating AMPK through both LKB1- and 
CaMKKβ- dependent mechanisms (Iwabu et al., 2010; Yamauchi et al., 2002; Zhou et al., 
2009). However, despite both of these groups illustrating that adiponectin increases 
intracellular calcium they disagree over the mechanism of calcium increase with the initial 
study identifying the ER as the source of calucium whereas Iwabu et al identified an influx of 
extracellular calcium as the  source (Iwabu et al., 2010; Zhou et al., 2009). Further work is 
required to determine the precise mechanisms through which adiponectin activates AMPK in 
different tissues (reviewed in Yamauchi and Kadowaki, 2008).  
Several cytokines have also been shown to regulate AMPK signalling. Both IL-6 and ciliary 
neurotrophic factor (CNTF) have been shown to activate AMPK and increase fatty acid 
oxidation in a number of tissues while CNTF also suppresses AMPK signalling in the 
hypothalamus (Carey et al., 2006; Steinberg et al., 2006c; Watt et al., 2006). TNFα, as 
discussed in section 1.1.2, reduces AMPK activity through up-regulation of a protein 
phosphatase (Steinberg et al., 2006b). 
Other factors that have been shown to alter AMPK activity include ghrelin, insulin and 
resistin (reviewed in Dzamko and Steinberg, 2009). As yet little detail is known about how 
any of these factors exert their effects and understanding how these proteins regulate AMPK 
activity could yield therapeutic treatments for many aspects of the metabolic syndrome. 
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Pharmacological manipulation of AMPK 
Activation of AMPK has been shown to have a wide variety of downstream effects beneficial 
in treating many aspects of metabolic diseases and in peripheral tissues it has been shown to 
alleviate the symptoms of type 2 diabetes. One of the first activators of AMPK to be 
identified was 5-aminoimidazole-4-carboxamide ribonucleoside (AICAR), a nucleoside 
which acts as an intermediate in the generation of inosine monophosphate and following 
uptake into cells is converted into ZMP which can mimic the effects of AMP (Corton et al., 
1995; Henin et al., 1996). In the short term AICAR treatment does not alter nucleotide levels, 
making it one of the most popular AMPK agonists. However, prolonged treatment does affect 
nucleotide levels and the triphosphorylated form, ZTP, accumulates which could act as an 
ATP analogue and inhibit AMPK (McCrimmon et al., 2004; Winder et al., 2000).  
A wide variety of cellular stresses have also been shown to activate AMPK including muscle 
contraction, glucose deprivation, hypoxia, oxidative stress, osmotic stress and treatment with 
metabolic poisons. In addition numerous drugs and chemicals have been found to activate 
AMPK, including the anti-diabetic biguanides (metformin and phenformin) and 
thiazolidiones, the barbiturate phenobarbitol as well as chemicals derived from traditional 
medicines or food extracts such as berberine, resveratrol and capsaicin (reviewed in Hawley 
et al., 2010). For many years there have conflicting reports about many of these activators, 
acting either by elevating cellular AMP or by other independent mechanisms. A recent study 
utilising an AMP-insensitive mutant of AMPK revealed that the majority of these activators 
exert the bulk of their effects via inhibition of mitochondrial ATP production, indirectly 
activating AMPK by altering cellular AMP: ATP ratios. The exceptions include AICAR 
(whereby ZMP mimics AMP), the calcium ionophore A23187 which activates the upstream 
kinase CaMKKβ, as well as osmotic stress and quercetin which appear to influence more than 
one mode of AMPK activation, potentially via regulation of the AMPK phosphatase 
(reviewed in Hawley et al., 2010; Lu et al., 2010). 
As described, the majority of these activators do not act directly on AMPK and ZMP has 
been found to stimulate glycogen phosphorylase and inhibit fructose-1,6-bisphosphatase 
independently of AMPK, making it difficult to attribute positive metabolic effects of 
treatment  directly to AMPK activation (Vincent et al., 1991; Young et al., 1996). Recently a 
small molecule compound that directly activates AMPK, A-769662, was shown to effectively 
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treat several aspects of type 2 diabetes and the metabolic syndrome (Cool et al., 2006). As 
with AMP, A-769662 inhibits T172 dephosphorylation as well as allosterically activating 
AMPK (Goransson et al., 2007; Sanders et al., 2007a). Several lines of evidence indicate that 
AMP and A-769662 operate through distinct mechanisms. Firstly, mutations in the γ subunit 
that eliminate regulation by AMP have no effect on A-769662 activation (Sanders et al., 
2007a). Secondly, complexes with a truncated β subunit or with a mutated 
autophosphorylation site, β1S108, are insensitive to A-769662 stimulation but remain 
sensitive to AMP (Sanders et al., 2007a). Interestingly there is also some data showing that 
this compound had much more potent effects on β1-containing complexes, emphasising the 
importance of this subunit in its mode of action (Scott et al., 2008). Although originally 
popular due to its direct activation of AMPK recent studies have called this into question, 
showing that A-769662 may also directly inhibit Na+-K+-ATPase activity, calling into 
question the use of this compound as a specific AMPK activator (Benziane et al., 2009; 
Garcia-Garcia et al., 2010). 
To date a single selective pharmacological inhibitor of AMPK has been reported, Compound 
C, which acts as a reversible ATP-competitive inhibitor (Zhou et al., 2001). However, 
Compound C appears to inhibit a range of other kinases as well as inhibiting a number of 
other biological processes independently of AMPK inhibition (Bain et al., 2007). 
Furthermore, the apparent inhibition of AICAR activation of AMPK by Compound C has 
been shown to be due to inhibition of AICAR uptake into cells (Fryer et al., 2002b). As such, 
the biological applications of this inhibitor remain limited and other genetic approaches, for 
example siRNA, must be used to verify AMPK-specific action of this compound. 
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1.1.3   Regulation by AMPK 
AMPK acts as a regulator of cellular energy homeostasis in order to balance nutrient supply 
and energy demand. Thus under conditions when there is a decrease in cellular energy 
AMPK switches off anabolic pathways such as fatty acid, cholesterol and triglyceride 
synthesis as well as protein transcription and synthesis and switches on catabolic pathways 
including glycolysis and fatty acid oxidation. Numerous direct downstream targets have been 
identified for AMPK and its effects on the pathways are summarised in Figure 1.9 and Table 
2. In every case AMPK phosphorylates a serine residue, although it is capable of 
phosphorylating a threonine, and examination of the recognition sequences have identified 
the most important aspects of the target motif through structural modelling and mutagenesis 
of synthetic substrates (Ching et al., 1996; Dale et al., 1995; Michell et al., 1996; Scott et al., 
2002). There are critical hydrophobic residues at residues P-5 and P+4 and at least one basic 
residue at P-4 or P-3 which interact with pockets in the substrate binding groove of the kinase 
domain giving AMPK the consensus motif Φ-β-X-X-X-S/T-X-X-X-Φ. The direct targets of 
AMPK are summarised in Table 2, showing their phosphorylation sequence and downstream 
affects. 
Carbohydrate metabolism 
The maintenance of glucose homeostasis is vital for survival and cellular levels are regulated 
at several levels by the rate of glucose uptake, glycolysis, glycogen metabolism as well as 
hepatic gluconeogenesis (Figure 1.9, left panel). 
Uptake of glucose is dependent on the expression of transporter proteins, GLUTs, and in 
several tissues where rapid influx of glucose is required, such as skeletal muscle or heart, 
GLUT4 is translocated to the plasma membrane in response to stimuli such as insulin or 
muscle contraction (reviewed in Huang and Czech, 2007). AMPK has been shown to regulate 
glucose uptake in both skeletal and cardiac muscle and adipocytes via a mechanism that is 
insulin independent. Studies with AICAR showed that this increase in glucose uptake was 
due to increased GLUT4 transcription and translocation (Kurth-Kraczek et al., 1999; Ojuka et 
al., 2000; Russell et al., 1999). A key role played by the α2β2γ3 heterotrimer was identified 
and AMPK regulation appears to only be present under times of stress and does not play a 
significant role in basal glucose uptake (Barnes et al., 2004; Jorgensen et al., 2004; Mu et al., 
2001).  
  Chapter 1 - Introduction 
Table 2 Protein targets of AMPK and their phosphorylation sites and tissue specific effects of AMPK 
Alignment of the consensus recognition motif for AMPK and the sequences around identified phosphorylation sites on physiological substrates 
of AMPK. Sequences are from the human. The phosphorylated serine residues are highlighted in red, Φ indicates hydrophobic residues (those 
believed to be important to recognition of the target sequence are in bold) and β indicates basic residues (those important for function are 
underlined in the target sequence). The panel on the right indicates the tissue specific effects of AMPK. Adapted from Towler and Hardie, 
2007. 
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Figure 1.9 AMPK Signalling Pathways 
A schematic diagram of AMPK activation and its effects on downstream targets is presented
above. AMPK  activation acts to positively regulate signalling pathways that will replenish
cellular ATP supplies, and it plays a central role as a regulator of both lipid and glucose
metabolism as well as regulating protein levels, cell growth and turnover. Adapted from
www.cellsignal.com/reference/pathway/AMPK.  
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AMPK exerts these effects on glucose transport by three different mechanisms. Firstly, 
AMPK directly phosphorylates the Rab GTPases AS160 and TBC1D1 which promotes their 
association with 14-3-3 proteins, in turn promoting GLUT4 vesicle recycling (Sakamoto and 
Holman, 2008; Zaid et al., 2008). Secondly, AMPK improves insulin sensitivity by 
phosphorylation of insulin receptor substrate 1 (IRS-1) on S789, stimulating downstream 
activation of the Akt/AS160 pathway as well as preventing inhibitory phosphorylation of 
IRS-1 (Jakobsen et al., 2001; Wang et al., 2007). Finally, AMPK regulates transcription of 
GLUT4 via indirect activation of myocyte enhancer factor (MEF) by activating the 
transcriptional coactivator proliferator-activated receptor gamma coactivator-1 alpha (PGC-
1α) and sequestering histone deacetylase 5 (HDAC5) from the nucleus (Horman et al., 2006; 
McGee et al., 2008; Zheng et al., 2001). 
Glycogen is an essential source of stored energy which is regulated by the balance of 
glycogen synthase (GS) and glycogen phosphorylase (GP). One of the first targets of AMPK 
to be identified, GS is phosphorylated on S7 inhibiting its activity, acutely leading to 
decreased glycogen synthesis (Carling and Hardie, 1989). Prolonged AMPK activation has 
been shown to have the opposite effect, increased glycogen synthesis; this is due to increased 
levels of glucose-6-phosphate (G6P) which allosterically activates GS regardless of its 
phosphorylation status (Aschenbach et al., 2002). In several tissues AMPK has also been 
shown to increase the rate of glycolysis by phosphorylating phosphofructokinase 2 (PFK2) on 
S466, a key enzyme responsible for regulating the rates of glycolysis and gluconeogenesis 
(Marsin et al., 2000; Marsin et al., 2002). 
Control of hepatic glucose production is one of the main ways glucose homeostasis is 
maintained. It is regulated by a swathe of transcription factors and co-regulators which in turn 
regulate their cognate promoters, altering expression of critical enzymes. Using knock-out 
models AMPK has been shown to inhibit hepatic glucose output, mediated by reducing the 
expression of gluconeogenic enzymes (reviewed in Canto and Auwerx, 2010; Viollet et al., 
2009). Some examples of transcriptional regulation by AMPK include the inhibition of the 
transcription factor hepatic nuclear factor 4α (HNF-4α) and the CREB coactivator CRTC2 
(formerly known as TORC2) which both play important roles in the regulation of 
gluconeogenesis. CREB, a transcription factor responsible for promoting transcription of 
gluconeogenic genes (including phosphoenol-pyruvate carboxykinase, PEPCK, and glucse-6-
phosphatase, G-6-Pase) requires the coactivator CRTC2 to recruit transcriptional machinary 
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and direct phosphorylation of CRTC2 by AMPK promotes the export of this factor into the 
cytosol, limiting expression of these genes (Koo et al., 2005; Screaton et al., 2004). HNF-4α 
and the carbohydrate response element binding protein (ChREBP) also control the expression 
of factors involved in glucose metabolism and these too have been shown to be directly 
phosphorylated by AMPK which compromises their activity (Hong et al., 2003b; Kawaguchi 
et al., 2002; Leclerc et al., 2001). AMPK also plays an important role in manipulating gene 
expression by controlling histone and transcription factor acetylation. Type II histone 
deacetylases also play an important role promoting transcription of gluconeogenic genes in 
addition to the regulation of GLUT4 expression described above, and are regulated by AMPK 
in a similar manner to CRTC2 whereby phosphorylation by AMPK results in nuclear 
exclusion (Mihaylova et al., 2011).  Recently the role of hypothalamic pathways in regulating 
hepatic glucose output have gained support and several studies have implicated AMPK 
activation in the hypothalamus in increasing hepatic glucose production, although the signals 
involved in this mechanism are not yet clear (McCrimmon et al., 2008). 
 
Lipid Metabolism 
During times of fasting when there is low carbohydrate availability energy-dense lipids are an 
important fuel source and controlling the balance between fat and carbohydrate metabolism is 
carefully integrated. AMPK determines the fate of fatty acids through regulation of their 
uptake and synthesis as well as by controlling mitochondrial β-oxidation (Figure 1.9, central 
panel). 
Fatty acid uptake into cells is mediated by fatty acid translocase (FAT/CD36) and fatty acid 
binding protein (FABP). AMPK has been shown to stimulate fatty acid uptake following 
pharmacological activation or endurance training although whether this is via direct 
phosphorylation or by increased FAT/CD36 transcription is yet to be established (Bonen et 
al., 2007; Long et al., 2005). 
Upon entry into cells fatty acids are converted to active fatty acyl-CoA from which they can 
either be immediately oxidised or stored. Acetyl-CoA carboxylase (ACC) was one of the first 
substrates of AMPK to be identified and remains one of the most common markers of 
downstream signalling for AMPK (Carling et al., 1989). ACC catalyses the conversion of 
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acetyl-CoA to malonyl-CoA which either goes on to be used during fatty acid synthesis or 
acts to allosterically inhibit carnitine palmitoyltransferase 1 (CPT1), a key factor in regulating 
fatty acid transport into the mitochondria for oxidation (Brownsey et al., 1997; Tong, 2005). 
These two functions are carried out by two isoforms of ACC, cytosolic ACC1 and 
mitochondrial ACC2, which are phosphorylated by AMPK at S80 and S221 respectively, 
inhibiting their function (reviewed in Hardie and Pan, 2002). Malonyl-CoA levels are also 
regulated by malonyl-CoA decarboxylase (MCD), increased activity of this enzyme is 
associated with increased rates of fatty acid oxidation, and there is some evidence that its 
activity is increased by AMPK (Saha and Ruderman, 2003). AMPK also plays an essential 
role negatively regulating the transcription of genes encoding lipogenic enzymes, including 
ACC and fatty acid synthase (FAS) which catalyses the formation of long-chain fatty acids 
for storage. AMPK affects this reduction in these genes by down-regulation of a key activator 
of cholesterol and fatty acid synthesis pathways, the transcription factor sterol regulatory 
element binding protein 1c (SREBP1c), although the precise mechanism of this reduction 
remains unclear (Foretz et al., 1998; Horton et al., 2002; Park et al., 2008; Woods et al., 
2000; Zhou et al., 2001). It has also been reported that AMPK inhibits FAS by direct 
phosphorylation at an unknown site (An et al., 2007). 
Other factors that play an important role in lipid metabolism include triglyceride turnover, 
mitochondrial biogenesis, and cholesterol synthesis. Triglycerides (TG) play an important 
role storing and transporting energy, containing double the amount of energy as carbohydrate, 
and their synthesis and turnover is a carefully regulated process. AMPK directly inactivates 
both mitochondrial glycerol-3-phosphate acyl-transferase (GPAT), a rate limiting enzyme in 
TG synthesis, as well as hormone-sensitive lipase (HSL) which is responsible for hydrolysis 
of TG into free fatty acids (reviewed in Steinberg et al., 2006a). Likewise, the rate-limiting 
enzyme in cholesterol synthesis, HMGR, is inhibited by phosphorylation by AMPK (Carling 
et al., 1987). Mitochondrial biogenesis is another facet of energy control in cells; insulin 
resistance is associated with decreased mitochondrial density and capacity while conversely 
exercise training induces a robust increase in this capacity (Irrcher et al., 2003; Ren et al., 
2010). AMPK activation has been shown to stimulate mitochondrial biogenesis by regulating 
transcription factors and co-activators involved in this mechanism, including PGC-1α and 
nuclear respiratory factors (NRF).  
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Overall, activation of AMPK under conditions of cellular stress result in increased fatty acid 
uptake and β-oxidation and reduced levels of synthesis of both TG and cholesterol. 
Protein Metabolism, Cell growth and Apoptosis 
AMPK plays an important role in coupling energy metabolism with cell growth and 
proliferation. One facet of this control is via the regulation of protein synthesis which 
accounts for a significant proportion of cellular energy consumption; under conditions of 
metabolic stress AMPK inhibits synthesis at several points (Figure 1.9, right panel).  
One of the central regulators of protein metabolism is the mammalian target of rapamycin 
complex (mTORC) which, when activated, promotes ribosome biogenesis and protein 
translation while inhibiting apoptosis (reviewed in Dowling et al., 2010). The two primary 
downstream targets of in this pathway are the ribosomal S6 kinases (S6K1 and S6K2), which 
stimulate mitochondrial biogenesis, and the eukaryotic initiation factor 4E-binding protein 
(4E-BP1), which allow formation of translation-initiation complexes, increasing the rate of 
peptide translation. This pathway is regulated by the tuberous sclerosis 1/2 (TSC1/TSC2) 
complex which acts as a Rheb-GAP, inhibiting Rheb-dependent activation of mTORC1 
complex (reviewed in Hay and Sonenberg, 2004; Kwiatkowski and Manning, 2005). AMPK 
directly phosphorylates TSC2 at two sites, enhancing the ability of the TSC1/TSC2 complex 
to act as a Rheb-GAP, thus inhibiting mTORC activity (Inoki et al., 2003). Furthermore, 
AMPK inhibits the complex by phosphorylating raptor, a member of mTORC, leading to its 
exclusion from the complex (Gwinn et al., 2008). Studies into the effects of hypoxia have 
also shown that AMPK can inhibit protein synthesis by phosphorylating eukaryote elongation 
factor 2 (eEF2) kinase which in turn inhibits eEF2, preventing translation elongation 
(Horman et al., 2002). There is also evidence that AMPK can also adapt RNA synthesis to 
nutrient availability and its activation results in decreased RNApol I activity due to 
phosphorylation of a member of the transcription initiation complex (Hoppe et al., 2009; 
Leff, 2003). 
In addition to these direct effects there is growing evidence that AMPK may also regulate cell 
growth and polarity, proliferation and apoptosis. Cells treated with low glucose or transfected 
with constitutively active AMPK were used to demonstrate that AMPK induces a p53-
dependent cell cycle arrest in the G1/S phase (Jones et al., 2005). Furthermore, AMPK may 
regulate cell growth by reducing the cytoplasmic level of the RNA-binding protein HuR 
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which is essential for stabilising mRNA cell cycle regulators including several cyclins (Wang 
et al., 2002). Several other models have identified potential roles for AMPK not only in cell 
division but also in polarity, a role in which LKB1 and the AMPK-related kinases also play 
important roles (Williams and Brenman, 2008). Under several stress conditions AMPK has 
also been shown to be one of the many kinases responsible for phosphorylating endothelial 
NO synthase (eNOS) and alters its activity in response to a range of stimuli (Chen et al., 
1999; Thors et al., 2004). 
 
1.1.4   AMPK in Health and Disease 
With its wide-reaching effects AMPK has the potential to play both positive and negative 
roles in a range of diseases associated with metabolic dysregulation. Given its central role in 
energy balance AMPK could play a key part in the treatment of different aspects of the 
metabolic syndrome as well as in cancer. Mutations in AMPK γ are also directly associated 
with the development of a cardiac phenotype in humans. These, and other roles of AMPK, 
are discussed in this section. 
Obesity and Type 2 Diabetes 
The world health organisation estimates that globally there are more than 1 billion 
overweight adults, 300 million of which are clinically obese. This significantly increases the 
risk of developing other chronic diseases including insulin resistance, type 2 diabetes, 
cardiovascular disease, and fatty liver disease, collectively referred to as the metabolic 
syndrome, as well as other factors such as stroke and certain forms of cancer. Given the rate 
at which instances of obesity are increasing, it is expected that the number of patients being 
treated for type 2 diabetes will double by 2030. Type 2 diabetes is associated with insulin 
resistance, increased levels of circulating insulin, glucose and lipids due to reduced glucose 
uptake in peripheral tissues and increased liver glucose output. The roles of AMPK in 
pathways associated with the metabolic syndrome make it a good candidate for combating 
many of these effects and α2 KO mice display many of these characteristics of type 2 
diabetes (Table 2, right panel) (Viollet et al., 2003). 
Genetic models of rodent obesity show reduced AMPK activity in peripheral tissues 
including the heart, skeletal muscle and liver (Barnes et al., 2002; Liu et al., 2006). However, 
51 
 
  Chapter 1 - Introduction 
its activity appears to remain intact in high fat diet induced obesity, suggesting that 
dysregulation of AMPK is not involved in the development of the metabolic syndrome and its 
function remains intact, at least in moderate obesity (Hojlund et al., 2004; Martin et al., 
2006). Initial experiments showing AICAR activation of AMPK in obese models (both 
rodent and human) illustrated the metabolic benefits associated with its activation, including 
increased glucose uptake, fatty acid oxidation and reduced lipid synthesis, validating its 
therapeutic potential (Bergeron et al., 2001; Koistinen et al., 2003). Furthermore, chronic 
treatment of insulin-resistant rodents with AICAR showed improved glucose tolerance and 
lipid profiles as well as decreased abdominal fat and blood pressure (Buhl et al., 2002). These 
data suggest that activation of AMPK in vivo can treat key components of obesity and 
associated type 2 diabetes. 
A major finding to support the concept of AMPK as a feasible drug target was the finding 
that the anti-diabetic drugs metformin and rosiglitazone activate AMPK (Fryer et al., 2002a; 
Zhou et al., 2001). In both cell culture and murine models, these anti-diabetic drugs were 
found to activate AMPK in the liver and it was proposed to mediate their actions by reducing 
gluconeogenic and lipogenic gene transcription as well as increasing glucose uptake into 
skeletal muscle (Shaw et al., 2005; Zang et al., 2004; Zhou et al., 2001). However, a recent 
study carried out in mice and on hepatocytes lacking AMPK α1 and α2 or LKB1 suggests 
that the positive effects of metformin on hepatic glucose output may be independent of the 
AMPK pathway (Foretz et al., 2010; Woods et al., 2011). These data showed that the actions 
of metformin and AICAR on hepatic glucose output are independent, not only of the LKB1 
and AMPK pathways, but also of gluconeogenic gene expression, acting via a decrease in 
hepatic energy levels.  Treatment with the small molecule AMPK activator A-769662 in 
ob/ob mice has illustrated the favourable effects of directly targeting AMPK on the metabolic 
syndrome, reducing plasma glucose, body weight, plasma/liver triglyceride levels and 
decreased transcription of gluconeogenic genes (Cool et al., 2006). 
Another facet of AMPK regulation that may prove useful in treatment of the metabolic 
syndrome is its role in appetite regulation. Several factors, including CNTF and α-lipoic acid 
(see section 1.1.2), inhibit AMPK signalling in the hypothalamus, reducing food intake (Kim 
et al., 2004; Steinberg et al., 2006c). Furthermore these factors stimulate AMPK activity in 
peripheral tissues, increasing insulin sensitivity, making them ideal candidates to develop in 
the future (Lee et al., 2005; Watt et al., 2006). 
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In the majority of tissues activation of AMPK is favourable for treatment of type 2 diabetes. 
One exception is in the regulation of insulin secretion from pancreatic β-cells where, under 
low glucose conditions or upon pharmacological activation, AMPK inhibits insulin secretion, 
playing a role in maintaining glucose homeostasis (da Silva Xavier et al., 2003; Salt et al., 
1998b). Studies using pancreatic β-cells lacking both catalytic subunits of AMPK have 
shown defective insulin secretion and glucose tolerance in vivo as a result of this deletion 
(Sun et al., 2010a). Reduced insulin secretion is not favourable for the treatment of type 2 
diabetes but despite this it is present following metformin treatment (Leclerc et al., 2004). 
This is an important factor to consider during the development of future drugs. Interestingly 
recent studies comparing knockout mouse models for AMPK and LKB1 have found distinct 
effects of these kinases in the regulation of glucose metabolism and insulin secretion, 
suggesting that alternative downstream targets of LKB1 (or LKB1 itself) could be important 
drug targets in the future (Claret et al., 2011; Sun et al., 2010b).  
 
Cardiac Hypertrophy and mutations in AMPK 
During normal cardiac function ATP is abundant and AMPK is relatively inactive. In 
clinically pathological states, e.g. cardiac hypertrophy, AMPK has been shown to play a 
protective role, attenuating hypertrophic growth by regulation of protein synthesis, 
particularly illustrated by adiponectin-dependant activation of AMPK following obesity 
induced hypertrophy (Chan et al., 2004; Shibata et al., 2004). Conversely, mutations in 
human γ2 have been identified that result in a glycogen storage disease associated with 
hypertrophic cardiomyopathy (HCM) and aberrant conduction in the heart resulting in pre-
excitation or Wolff-Parkinson-White (WPW) syndrome (Gollob et al., 2001). To-date ten 
mutations have been identified in γ2, several of which lie within the AMP-binding domains 
(Figure 1.10). Gollob et al. originally identified the Arg531Gly mutation that was responsible 
for WPW, glycogen accumulation, hypertrophy and impaired contractile function (Gollob et 
al., 2001). While AMPK knock-out or dominant-negative models show that total loss of 
function does not result in these phenotypes the effects of these mutations on AMPK activity 
appeared to vary with the mutation and model (reviewed in Arad et al., 2007; Dyck and 
Lopaschuk, 2006). Briefly, studies in yeast show increased basal activity with some 
mutations, whereas mammalian cell-based studies show little consensus with identical 
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Figure 1.10 Mutations in human γ2 associated with glycogen storage disease 
The above table indicates identified disease causing mutations in human γ2 and their
equivalent locations in γ1 as well as their effects on AMP regulation. These mutations are
mapped to the γ1 subunit worm structure in the bottom panel. All but three of the identified
disease causing mutations are located in one of the nucleotide binding pockets of the γ
subunit (Xiao et al., 2007).  
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mutations resulting in both increased and decreased basal activity (Arad et al., 2002). Several 
of the mutations found to lie in the CBS domains show reduced AMP binding and activation 
of AMPK (Daniel and Carling, 2002b; Scott et al., 2004). Interestingly one of the mutations, 
a leucine insertion, appears to have no significant effect on AMPK activity or AMP 
stimulation. These discrepancies in the effects on basal AMPK activity were attributed to 
differences in the cell line used and in the presence of LKB1, the predominant upstream 
kinase in the heart, basal activity appeared to be elevated (Burwinkel et al., 2005).  
Mouse models of several of these mutations show elevated AMPK activity at early stages (up 
to 2 weeks) but at later stages (4 weeks or later) AMPK activity is decreased, potentially due 
to glycogen accumulation and inhibition, although all remain insensitive to AMP stimulation 
(Arad et al., 2003; Davies et al., 2006; Sidhu et al., 2005; Zou et al., 2005). Animal crosses of 
dominant-negative α2 with the γ2N488I activating mutation resulted in reduced AMPK 
activity and cardiomyopathy, further indicating that the mutations act by altering the catalytic 
activity (Ahmad et al., 2005). Taken together these data suggest that, for the majority of these 
mutations, under basal conditions mutation results in decreased affinity for nucleotides, 
including ATP, resulting in inappropriate baseline activation as well as a reduced capacity to 
respond to cellular stress. 
These mutations cause severe glycogen accumulation in the heart, over 30-fold in the case of 
the N488I mutation (Arad et al., 2003). Given that WPW syndrome and cardiomyopathy are 
also associated with other glycogen storage disorders (e.g. Danon and Pompe disease) it is 
thought that it is this glycogen build-up that subsequently leads to hypertrophy and disruption 
of normal electrical transmission seen with these mutations (Arad et al., 2005). The excess 
glycogen present following γ2 mutation appears to be due to dysregulation of the balance 
between synthesis and consumption rather than irreversible glycogen storage. With the N488I 
mutation these glycogen stores have been shown to be available for use during exercise, 
highlighting the possibility of directing therapeutic approaches towards decreasing these 
stores (Ahmad et al., 2005; Zou et al., 2005). Studies have also found that the glycogen 
present in these transgenic hearts may be less branched than in normal cardiac glycogen, 
potentially contributing to the increased basal activity due to reduced AMPK inhibition by 
glycogen branch points (Davies et al., 2006; McBride et al., 2009). The phenotype associated 
with these mutations may not purely be due to glycogen accumulation as AMPK is also 
involved in regulating several ion channels which could contribute to arrhythmogenic 
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phenotypes (Light et al., 2003). Taken together, these data indicate that the γ2 subunit in the 
heart may have specialised roles in mediating glycogen metabolism. 
 
Other roles of AMPK 
Cell metabolism regulation is integral to the tumorigenic process and diabetic patients treated 
with metformin, an activator of AMPK, show a 30% reduction in cancer deaths relative to 
controls (Evans et al., 2005). A range of AMPK activators including anti-diabetics, AICAR 
and A-769662 have since been found to confer increased resistance to tumour generation and 
growth in both cell lines and animal models (Hadad et al., 2008; Swinnen et al., 2005; 
Zakikhani et al., 2006). AMPK exerts these effects on tumorigenesis by inhibiting a number 
of different pathways, including mTOR and FAS regulation, that are known to play an 
important role in a broad range of cancers (Hadad et al., 2008).  
However, during specific stages of tumorigenesis AMPK could provide a survival advantage, 
helping to combat stresses such as hypoxia, nutrient shortage or apoptosis and several studies 
have implicated AMPK in cancer cell survival (Kato et al., 2002; Laderoute et al., 2006). 
There is potential for the use of both AMPK activators and inhibitors for the treatment of 
different types and stages of cancer although caution will be required when testing these 
therapies.  
AMPK has also been implicated in other important processes, one of which is in aging and 
lifespan. In lower organisms including S. cerevisiae and C. elegans studies have shown that 
increased AMPK activity correlates with increased lifespan (Ashrafi et al., 2000; Curtis et al., 
2006). The effects of AMPK on aging and on susceptibility to age-related diseases in 
mammals however remain ambiguous although recent study using mice lacking a component 
of the mTOR nutrient signalling pathway showed increased AMPK signalling during ageing 
(Selman et al., 2009). However, there remain numerous contrary reports (reviewed in Finley 
and Haigis, 2009). 
Other potential roles of AMPK in disease processes, ranging from stroke and 
neurodegenerative disease through to reperfusion injury are discussed in several excellent 
reviews (Richter and Ruderman, 2009; Ronnett et al., 2009; Steinberg and Kemp, 2009; 
Viollet et al., 2009; Viollet et al., 2010). 
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1.2  Snf1 kinase 
Adaptation of cellular metabolism to changes in environmental conditions is vital and many 
signal transduction networks are highly conserved. Budding yeast, Saccharomyces cerevisiae, 
is a model organism commonly used for studying cell signalling. Glucose is the preferred 
carbon source for budding yeast and when it is available the expression of genes regulating 
adaption to alternative sources, gluconeogenesis and respiration are all repressed. Nutrient-
induced signalling networks allow rapid adaption to changes in conditions and derepression 
of these processes is crucial for adaption and survival. 
In 1981 the sucrose non-fermenting-1 (SNF1) gene was identified in a screen for mutants 
unable to utilise alternative carbon sources and was found to encode a serine/threonine 
protein kinase (Carlson et al., 1981; Celenza and Carlson, 1984, 1986). SNF1 was found to be 
active under conditions of low glucose and is essential for both aerobic growth and 
fermentation of alternative carbon sources (Hardie et al., 1998). It plays a role in the 
transcription of glucose-repressed genes, sporulation, glycogen storage, thermotolerance and 
peroxisome biogenesis (Figure 1.11) (Simon et al., 1992; Thompson-Jaeger et al., 1991). 
SNF1, as was subsequently found with AMPK, exists as a heterotrimer with a single catalytic 
subunit (α, Snf1) and two non-catalytic regulatory subunits homologous to AMPK β and γ, 
forming the SNF1 complex. Furthermore, both SNF1 and AMPK retain cross-species 
functionality of upstream kinases and phosphatases regulating activity by kinase domain 
phosphorylation, indicating conservation of the pathways (Hong et al., 2005). Unlike AMPK, 
the intracellular signal/s that activate SNF1 remain unidentified and although genetic 
approaches have allowed significant understanding of its physiological roles aspects of its 
regulation and biochemical properties remain unknown. 
1.2.1   SNF1 Structure 
The SNF1 heterotrimeric complex consists of one α, one β and one γ subunit. The catalytic α 
subunit is encoded by the originally identified SNF1 gene and the regulatory γ is encoded by 
the SNF4 gene. Yeast express three β subunit isoforms, Sip1, Sip2 and Gal83 which allow for 
up to three different isoforms of the SNF1 complex. Together they allow acute regulation of 
the complex, regulating factors such as substrate preference, subcellular localisation and 
stress responses as discussed in this section. 
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Figure 1.11 Roles of SNF1 in regulating energy homeostasis 
SNF1 is primarily activated by glucose limitation and responds to allow the yeast to adapt to
the energy limiting conditions. SNF1 plays a central role in regulating the transcription of
glucose-repressed genes as well as regulating other energy-dependent pathways such as
sporulation, glycogen storage, fatty acid metabolism.  
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The Snf1 subunit 
The SNF1 gene was found to encode a 633 amino acid protein, Snf1, which is closely related 
to AMPKα and consists of an N-terminal kinase domain and a C-terminal regulatory region 
(see Figure 1.12) (Celenza and Carlson, 1986). There is also a short sequence N-terminal to 
the kinase domain which is not conserved in mammals and contains a stretch of 13 histidines 
which do not appear to be essential for function (Celenza and Carlson, 1989). Snf1 is 
phosphorylated by upstream kinases on a threonine residue equivalent to T172 in AMPK and 
mutation of this residue, T210, to an alanine results in a phenotype similar to that of the snf1Δ 
mutant (Estruch et al., 1992; Hawley et al., 1996). Furthermore, complex formation with the 
β and γ subunits is essential for kinase activity even when T210 is phosphorylated (Elbing et 
al., 2006b). Functions of the Snf1 subunit are summarised in Table 3. 
Table 3 Functions of the Snf1 subunit 
Function Detail Reference 
Kinase Activity The kinase domain contains the 
critical threonine residue essential 
for activity, allowing 
phosphorylation of metabolic 
enzymes and transcriptional 
reprogramming  
(Celenza and Carlson, 
1989; Hawley et al., 1996; 
Usaite et al., 2009; Young 
et al., 2003) 
Activity regulation The Snf1 subunit has an auto-
inhibitory region that modulates 
complex activity by interacting 
with Snf4 
(Celenza and Carlson, 
1989; Jiang and Carlson, 
1996) 
Association with/ 
regulation of Reg1 
Reg1 interacts directly with the 
kinase domain. Reg1 has been 
shown to be phosphorylated in a 
SNF1-dependent manner. 
(Ludin et al., 1998; Sanz et 
al., 2000; Tabba et al., 
2010) 
 
In addition to the highly conserved kinase domain the Snf1 subunit contains a C-terminal 
regulatory region. Under conditions of high glucose Snf1 activity is suppressed and 
experiments show that it is subject to auto-inhibition by a region between residues 392 and 
518 (Jiang and Carlson, 1996). The γ subunit, Snf4, appears to play a role in antagonising this 
auto-inhibition in glucose deprived cells by binding to the regulatory region and freeing the 
kinase domain (Jiang and Carlson, 1996). Similarly, truncation of the C-terminal region to 
leave the isolated Snf1 kinase domain (residues 1-309), as with AMPK, negates the 
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Figure 1.12 Subunit structure of the SNF1 complex 
The SNF1 complex consists of a catalytic Snf1 subunit and two regulatory subunits, Snf4 or
one of three isoforms of the β subunit, either Sip1, Sip2 or Gal83. The Snf1 subunit contains
the highly conserved kinase domain with T210, and auto-inhibitory region (AID) that also
mediates Snf4 binding, and a C-terminal scaffold region. All three β subunits contain a
conserved glycogen binding domain (GBD) and C-terminal regions required for complex
interaction but vary in their N-terminal extension lengths. The Snf4 subunit contains four
tandem Cystathionine β-synthase (CBS) domains. 
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requirement for the other subunits (Celenza and Carlson, 1989). Deletion analysis has not 
only identified the region of this regulatory domain but also the regions of Snf1 required for β 
and γ interaction. The region required for interaction with the β subunits is at the C-terminus 
and residues 515-633 are sufficient for interaction with Sip2 (Jiang and Carlson, 1997).While 
residues 392-518 regulate auto-inhibition, 392-495 are also required for interaction with 
Snf4, showing considerable overlap of these regions. Interestingly a mutation in this region, 
Leu470Ser, abolishes Snf4 interaction but not kinase domain inhibition, indicating distinct 
roles for residues within this overlapping region (Jiang and Carlson, 1996). The recent 
crystallisation of the heterotrimer core of SNF1 shows that residues 460-495 of Snf1 have 
direct interactions with CBS4 of Snf4, demonstrating a direct interaction between the 
regulatory domain and Snf4 (Amodeo et al., 2007). 
The β subunits 
S. cerevisiae expresses three isoforms of the β subunit. Two, Gal83 and Sip2, are very similar 
both in size and sequence identity while the third isoform, Sip1, is nearly twice the size 
(Yang et al., 1992; Yang et al., 1994). Genetic approaches were first used to identify Sip1 and 
Sip2 (Snf1-interacting proteins) and Gal83 was subsequently identified by its sequence 
similarity to Sip2 (Figure 1.12). Although it was initially thought that the β subunit was not 
essential due to the fact that a triple sip1Δsip2Δgal83Δ mutant retained Snf1 function this was 
shown to be an artefact of incomplete deletion of the proteins and it is now known that the β 
subunit is essential for Snf1 kinase function in vivo (Erickson and Johnston, 1993; Schmidt 
and McCartney, 2000). Expression of the β subunits is glucose dependent; under high glucose 
conditions Gal83 is the predominant β subunit in the complex whereas upon transfer to non-
fermentable carbon sources Sip2 levels increase (although Gal83 remains the most abundant) 
and under all conditions Sip1 remains consistently low (Ghaemmaghami et al., 2003; Vincent 
et al., 2001). Although each isoform confers comparable activity levels to the complex, as the 
most abundant Gal83 contributes the most activity following glucose limitation and this study 
also shows that the non-conserved N-terminus of Sip1 is in part responsible for its low 
expression (Mangat et al., 2010). 
As with AMPK the yeast β subunits have a C-terminal region mediating complex association. 
A conserved sequence of ~80 amino acids in the C-termini of the β subunits, termed the ASC 
domain, was found to bind to Snf4 independently of Snf1, and a second region N-terminal to 
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the ASC, is sufficient for interaction with Snf1 (Jiang and Carlson, 1997; Yang et al., 1994). 
In the absence of a β subunit, Snf4 is unable to associate with Snf1 and similarly in the 
absence of Snf4, only trace amount of the β subunits are in complex with Snf1, highlighting 
that the β subunit is not simply a scaffold protein and complex assembly is dependent on all 
three subunits (Elbing et al., 2006b). However, it is differences in the N-terminal of the β 
subunit that give each complex distinct substrate preferences, subcellular localisations and 
responses to stress, playing a central role in regulation of activity (summarised in Table 4). 
Table 4 Functions of the beta subunits 
Function Detail Reference 
Glucose-dependent re-
localisation 
Sip1 – Vacuolar membrane 
Sip2 – Remains cytoplasmic 
Gal83 – Nuclear 
(Hedbacker and Carlson, 
2006; Hedbacker et al., 
2004a; Hedbacker et al., 
2004b; Vincent et al., 
2001) 
Complex activity and 
downstream function 
Sip1 – Little activity in cells. Minor 
role in glucose de-repression 
Sip2 – Mainly activated by Sak1. 
Can compensate for the loss of 
Gal83. 
Gal83 – The most abundant 
isoform in the complex which can 
be activated by all three upstream 
kinses. Predominant role in 
transcriptional reprogramming. 
(Hedbacker et al., 2004a; 
Hedbacker et al., 2004b; 
Mangat et al., 2010; 
Vincent et al., 2001; 
Zhang et al., 2010) 
Glycogen binding The GBD is capable of binding 
glycogen and mutations in this 
region can cause dysregulation of 
the complex. However, cells unable 
to synthesise glycogen show 
normal SNF1 regulation. 
(Mangat et al., 2010; 
Momcilovic et al., 2008; 
Vincent and Carlson, 
1999) 
Regulatory interaction 
with Snf4 
Regions of the beta subunit appear 
to interact closely with Snf4 as well 
as with potential nucleotide binding 
sites.  
(Amodeo et al., 2007; Jin 
et al., 2007; Momcilovic 
et al., 2008; Townley and 
Shapiro, 2007) 
Association with Reg1 The GBD may associate with Reg1 (Mangat et al., 2010) 
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Glycogen is an essential storage carbohydrate in yeast and accumulated stores are used for 
survival under starvation conditions (Francois and Parrou, 2001; Thompson-Jaeger et al., 
1991). SNF1 is one of the many kinases regulating glycogen metabolism, required for its 
accumulation and maintenance by regulating the expression of essential enzymes (see section 
1.2.3). All three β isoforms contain a conserved GBD and in vitro Gal83 binds glycogen very 
tightly (Wiatrowski et al., 2004). The crystal structure of the heterotrimeric core of SNF1 
identifies a putative glycogen binding site by co-crystallising in the presence of β-
cyclodextrin (Amodeo et al., 2007).  Mutations in the GBD, including those that abolish 
glycogen binding in AMPKβ, and deletion of this domain result in dysregulation of the 
complex, relieving glucose inhibition of SNF1 (Momcilovic et al., 2008; Vincent and 
Carlson, 1999; Wiatrowski et al., 2004). This leads to up-regulation of SNF1-dependent 
processes including glycogen accumulation, expression of glycogen synthase, haploid 
invasive growth and Sip4 activation. A recent study has shown that deletion of the GBD from 
the Gal83 isoform has the most significant effect on downstream signalling and these 
complexes require the Gal83-GBD to be maintained in an inactive state (Mangat et al., 2010). 
This study also identifies a role for the GBD in regulating association with factors involved in 
dephosphorylation of the SNF1 complex (discussed in section 1.2.2). However, the 
importance of this interaction is ambiguous as cells unable to synthesise glycogen exhibit 
normal regulation of SNF1 in response to glucose limitation and these phenotypes most likely 
result from loss of the GBD rather than loss of glycogen binding (Momcilovic et al., 2008). 
Furthermore, mutations in the GBD confer phenotypes in the absence of glycogen and 
mutation of a residue in Snf4 that forms a hydrogen bond with the GBD (Snf4-Asn177) 
similarly affects SNF1 regulation (Momcilovic et al., 2008; Ruiz et al., 2011). Taken together 
these studies do not support a role for glycogen binding in directly regulating SNF1 
phosphorylation in vivo and the absence of critical residues conserved in other GBDs raises 
the possibility that they may not bind glycogen under physiological conditions (Machovic 
and Janecek, 2006; Polekhina et al., 2005). This suggests a role for this domain in glucose 
mediated regulation of SNF1 in areas beyond glycogen sensing. 
The β subunits play a central role in directing the subcellular localisation of the SNF1 
complex. Experiments by Vincent et al. using green fluorescent protein (GFP)-tagged 
subunits have shown that in glucose-grown cells all of the subunits are cytoplasmic, but 
transfer to a less favourable carbon source results in redistribution (Vincent et al., 2001). Sip1 
relocates to the vacuolar membrane, requiring N-terminal myristoylation (also present in 
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Sip2) and this relocation appears to be inhibited by PKA under conditions of high glucose 
(Hedbacker et al., 2004b; Lin et al., 2003). Sip2 remains cytoplasmic despite the presence of 
N-myristoylation although its expression is upregulated. Upon shifting glucose-grown cells to 
glycerol Gal83 complexes are rapidly imported to the nucleus and upon re-addition of 
glucose are rapidly exported (Vincent et al., 2001). This nuclear import is likely to play a 
vital role in the regulation of SNF1 targets located there and this translocation appears to be 
tightly regulated. Gal83 contains a nuclear export signal required for its cytoplasmic 
distribution and inactive Snf1, via an unknown mechanism, retains the complex in the 
cytoplasm to allow phosphorylation by the upstream kinases. Interestingly only 
phosphorylation by Sak1, just one of the three upstream kinases, allows relocation of the 
Gal83 complexes to the nucleus (Elbing et al., 2006b). 
Studies have also found that the Snf1 and β subunits are phosphorylated in vitro (Mangat et 
al., 2010; Yang et al., 1994). In the β subunits one of these sites has been mapped to a Snf1 
consensus site, responsible for auto-phosphorylation at this site. These studies also showed 
that Gal83 is subject to phosphorylation by a second kinase in vivo, likely to be CKII, a 
component of the Sak1 complex which has been shown to phosphorylate it in vitro. However, 
the function of these phosphorylation sites remains ambiguous due to the fact that deletion of 
that region of Gal83 did not appear to alter SNF1 function or regulation under the conditions 
examined (Mangat et al., 2010). 
 
The Snf4 subunit 
The Snf4 subunit, like the AMPK γ subunits, consists of four CBS repeats which fold to form 
two Bateman domains and a C-terminal domain required for interaction with Snf1 and the 
three β subunits. It is essential for SNF1 function both in vitro and in vivo and snf4Δ cells 
exhibit a phenotype similar to that of snf1Δ cells (functions of Snf4 are summarised in Table 
5) (Neigeborn and Carlson, 1984; Woods et al., 1994). Snf4 is constitutively expressed and 
formation of the complex occurs independently of glucose availability (Celenza et al., 1989). 
Association of Snf4 with Snf1 appears to be mediated by the β subunits, as described in the 
previous section, and in the absence of a β subunit this association is significantly impaired, 
(Jiang and Carlson, 1997).  
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Table 5 Functions of the Snf4 subunit 
Function Detail Reference 
Stabilisation/activation 
of the complex 
Interacts with the regulatory region 
of the Snf1 subunit to fully activate 
the complex 
(Jiang and Carlson, 1996; 
McCartney and Schmidt, 
2001) 
Regulating activity Mutations in Snf4 have been shown 
to disrupt basal complex activities. 
Evidence from crystal structures 
indentifies potential nucleotide 
binding sites in S. pombe  
(Jin et al., 2007; 
Momcilovic et al., 2008; 
Townley and Shapiro, 
2007) 
 
There is some evidence that Snf4 is in excess in the cell although the majority appears to be 
in the SNF1 complex (Elbing et al., 2006b; Ghaemmaghami et al., 2003). It is possible that 
the remaining free Snf4 could have additional functions, particularly since Snf4 is 
constitutively localised to both the nucleus and cytoplasm whereas the other subunits are 
excluded from the nucleus in the presence of glucose (Vincent et al., 2001). Snf4 also 
contains a consensus site for elongin C binding and binds to Elc1 and although the purpose of 
this interaction isn’t clear it may play a role in regulating Snf4 degradation (Hyman et al., 
2002; Jackson et al., 2000) 
Despite the fact that removal of glucose from yeast media triggers activation of SNF1 and is 
coupled with a 200-fold increase in the AMP:ATP ratio SNF1 is not activated directly by 
AMP (Mitchelhill et al., 1994; Wilson et al., 1996; Woods et al., 1994). The reason for this 
lack of regulation by AMP remains unclear. Mutations in Snf4 that disrupt nucleotide binding 
in AMPK have been shown to affect SNF1 regulation (Momcilovic et al., 2008). Recently 
crystal structures of the Snf4 subunit as well as the S. pombe γ subunit have identified 
potential nucleotide binding sites (Amodeo et al., 2007; Jin et al., 2007; Townley and 
Shapiro, 2007). Although the S. cerevisiae structure only showed weak electron density for 
one AMP bound to Snf4 it was at a similar position to that seen in the S. pombe structure 
which showed that nucleotide binding alters the surface charge of the subunit, potentially 
altering the properties of the complex (Townley and Shapiro, 2007). Taken together these 
data suggest that nucleotides may play an as yet unidentified role in regulating SNF1 activity. 
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1.2.2   SNF1 regulation 
SNF1 is rapidly activated by phosphorylation of T210 in its kinase domain as a result of 
different stress factors. This activation is often rapid and is transient, after adaption minimal 
SNF1 activity is required for continued growth, and it is subject to inactivation by 
dephosphorylation (see Figure 1.13A) (Hedbacker and Carlson, 2006). Although nutrient 
stresses have been shown to induce phosphorylation of SNF1, it also mediates resistance to 
heat shock, toxic cations and hydroxyurea in a manner that apparently does not require 
increased T210 phosphorylation, indicating that under certain conditions basal SNF1 activity 
is sufficient for its function (Hong and Carlson, 2007; Portillo et al., 2005). 
As described in previous sections the regulation of SNF1 by either the glycogen binding 
domain or by nucleotides binding to Snf4 remains an enigma. Numerous studies have shown 
that despite a correlation between AMP levels and SNF1 activation there is no direct effect of 
the nucleotide on activity and it remains possible that the activating signal in yeast is another 
metabolite that varies with AMP. It is also not yet clear whether the activity of the upstream 
kinases, phosphatases or the activity of the SNF1 complex itself is regulated by such a 
metabolite. 
 
T210 phosphorylation 
For many years the identity of the SNF1 kinase remained a mystery as genetic approaches 
failed to identify a single target, suggesting that multiple kinases could activate SNF1. Finally 
the three upstream kinases were identified through a combination of genetic screens and mass 
spectroscopy of affinity purified protein complexes. Initially Tos3 and Sak1 (initially termed 
Pak1) were identified due to their interaction with the SNF1 complex and Elm3, which is 
closely related to these two kinases, was found to be the third kinase (Hong et al., 2003a; 
Nath et al., 2003; Sutherland et al., 2003). As predicted from genetic studies these three 
kinases are highly similar and are functionally redundant, only loss of all three kinases results 
in a snf1Δ phenotype (functions of the SNF1-kinases are summarised in Table 6). These 
kinases share a degree of functional inter-changeability with the mammalian system and Tos3 
and Elm1 are capable of phosphorylating AMPK in vitro and any of the AMPK kinases 
relieve the snf1Δ phenotype in sak1Δtos3Δelm3Δ mutants (Hong et al., 2005; Woods et al., 
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2005). Taking advantage of this system, studies have shown that mammalian CaMKKα 
activates SNF1 under diverse stress conditions and given that it is unlikely that a mammalian 
kinase would be positively regulated by these stresses in yeast cells this suggests that stress 
signals regulating SNF1 activity act via a mechanism that is independent of the upstream 
kinase (Hong and Carlson, 2007). 
Table 6 Functions of the SNF1-activating kinases 
Function Detail Reference 
Activation of SNF1 All three kinases activate SNF1 via 
phosphorylation of T210 and are 
redundant in their SNF1-activating 
capacity 
(Hedbacker et al., 
2004a; Hong et al., 
2003a) 
Sak1-specific actions Plays a primary role in activating SNF1. 
Tightly associates with Snf1. Essential 
for nuclear localisation of Gal83-
containing complexes. 
(Hedbacker et al., 
2004a; Liu et al., 2011; 
Nath et al., 2003) 
Elm1-specific actions Most effective at activating Gal83-
containing complexes. Elm1Δ mutants 
have distinct cell cycle phenotypes and 
it is localised to the septum. 
(Hedbacker et al., 
2004a; Sreenivasan et 
al., 2003; Sutherland et 
al., 2003) 
Tos3-specific actions Specific roles in long-term adaption to 
growth on glycerol-ethanol. 
Phosphorylated in a SNF1-dependent 
manner 
(Kim et al., 2005; 
McCartney et al., 2005) 
 
Analysis of truncations of the upstream kinases identified the non-conserved C-terminal 
domains as being essential for directing pathway specificity and further studies of Sak1 also 
showed that a region in the N-terminus is also vital for SNF1 regulation (Rubenstein et al., 
2006). Investigation of the localisation of the upstream kinases showed that Sak1 has a 
similar localisation pattern to Sip1-containing complexes, cytosolic in the presence of glucose 
and then at the vacuolar membrane under stress conditions, while Tos3 is cytosolic under all 
conditions and Elm1 is present at the bud neck (Bouquin et al., 2000; Hedbacker et al., 
2004a; Kim et al., 2005).  
Further investigation showed that the three upstream kinases are not linked to specific β 
isoforms and all three are capable of phosphorylating the SNF1 complex with similar 
67 
 
  Chapter 1 - Introduction 
activities (Rubenstein et al., 2008). However, analysis of kinase deficient mutants identified 
Sak1 as the most important of the kinases (Hong and Carlson, 2007; Hong et al., 2003a; 
McCartney et al., 2005). Despite this the β isoforms do display some stress-dependent 
preferences for the upstream kinase and their contributions appear to vary with the type of 
stress, for example Tos3 has been shown to play a particular role in growth on glycerol-
ethanol and Sip2 exhibits a strong preference for Sak1 activation under low glucose 
conditions (Kim et al., 2005; McCartney et al., 2005). Interestingly a specific role for Sak1 
has been identified in regulating the nuclear localisation of Gal83-containing complexes. 
Phosphorylation by Sak1, but not by Tos3 or Elm1, is responsible for the relocation of the 
Gal83 complexes to the nucleus following carbon stress, highlighting a potential role for the 
upstream kinase in determining localisation as well as activity (Hedbacker et al., 2004a). It is 
also interesting to note that activation of SNF1 by salt stress is not accompanied by nuclear 
localisation of the complex, with the upstream kinase potentially contributing to the 
specificity of stress responses (Hong and Carlson, 2007). This central role of Sak1 is further 
emphasised by the fact that it forms a stable complex with Snf1 and while a transient 
interaction is sufficient to activate the SNF1 complex, as seen with Tos3 and Elm1, it is likely 
that this close association allows for rapid phosphorylation (Elbing et al., 2006a; Elbing et al., 
2006b; Liu et al., 2011). 
 
Dephosphorylation 
Following phosphorylation and activation of SNF1 phosphatases play an equally important 
role in down-regulating its activity, and glucose regulation occurs via the dephosphorylation 
step with the rate of dephosphorylation being more closely regulated than that of 
phosphorylation (Rubenstein et al., 2008). This dephosphorylation appears to be nutritionally 
regulated and the rate of dephosphorylation is over 10-fold slower under conditions when 
SNF1 activation is favourable (Rubenstein et al., 2008). Several studies showed that 
mammalian phosphatases could inactivate SNF1 but it was a genetic approach that first 
identified protein phosphatase 1 (Glc7) together with the Reg1 targeting subunit as the SNF1 
phosphatase (Tu and Carlson, 1994, 1995). Glc7 PP1 has multiple roles in diverse cellular 
processes and its activity is regulated and targeted by associated regulatory subunits, Reg1 in 
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the case of SNF1, and were identified by mutations glc7-T152K and reg1Δ which relieve 
glucose repression of gene expression and results in hyper-phosphorylated Snf1.  
Subsequent yeast 2-hybrid studies showed that Reg1, but not Glc7, interacts directly with the 
Snf1 kinase domain, even in the absence of the PP1, and this interaction is dependent on 
T210 phosphorylation and kinase activity (Elbing et al., 2006a; Ludin et al., 1998). Reg1 
appears to exert its regulatory effects on the SNF1 complex by promoting autoinhibition of 
the kinase domain by inhibiting the interaction of Snf4 with Snf1 AID (Elbing et al., 2006b; 
Ludin et al., 1998). A role for the GBD of the β subunits has also been implicated in this 
association, deletion of the GBD from Gal83 results in a 3-fold reduction in SNF1 association 
with Reg1 and a subsequent increase in basal SNF1 activity (Mangat et al., 2010). Reg1 has 
also been shown to be phosphorylated in a SNF1-dependent manner, an action which allows 
dissociation of Glc7-Reg1 from the SNF1 complex and appears to stimulate Glc7 activity, 
resulting in dephosphorylation of both Snf1 and Reg1 (see Figure 1.13B) (Sanz et al., 2000). 
Interestingly it was found that Reg1 interaction with Snf1 was increased in response to 
glucose limitation, when Snf1 is protected from dephosphorylation, suggesting that Reg1 
does not play a simple targeting role (Ludin et al., 1998). Recent data has shown that the 
interaction between Reg1 and either Snf1 or Glc7 is very dynamic, utilising the same residues 
to bind to either partner in a mutually exclusive manner (Tabba et al., 2010). Reg1 
association with Snf1 required T210 phosphorylation and the authors propose a model 
whereby Glc7 and Snf1 dynamically compete for Reg1 binding, potentially dependent on 
factors such as the availability of alternate Glc1 regulatory subunits or the phosphorylation of 
Reg1 itself. Recently a second SNF1 phosphatase was identified, Sit4 (Ruiz et al., 2011). 
Deletion studies were used to identify a role for this PP2A-like phosphatase in glucose-
dependent dephosphorylation of T210 and like Reg1 it was found to physically associate with 
tagged Snf1. This opens up the possibility of more diverse regulation of SNF1 
dephosphorylation and despite knowing the identity of a key phosphatase for over 10 years 
there still remains a lot to be determined in this complex mechanism. 
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A. 
 
B. 
Figure 1.13 Regulation of SNF1 by phosphorylation 
A. As with AMPK, SNF1 is activation by phosphorylation of T210 in the catalytic domain by
one of three upstream  kinases, Tos3, Sak1 or Elm1. This residue is dephosphorylated by the
Glc7-Reg1 phosphatase. Under conditions of glucose limitation dephosphorylation is reduced
by an unknown mechanism. 
B. Following activation by one of the SNF1 kinases, the complex associates with Reg1 and
phosphorylates both Reg1 and autophosphorylates the β subunit. This allows Reg1 to interact
with Glc7 and dephosphorylate SNF1.  
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Hexokinase PII 
Hexokinase PII (Hxk2), in addition to acting at the first step in glycolysis, may also play a 
role in glucose repression pathways acting as a glucose signal sensor or transducer (see 
Figure 1.14) (Entian, 1980). Mutation of hxk2Δ revealed derepression of several glucose 
repressed genes, increased interaction between Snf1 and Snf4 as well as increased Snf1 
phosphorylation of one of its substrates, Mig1, in the presence of glucose (Jiang and Carlson, 
1996; Moreno et al., 2005; Sanz et al., 2000; Treitel et al., 1998). Hxk2 is present in both the 
cytoplasm and the nucleus, consistent with a role in signalling as well as catalysis (Herrero et 
al., 1998) but currently its role in glucose repression is not fully understood. There is some 
data indicating that the effects it has are mediated by interacting with the Glc7-Reg1 
phosphatase; it has been shown to phosphorylate Reg1, promoting inactivation of SNF1 and 
over expression of Reg1 has been shown to counteract the defects of the hxk2Δ phenotype 
(Figure 1.14)(Sanz et al., 2000).  There is also evidence that Hxk2 acts further downstream, 
interacting with Mig1 in the nucleus to limit its interaction with SNF1 (Ahuatzi et al., 2004; 
Ahuatzi et al., 2007). 
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1.2.3  Regulation by SNF1 
There is growing evidence that SNF1 acts as a master regulator of carbon and energy 
metabolism and genome-wide transcription analysis has shown that more than 400 of the 
1500 gene expression changes under glucose-limitation are SNF1-dependent (Young et al., 
2003). Furthermore, Snf1 is predicted to associate with 209 proteins, many of which are 
involved in pathways outside carbohydrate metabolism (Usaite et al., 2009). While SNF1 
directly affects the activities of several enzymes involved in metabolism it exerts the majority 
of its effects through regulation of gene expression and the key downstream targets of SNF1 
in response to glucose limitation are summarised in Figure 1.14.  
Transcriptional Regulation 
Under conditions of nutritional stress SNF1 is one of three glucose sensing systems that 
respond to glucose limitation, primarily by altering gene expression. Of these three 
mechanisms, one acting via the glucose sensors Snf3 and Rgt2 which induce expression of 
glucose transporters and the other via the second messenger cyclic AMP, SNF1 is the main 
player in regulating the expression of genes involved in the utilisation of alternative carbon 
sources, altering the balance of positive and negative regulators (Figure 1.15) (reviewed in 
Rolland et al., 2002). 
A major effector of glucose repression is Mig1, a C2H2 zinc-finger protein that binds to GC-
rich sites in several glucose-repressible promoters (Lundin et al., 1994). Mig1 in the nucleus 
recruits the Ssn6-Tup1 co-repressor complex to various promoters in response to glucose, 
inhibiting their activity by interacting with both chromatin components and general 
transcription machinery (Frolova et al., 1999; Treitel and Carlson, 1995). SNF1 inhibits this 
repression by directly phosphorylating Mig1 at four sites under low glucose conditions, 
preventing its association with the co-repressor complex and promoting its export from the 
nucleus (De Vit et al., 1997; Smith et al., 1999). Other Mig1 paralogues are not SNF1 
regulated (Lutfiyya et al., 1998). An example of a stress response mediated by Mig1 
inactivation is sodium salt stress; loss of SNF1 activity results in growth defects and 
increased sensitivity to sodium salt stress due to loss of expression of the ENA1 gene, a P-
type ATPase that extrudes cytosolic Na+ (Alepuz et al., 1997). More recently there has been 
some evidence to suggest that Mig1 acts in association with Hxk2 which appears to interact 
with a phosphorylation site on Mig1 (Ahuatzi et al., 2004; Ahuatzi et al., 2007). 
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B. 
A. 
Figure 1.14 Roles of SNF1 in response to glucose limitation 
In the presence of glucose (top schematic, A) ATP is produced via fermentation and SNF1 is
inactivated by dephosphorylation by the Glc7-Reg1 phosphatase complex or by hexokinase.
Under these conditions Mig1 is the primary transcription repressor of genes required for
adaption to alternative carbon sources. In the absence of glucose (bottom schematic, B.)
SNF1 is activated by phosphorylation by an upstream kinase (Tos3, Sak1 or Elm1) and by a
reduction in dephosphorylation. It then goes on to promote adaption to alternative carbon
sources, either through inhibition of Mig1, activation of transcriptional activators, regulation
of RNA polymerase or modification of histones (Adapted from Polge and Thomas, 2007). 
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The carbon source responsive element (CSRE) is present in the promoter regions of several 
genes of the gluconeogenic pathway and activation of this element is dependent on SNF1 
activity (Scholer and Schuller, 1994). Cat8, a transcriptional activator with a C6 zinc cluster 
DNA-binding motif, was identified as one of the first factors required for the derepression of 
gluconeogenic genes, acting indirectly as a CSRE activator (Hedges et al., 1995). Its 
expression and activation is repressed by glucose and both factors were subsequently shown 
to be SNF1-dependent; Cat8 is directly phosphorylated by SNF1, activating its transcriptional 
activity, and the CAT8 gene is subject to Mig1-dependent inhibition under high glucose 
which is relieved by SNF1 activity (Rahner et al., 1996; Randez-Gil et al., 1997). Cat8 acts as 
an indirect activator of CSRE by inducing expression of another transcriptional activator, 
Sip4, which is a CSRE-binding factor (Vincent and Carlson, 1998). Sip4, initially identified 
by yeast 2-hybrid as interacting with the SNF1 complex through Gal83, is also 
phosphorylated and activated under low glucose conditions, dependent on SNF1 activity 
(Lesage et al., 1996; Vincent and Carlson, 1998, 1999). Analysis of genes under the control 
of CSRE motifs in mutants completely lacking cat8 and sip4 indicates that these two genes 
are fully responsible for this regulation and are the only two activators required for maximum 
expression of these genes (Schuller, 2003). However, these two factors are not fully 
redundant and each has specific targets, for example, Cat8 has a more variant binding motif 
compared to Sip4, binding to a much wider range of CSRE motifs and also deletion mutants 
of these two proteins show varying abilities to adapt to different carbon sources (Roth et al., 
2004; Zaman et al., 2008). 
Another transcription factor, Adr1, plays an important role in mediating genes involved in β-
oxidation of fatty acids and genes for utilisation of ethanol, glycerol and lactate (Simon et al., 
1992; Young et al., 2003). Deletion of the ADR1 gene results in reduced expression of ~100 
genes under glucose limitation in comparison to wild-type cells and over 30 genes have been 
shown to be directly bound by Adr1 in glucose-free media (Tachibana et al., 2005; Young et 
al., 2003). Binding of Adr1 to several of these target genes is Snf1-dependent but the exact 
mechanism of this regulation is not fully understood (Young et al., 2002). Other factors that 
regulate this transcription factor include PKA, which negative regulates Adr1 in glucose 
grown cells, as well as negative regulation by both Reg1 and yeast 14-3-3 proteins, 
illustrating that Adr1 is sensitive to a number of inputs (Dombek et al., 2004; Schuller, 2003). 
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Figure 1.15 A model for transcriptional regulation by SNF1 
Upon activation in response to glucose limitation, SNF1 positively regulates transcription by
at least four independent mechanisms. SNF1 both up-regulates transcription activators (e.g.
Cat8) and inhibits transctiptional repressors (e.g. Mig1) as well as altering the chromatin
structure and stimulating the transcriptional apparatus. At a given promoter, some or all of
these mechanisms could function. Adapted from Kuchin et al., 2000. 
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The general stress response is another way in which yeast cells react to several stresses, 
allowing the coordinated induction of stress genes via a common cis element on promoter 
regions, the stress-response element (STRE) (Estruch, 2000). This is regulated by two trans-
activating factors, Msn2 and Msn4, and under conditions of stress Msn2 has been shown to 
relocate from the cytosol to the nucleus, inducing STRE genes (Martinez-Pastor et al., 1996). 
Two pathways are known to regulate Msn2 nuclear exclusion, cAMP-PKA and the TOR 
kinase pathways which, under conditions of high glucose, inhibit Msn2 nuclear import 
(Jacquet et al., 2003). Under low glucose the TOR pathway is inactivated and Msn2 is 
dephosphorylated by Reg1-Glc7, allowing its nuclear import and induction of target genes 
(De Wever et al., 2005). Long-term glucose limitation induces rephosphorylation of Msn1 in 
a SNF1-dependent manner, preventing this import and potentially acting as a feedback loop 
(Mayordomo et al., 2002). This highlights a potential role of SNF1 in long-term adaption to 
carbon stress.  
Finally, there is some evidence that SNF1 regulates transcription by altering both the 
chromatin structure and transcriptional apparatus. Recent studies in vitro have shown that 
transcription by RNA polymerase II holoenzyme is stimulated by SNF1 and that it also plays 
a role in preinitiation complex formation (Kuchin et al., 2000; Tachibana et al., 2007). 
Consistent with its role in transcriptional regulation SNF1 also phosphorylates histone H3, 
facilitating acetylation by the acyl transferase Gcn5, stimulating chromatin remodelling 
directly linked to transcriptional activation (Liu et al., 2010; Lo et al., 2000). 
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Non-transcriptional regulation 
One of the first conserved substrates between mammalian and yeast systems, ACC was also 
found to be negatively regulated by SNF1. Under conditions of nutrient limitation SNF1 has 
been shown to phosphorylate and inactivate ACC, inhibiting lipid biosynthesis as in the 
mammalian system (Mitchelhill et al., 1994; Woods et al., 1994).  
SNF1 also plays a central role in the regulation of glycogen accumulation which occurs under 
conditions of reducing glucose supply, providing stores when the yeast are fully deprived of 
nutrients, (Hardy et al., 1994). Snf1Δ mutants do not accumulate glycogen and this is 
potentially one of the main factors contributing to their loss of viability (Hardy et al., 1994; 
Thompson-Jaeger et al., 1991). In addition to its major role in the derepression of glucose-
repressed genes (as described in the previous section) it also controls carbohydrate reserves 
and cells lacking SNF1 have a 2-4-fold reduction in genes involved in glycogen metabolism, 
(Hardy et al., 1994). Post-transcriptionally SNF1 favours glycogen synthase activation, one 
of the main enzymes that control this accumulation, by promoting its dephosphorylation (and 
subsequent activation). SNF1 acheives this by directly inhibiting Pho85 kinase (Huang et al., 
1996), which phosphorylates glycogen synthase, and activating the Gac1-Glc7 phosphatase 
complex which dephosphoylrates the synthase (reviewed in Francois and Parrou, 2001; 
Hardy et al., 1994).  
As with AMPK, glucose limitation in yeast triggers a rapid inhibition of protein synthesis that 
appears to be SNF1-dependent. Although the precise mechanism for this regulation was 
unknown this inhibition was initially thought to be independent of traditional translational 
inhibitory pathways (Ashe et al., 2000; Schmelzle and Hall, 2000). However, a recent study 
by Cherkasova et al. has shown that SNF1 promotes the phosphorylation of eukaryotic 
translation initiation factor 2 (eIF2α) which itself inhibits general protein synthesis 
(Cherkasova et al., 2010). This occurs via a two-pronged regulatory mechanism, activating 
the eIF2α kinase Gcn2 or inhibiting dephosphorylation by the protein phosphatases Glc7 and 
Sit4, the contributions of which appear to be dependent on the type of stress cells are subject 
to. 
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1.3 Summary and Aims 
Understanding how AMPK functions and how it is regulated is essential to facilitate research 
into potential treatments of diseases with underlying defects in energy homeostasis. As 
outlined in this chapter AMPK, and its yeast counterpart SNF1, are activated by 
phosphorylation of a critical threonine residue in their kinase domain under conditions of 
cellular stress and this results in the rapid alteration of the balance of anabolic and catabolic 
pathways. An important step in the regulation of this activity is controlling the rate of 
dephosphorylation of this threonine residue. In AMPK it is known that binding of AMP to the 
γ subunit sustains its activity by preventing dephosphorylation, in addition to allosteric 
activation, although the precise molecular mechanisms underlying this regulation remain 
unknown. In yeast however, the metabolic signal that translates glucose limitation into 
activation of SNF1 is not known. Although many studies have shown a correlation between 
SNF1 activity and nucleotide levels, similar to that seem in mammalian cells with AMPK, 
there is no direct evidence that AMP regulates its activity. 
The aim of this study was to understand the mechanisms through which AMPK is regulated 
by nucleotides. Three molecules of AMP are known to bind to one molecule of the AMPK γ 
subunit and a highly conserved aspartic acid residue involved in binding AMP (and/or ATP) 
has been identified within these three CBS domains, but is absent from the ‘empty’ CBS 
domain (Xiao et al., 2007). In order to determine the precise role of each AMP molecule 
and/or CBS domain in the regulation of AMPK the effects of loss of these aspartic acid 
residues on the function and regulation of the complex was investigated. To further 
characterise the contributions of the different nucleotide binding sites studies were also 
conducted on wild-type AMPK. Finally, work was undertaken to try to identify the elusive 
activating signal for yeast SNF1 and to compare and contrast this regulation to that of 
AMPK. 
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2.1  Materials 
2.1.1 Chemicals and materials 
All of the chemicals, unless otherwise stated, were obtained from commercial sources and 
were of at least reagent grade. 
AMP, ADP, ATP, HEPES, Tris, glycine, EDTA, EGTA, NAD+, NADH, NADP+, NADPH, 
ammonium persulphate, magnesium chloride (MgCl2), sodium fluoride (NaF), sodium 
pyrophosphate (Na4P2O7), benzamidine, phenylmethyl sulphonyl fluoride, dithiothreitol,  
N,N,N’,N’-tetramethylethylenedamine (TEMED), β-mercaptoethanol, perchloric acid, 
hydrochloric acid, imidazole, Tween20, protein A/G-sepharose, and amino acids were 
obtained from Sigma (Poole, UK). Protogel bisacrylamide, 10x Tris/glycine/SDS buffer and 
Ecoscint scintillant were purchased from National Diagnostics (Atlanta, USA). 
Polyvinylidene difluoride (PVDF) membrane was from Perkin Elmer (Beaconsfield, UK). 
PageRuler™ plus protein ladders and 0.22 µM filters were from Millipore Ltd. (Croxley 
Green, Watford, UK). Vivaspin concentrators were from VivaSciences. Oligonucleotides 
were generated by Sigma-Genosys, the sequences of all oligonucleotides used in this study 
can be found in Appendix 2. dNTPs and restriction enzymes were purchased from Promega 
(Southampton, UK). Plasmid miniprep and maxiprep kits were from Qiagen (Crawley, UK). 
3MM chromatography paper and P81 phosphocellulose paper were obtained from Whatman 
(Maidstone, UK). HMRSAMSGLHLVKRR (SAMS) peptide was synthesised by the peptide 
synthesis group (MRC, Clinical Sciences Centre, Hammersmith Hospital).  
2.1.2 Buffers and media 
SDS-PAGE buffer – 50 mM Tris-HCl, pH8.4, 400 mM glycine, 0.1% (w/v) SDS 
Tris/Glycine buffer. 
HST (High-salt Tween) buffer – 20 mM Tris-HCl, pH7.4, 0.5 M NaCl, 0.5% Tween20. 
Protein binding buffer – 50 mM HEPES, pH7.4, 300 mM NaCl, 25 mM Imidazole. 
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Protein elution buffer – 50 mM HEPES, pH 7.4, 300 mM NaCl, 200 mM Imidazole. 
Protein storage buffer – 50 mM HEPES, pH 7.4, 300 mM NaCl and 1 mM Tris(2-
carboxyethyl) phosphine Hydrochloride (TCEP). 
HGE – 50 mM HEPES, pH 7.4, 10% (v/v) glycerol, 1 mM EDTA. 
Cell Lysis Buffer – 50 mM HEPES, pH7.4, 10% (v/v) glycerol, 1 mM EDTA, 1 mM 
benzamidine, 0.1 mM PMSF and 4 μg/ml trypsin inhibitor, 0.5% Triton. 
Western blot buffer – 10 mM N-Cyclohexyl-3-aminopropanesulfonic acid (CAPS), pH 11, 
10% methanol. 
Phosphate-buffered Saline (PBS) – 137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4, 1.4 
mM KH2PO4, pH 7.4 
Coomassie stain – 40% Methanol, 10% acetic acid, 0.1% Coomassie Brilliant blue (Sigma) 
TAE – 40 mM Tris, 20 mM acetic acid, 1 mM EDTA, pH 8.0. 
Destain – 12.5% Isopropanol, 10 % acetic acid. 
Luria Burtani (LB) broth – 1% (w/v) tryptone, 0.5% yeast extract, 0.5% (w/v) NaCl 
SOC media – 2% (w/v) tryptone, 0.5% yeast extract, 0.05% (w/v) NaCl, 20 mM glucose (add 
immediately before use).  
2.1.3 Bacterial and mammalian cells 
JM109 competent cells (endA1, recA1, gyrA96, thi, hsdR17 (rk-, mk+), relA1, supE44, 
Δ(lac-proAB), [F’ traD36, proAB, laqIqZΔM15]) were obtained from Promega (Sussex, 
UK). These were used for the transformation and amplification of plasmid DNA. The (endA) 
endonuclease deficiency allows high quality plasmid mini-prep to be made and the (recA) 
recombinase deficiency improves insert stability. The hsdR mutation prevents cleavage of the 
plasmid DNA by the EcoK endonucleases system. 
E.coli XL10-Gold ultracompetent cells (Tetr Δ(mcrA)183 Δ(mcrCB-hsdSMR-mrr)173 
endA1 supE44 thi-1 recA1 gyrA96 relA1 lac Hte [F’ proAB lacIqZΔM15 Tn10 (Tetr) Amy 
Camr]a) from Stratagene. These cells were used for transformation of all plasmids generated 
during site-directed mutagenesis and grown in LB supplemented with appropriate antibiotic. 
The Hte phenotype increases the transformation efficiency of DNA. The endA and recA 
mutations allow the preparation of high quality mini-prep DNA (as in the JM109s) and the 
lacIqZΔM15 allows blue/white screening. 
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E.coli strain BL21-Codon-Plus (DE3)-RIL (B F- dcm ompT hsdS (rB- mB) gal) competent 
cells from Stratagene were used for expression of recombinant proteins and grown in LB 
supplemented with appropriate antibiotic. These calls are naturally deficient in the Lon 
protease and are engineered to be deficient in the ompT protease, reducing the risk of 
degradation of expressed proteins. The DE3 designation means the strains contain the λ DE3 
lysogen and carries the gene for T7 RNA polymerase under the control of the lacUV5 
promoter allowing high levels of protein expression controlled by induction with isopropyl-1-
thio-b-D-galactopyranoside (IPTG). The RIL strain of cells also carries plasmids encoding 
for extra copies of the argU, ileY and leuW tRNA genes which are rare in E.coli; the lack of 
which can lead to the formation of truncated and degraded protein products. 
Ampicillin (100 mg/ml) and chloramphenicol (30 mg/ml) were prepared as stock solutions in 
ddH2O and/or ethanol and stored at –20oC. Ampicillin and chloramphenicol were used at a 
final concentration of 100 µg/ml and 30 µg/ml, respectively. All E.coli strains were grown in 
Luria Broth and standard molecular biology procedures were used for the growth and 
manipulation of bacteria. 
CCL13 (human liver) and COS7 (African Green Monkey SV40-transf'd kidney fibroblasts) 
cells were obtained from the American Type Culture Collection (ATCC) (Middlesex, UK) 
and maintained in Dulbecco’s modified Eagle’s medium (without sodium pyruvate, 
supplemented with 4500 mg/L glucose and pyridoxine) (DMEM) (Invitrogen) containing 
10% foetal bovine serum (BioWest; East Sussex, UK) and 2 mM L-glutamate (Invitrogen). 
Cells were passaged twice weekly using trypsin-EDTA (Invitrogen). 
2.1.4 DNA constructs 
A tricistronic vector (pET.γ1β1α1HIS) developed by the laboratory to allow for recombinant 
AMPK expression was used for expression of α1β1γ1 complexes in Escherichia coli (E. 
coli)(Neumann et al., 2003b). CaMKKβ had previously been cloned into the pET DUET-1 
vector (Novagen) to allow for expression of CaMKKβ with an N-terminal His-tag (Woods et 
al., 2005). For expression of recombinant proteins in mammalian cells myc-α1, β1 and flag-
γ1 were kindly provided in the pcDNA3 (myc-α1 and β1) or pcDNA1.1 (flag-γ1) vectors by 
Zahabia Ali.  
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2.1.5 Proteins 
Recombinant human His-tagged PP2Cα protein was a kind gift to the lab from Raj Beri 
(AstraZenica, Alderley Edge)(Marley et al., 1996). The LKB1 complex, obtained by the co-
expression of human His-LKB1, STRADα and GST(glutathione S-transferase)-MO25α using 
a baculovirus-insect cell expression system (Bac-to-Bac® Baculovirus Expression System, 
Invitrogen), was kindly provided by Dr Bronwyn Hegarty. SNF1 protein complexes were 
generated by Dr David Carmena (Clinical Science Centre, MRC). 
2.1.6 Antibodies 
T172 (AMPK) and T210 (SNF1) phosphorylation was determined using rabbit polyclonal 
(for recombinant complexes) or monoclonal (for cell lysates) antibodies against phospho-
T172 (Cell Signalling). Total AMPK was detected using non-commercial antibodies from the 
University of Dundee. Antibodies targeting the individual AMPK subunit were genearated in 
house; α1 (peptide antigen TSPPDSFLDDHHLTR) and γ1 (peptide antigen) were raised in 
sheep and a pan-β(Sip2) antibody was raised in rabbit against a β-GST fusion protein 
(lacking the N-terminal 68 amino acids). Total SNF1 was detected using mouse anti-His 
antibody (Abcam). PP2C was detected using mouse anti-PP2C antibody (Acris). The anti-
Myc (9E11) antibody was obtained from Cell Signalling and M2 mouse anti-flag antibody 
from Sigma (F1804). 
Secondary antibodies for use with the Li-COR infra-red (IR) scanner were used in all 
instances unless otherwise stated. IRDye800 goat anti-mouse, donkey anti-goat and goat anti-
rabbit were from LI-COR Biosciences UK Ltd (Cambridge, UK). AlexaFluor 680 donkey 
anti-sheep, donkey anti-goat, goat anti-mouse and goat anti-rabbit antibodies were from 
Invitrogen. 
2.1.7 Radiochemicals 
γ32P-ATP (6000 Ci/mmol) stocks were from Amersham Biosciences (GE Healthcare) and 
later Perkin Elmer, after Amersham ceased production of γ32P-ATP.  
2.1.8 Compounds 
A-769662 (synthesised by MRC-Technology, Dundee) was accurately weighed and dissolved 
in DMSO on the day of treatment.  
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2.2 Methods 
2.2.1 Site-directed mutagenesis 
Site-specific point mutations were generated using the QuikChange® site-directed 
mutagenesis kit (Stratagene) according to the manufacturer’s protocol. This method was 
performed using the PfuUltra DNA polymerase which replicates both plasmid strands with 
high fidelity without displacing the mutant oligonucleotide primers. Briefly, the procedure 
uses a vector DNA with the insert of interest and two synthetic oligonucleotide primers 
containing the desired mutation. The desired mutation should be situated in the middle of a 
25-45bp primer, with 10-15bp of correct sequence on either side of the altered codon. Primers 
used in this project were synthesised by Sigma Genosys and the sequences of all those used 
are shown in Appendix 2. A GC clamp of one or two bases is desirable at one end to help 
annealing to the plasmid. PCR extension occurs from the annealed primers resulting in the 
generation of new plasmids containing the mutated codon. Mutagenesis was carried out in a 
50 μl reaction volume containing: 50 ng plasmid DNA, 10 ng of forward and reverse primer, 
0.2 mM dNTPs, 1% DMSO, and Pfu Ultra buffer containing 2 mM MgCl2, and Pfu Ultra 
enzyme. A polymerase chain reaction (PCR) was programmed for an initial heating step of 1 
min at 95oC followed by 20 cycles of denaturation step at 95oC for 1 min, annealing step at 
60oC for 1 min and extension step at 68oC for 9 min and then a final extension step of 68oC 
for 4 min. Following PCR, 10 μl of the reaction was incubated in another 50 μl reaction with 
2U of DPNI endonuclease (specific for methylated DNA) at 37ºC for 1h to digest the parental 
DNA template. This protocol takes advantage of the fact that the template DNA, having been 
purified from bacteria, is methylated whereas the mutated products are unmethylated. The 
product vector DNA incorporating the desired mutations was then transformed into E.coli 
XL-Gold competent cells (section 2.1.3) and the DNA was prepared from small-scale 
cultures from isolated colonies using either the plasmid mini-prep or maxi-prep kit (Qiagen). 
The introduction of the desired mutations, and no others, was verified by sequencing 
performed by the Sequencing Service, MRC, Clinical Sciences Centre using vector primers. 
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2.2.2 Plasmid DNA purification 
Small-scale purification of plasmid DNA was prepared from overnight 5ml cell culture using 
a Qiagen miniprep kit and large-scale plasmid DNA purifications were obtained from 250ml 
cultures using a Qiagen maxiprep kit following the manufacturer’s standard protocol. Briefly, 
bacterial cells were pelleted by centrifugation before resuspension in P1 buffer containing 
RNAaseA. Alkaline lysis buffer was added to the cells and mixed gently and then this 
mixture was neutralised by the addition of acidic potassium acetate. This results in the 
precipitation of proteins and genomic DNA which can be removed by centrifugation while 
plasmid DNA remains in the soluble supernatant. This supernatant is then applied to an anion 
exchange DEAE DNA binding column and washed thoroughly before elution with sterile 
water and storage at -20ºC. The concentration of plasmid DNA was determined 
spectrophotomerically using a NanoDrop® ND-1000 UV-Vis spectrophotometer set to 
absorbance at 260nm. 
2.2.3 Expression of recombinant proteins 
Recombinant AMPK complexes were expressed and purified from E. coli as described 
previously (Neuman et al., 2003). Briefly, BL21-Codon-Plus (DE3)-RIL competent cells 
(section 2.1.3) were transformed with the plasmid of interest and colonies selected by growth 
on agar plates supplemented with the appropriate antibiotic. A single clone was selected and 
grown in LB containing the appropriate antibiotic overnight at 37ºC in a shaking incubator. 
This overnight culture was used to inoculate a larger culture (250-1000 ml) in LB medium 
and grown at 37ºC until an OD600 of 1.0 was achieved. Subsequently, the culture was 
transferred to a 25oC incubator and protein expression was induced with a final concentration 
of 1 mM IPTG for an additional 4 h. Cells were harvested by centrifugation and lysed by 
sonication in lysis buffer (500 mM Hepes, 300 mM NaCl, 10 mM imidazole, pH 8.0). His-
tagged proteins were isolated from the lysate using nickel affinity chromatography according 
to manufacturer’s guidelines (Qiagen, Basel). After elution protein containing fractions 
(assessed by Bradford protein assay [BioRad], Bradford, 1976) were pooled in HBA buffer 
(0.5M Hepes pH 7.4, 50 mM NaF, 5 mM NaPP, 0.5 M EDTA, 10% glycerol) and 
concentrated using centrifugal vivaspin concentrators (Millipore). Expression of protein was 
assessed by SDS/PAGE. 
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2.2.4 AMPK activity (SAMS peptide) assay 
Recombinant AMPK (or SNF1) complexes (1 μg) were incubated in the presence or absence 
of CaMKKβ or LKB1 in kinase kinase buffer (KK buffer; 200 μM AMP, 200 μM ATP, 5 
mM MgCl2, 10 mM DTT in 50 mM HEPES, 10% glycerol, 1 mM EDTA buffer pH 7.4) for 
20 minutes at 37°C. The reaction mix was then diluted 200 times in HBA buffer. AMPK 
activity was assessed by incorporation of radiolabelled [32P]γ-ATP into the SAMS peptide, 
HMRSAMSGLHLVKR+R+ (Davies et al., 1989), a synthetic peptide based on the 13-residue 
sequence around the unique AMPK phosphorylation site of rat acetyl-CoA carboxylase 
(ser79, S). The site for cyclic-AMP-dependant protein kinase phosphorylation (ser77) is 
replaced by an alanine (A) to allow specific phosphorylation by AMPK and two C-terminal 
arginine residues (positively charged) to facilitate binding to  phosphocellulose P-81 paper 
(Whatman). Test samples (5 µl) were assayed in the presence or absence of AMP or A-
769662, as stated in figure legends, with 0.2 mM [32P]γ-ATP, 0.1 mM SAMS peptide, and 5 
mM MgCl2 in 50 mM HEPES buffer pH 7.4 (total 25µl) by incubation at 37°C for 15 
minutes on a shaking platform. The reaction was terminated by spotting aliquots (20 µl) onto 
P-81 paper and unincorporated [32P]γ-ATP removed by washing with 1% (v/v) phosphoric 
acid until blank samples reached background levels as assessed with a Geiger counter. 
Following drying of the sample papers, phosphate incorporation was determined via liquid 
scintillation counting for 30 seconds. Specific activity was calculated by subtraction of the 
background level (lacking SAMS peptide) from the averaged duplicates and the cpm values 
normalised against assay time and [32P]γ-ATP activity on that day. 
2.2.5 Dephosphorylation of AMPK 
Recombinant AMPK (or SNF1) complexes, as indicated in figure legends, were 
phosphorylated by CaMKKβ or LKB1 as described above and aliquots (5 µl) were removed 
and incubated in the presence of 50 mM HEPES, pH 7.4, and 2.5 mM MgCl2 and in the 
presence or absence of PP2Cα (26 ng, or as indicated in figure legends), nucleotides or A-
769662 for a further 20 min (10 min for SNF1 samples) at 37ºC. The level of 
dephosphorylation was assessed by either SAMS peptide assay or by western blotting for the 
level of T172 phosphorylation. For determination via SAMS assay the reaction was 
terminated by dilution into HBA buffer (usually by a factor of 1:60 unless stated otherwise) 
and 5 μl assayed for activity as described in section 2.2.4. Note that in this dilution step the 
HBA was supplemented with either the nucleotide or compound of interest so that the levels 
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carried over into the SAMS assay were consistent throughout the samples regardless of the 
concentrations present in the dephosphorylation step. For western blotting the reaction was 
terminated by the addition of SDS sample buffer (50mM Tris-HCl (pH 7.4), 2.5% (w/v) SDS, 
1% (v/v) β-mercaptoethanol, 10% (v/v) glycerol and 0.05% (w/v) bromophenol blue). 
Samples were then resolved by SDS/PAGE and subjected to Western blot analysis, as 
described below.  
2.2.6 SDS/PAGE 
Gels were freshly made on the day of the experiment and consisted of a resolving gel 
containing 10-12% (v/v) bisacrylamide and a stacking gel containing 5% (v/v) bisacrylamide 
which were polymerised by the addition of ammonium persulphate (10% v/v) and 
tetramethyllethylenediamine (TEMED, 0.5% v/v) at room temperature.  Prior to loading 
protein samples were denatured at 90°C for 5 minutes in SDS sample buffer and were 
subsequently subject to electrophoresis in SDS running buffer (50mM Tris-HCl, pH 8.3, 
400mM glycine, 0.1% (w/v) SDS) at 200V for approximately 1 hour.  
2.2.7 Western blot analysis 
Samples resolved by SDS/PAGE were transferred to immobilon-FL transfer membrane 
(Millipore) by electrotransfer in pre-chilled Tris-Glycine buffer (25mM Tris, 192mM 
glycine) with 10% methanol (v/v) at 100V for 1.5 hours. The membrane was blocked in 
phosphate buffered saline (PBS) containing 5% skimmed milk powder for 20 minutes at 
room temperature. The primary antibody was added to high-salt tween (HST) (20 mM Tris, 
pH 7.4, 500 mM NaCl, 0.5% Tween (v/v)) buffer containing 5% milk powder and incubated 
with the membrane for either 2 hours at room temperature or overnight at 4ºC. After 
extensive washing in HST the membrane was incubated with the infrared-labelled secondary 
antibody in HST containing 5% milk powder for 1 hour at room temperature and finally 
washed again. Primary antibodies were detected using LI-COR IRDye® Infrared Dye 
secondary antibodies and were visualized using an Odyssey Infrared Imager (LI-COR 
Biotechnology). Quantification of results was carried out using the Odyssey software.  
2.2.8 Cell transfection and harvesting 
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COS7 or CCL13 cells were maintained as previously described (section 2.1.3). For 
transfection, cells were seeded into 10cm3 plates at a density of 0.5×106 cells per plate and 
allowed to adhere overnight. Cells were transfected with a total of 30µg of the desired 
plasmid/s using a CalPhos™ mammalian transfection kit (Clontech) according to the 
manufacturer’s protocol for 16 hours before being washed with PBS and fresh media added. 
Briefly, plasmid DNA interacts with calcium ions in a calcium chloride solution and mixing 
with a phosphate-buffered solution generates fine precipitates which are applied to the cells 
and taken up by an uncharacterised mechanism. Cells were returned to the incubator for 30h 
before being transferred into serum-free media prior to treatment as indicated in figure 
legends. Cells were rapidly lysed in ice-cold HBA buffer containing 1% TritonX-100 and 
complete EDTA-free protease inhibitor cocktail (Roche) and insoluble material removed by 
centrifugation at 10000×g for 10 min at 4ºC. Total protein content was determined via 
Bradford assay.  
2.2.9 Immunoprecipitation 
AMPK complexes were isolated from 100 µg of total cell lysate by incubation with 50% 
(v/v) slurry of anti-flag M2 agarose (for flag-γ1) (Sigma) for 2 hours at 4ºC on a shaking 
vibrax. The immune complexes were washed extensively in HBA buffer containing 1% 
TritonX-100 and complete EDTA-free protease inhibitor cocktail and then a final wash in 
50mM HEPES, pH 7.4. The isolated AMPK complexes were then analysed by western 
blotting or assayed for activity in the SAMS peptide assay (as detailed before). 
2.2.10 Detection of tightly bound nucleotides in recombinant 
AMPK by HPLC 
Concentrated preparations of recombinant AMPK complexes were prepared and 4 nmole 
protein was diluted up to 150 µl in 50 mM Tris, pH 8.0 with 2 mM β-mercaptoethanol to 
reduce the concentration of salt in the buffer to below 100 mM and the protein precipitated by 
the addition of 5% (v/v) perchloric acid (Sigma). Acid-insoluble material was removed by 
centrifugation at 10,000 × g for 2 minutes. The nucleotides were extracted from the acid by 
three washes with 10% excess of extraction buffer (1:1 mix of tri-n-octyl-amine and 1,1,2-
trichlorotrifloroethane). The nucleotides were separated by ion-exchange chromatography on 
a monoQ PC1.6/5 column run on a SMART system (Amersham Biosciences). Following 
equilibration of the column in buffer A (10 mM KPO4, pH 8.0) the sample was injected onto 
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the column and the nucleotides eluted by a gradient of buffer B (50 mM KPO4, 250 mM 
NaCl, pH 8.0) over 5 ml at a flow rate of 0.2 ml/min. Nucleotides were detected by their 
absorbance at 254 nm and identified by their elution position on the gradient relative to 
known standards. Results obtained from the SMART system were confirmed for each 
independent protein preparations using a NanoDrop® ND-1000 UV-Vis spectrophotometer 
set to absorbance at 260 nm. 
2.2.11 Detection of tightly bound nucleotides in mammalian 
expressed AMPK by mass spectroscopy 
AMPK complexes of interest were expressed and isolated from mammalian cells as 
previously described. The concentration of AMPK in the lysates was determined by western 
blotting alongside standard concentrations of recombinant AMPK. Subsequently cell lysate 
containing 100 µg AMPK was immunoprecipitated using anti-flag M2 agarose (Sigma). The 
immune complexes were initially washed in cell lysis buffer and then extensively washed in 
50 mM HEPES, pH 7.4, 100 mM NaCl. Any nucleotides present in the isolated AMPK 
complexes were extracted by the addition of 5% (v/v) perchloric acid (in MS grade dH2O) 
and acid-insoluble material removed by centrifugation at 10,000 × g for 2 minutes.  
The nucleotide solution was diluted 1:2 with 0.16% trifluoroacetic acid (TFA) to a final 
volume of 100 µl. A 40 µl sample of each aliquot was analysed by LC/MS using the Agilent 
Technologies 6410 Triple Quad mass spectrometer courtesy of Liam Sawbridge (Nitric 
Oxide Signalling Group, MRC Clinical Science Centre). Briefly, samples were injected onto 
an Agilent Zorbax SB-C18 Rapid Resolution HT 2.1 x 50 mm 1.8 micron column and the 
nucleotides eluted by 2% methanol (MS grade, Sigma) into the mass spectrometer. The most 
abundant AMP fragment was scanned multiple times for improved reproducibility. 
2.2.12 Statistical analysis 
Data are expressed as the mean ± standard error of the mean (S.E.M.). The Student’s t-test, or 
an ANOVA followed by an appropriate posthoc test, was used to determine statistical 
significance. The means were considered to be significantly different if a value of p<0.05 was 
obtained.
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3 Investigating the regulation of AMPK by the 
γ subunit 
 
3.1 Introduction 
It is now well established that AMPK is predominantly regulated by AMP via two distinct 
mechanisms: either through direct allosteric activation or through prevention of 
dephosphorylation (see section 1.1.2). Recent data stemming from the crystal structures of 
mammalian AMPK and two yeast AMPK homologues bound to different nucleotides 
provided a significant step towards understanding the regulation of AMPK (Amodeo et al., 
2007; Townley and Shapiro, 2007; Xiao et al., 2007). In mammalian AMPK two nucleotides 
were shown to bind to the isolated γ subunit, one to each Bateman domain (Cheung et al., 
2000; Kemp, 2004; Scott et al., 2004). The crystal structure, however, clearly showed three 
nucleotides bound to AMPK (see Figure 1.6). One of these was a tightly bound non-
exchangeable AMP, bound in site-4, whereas the remaining two nucleotides bound in an 
exchangeable fashion at site-1 and site-3, leaving site-2 empty. The yeast structures have also 
identified two potential binding sites, in S. pombe corresponding to site-2 and site-4. 
Previous studies have reported that mutations in the γ1 subunit of AMPK, equivalent to 
disease-causing mutations in human γ2, disrupt the ability of AMP to both allosterically 
activate the complex and also to protect the complex from dephosphorylation (Daniel and 
Carling, 2002b; Scott et al., 2004). Furthermore, these mutations appear to affect basal 
activity levels of the AMPK complexes, discussed in section 1.1.4. The crystal structure of 
the γ1 subunit enabled the mapping of these mutations and the majority are present in or 
around the nucleotide binding sites (Figure 1.10).  
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B. Orientation of the nucleotides in the CBS domains of the rat γ1 subunit. These space
filling (left panel) and ribbon (right panel) diagrams indicate the location of the three AMP
residues within the CBS domains from two orientations. The conserved aspartic acid residues
(Asp) thought to interact with these AMP are highlighted (accession code, 2V8Q). 
A. A Clustal alignment of rat and human γ1 and S. cerevisiae Snf4. Highlighted residues
show the conserved aspartic acids thought to be important for AMP regulation in addition to
the substituted arginine present in the ‘empty’ binding pocket. 
Figure 3.1 Structure of the CBS domains and location of γ subunit mutants 
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These data raise a number of questions, including: 
- What is the function of the non-exchangeable AMP? 
- What are the binding affinities at the exchangeable AMP binding sites? 
- Do the different exchangeable binding sites have different functions?  
- Are the allosteric activation and protection from dephosphorylation affected through 
the same binding site?  
- How do mutations in the different nucleotide binding sites result in loss of both 
allosteric and dephosphorylation regulation? 
- How is nucleotide binding to the γ subunit transmitted to the α catalytic subunit to 
regulate T172 phosphorylation levels? 
The aim of this chapter was to address these questions and clarify the regulation of AMPK by 
each of the nucleotide binding sites in γ, assessing if they each separate roles in the enzyme 
regulation and how this ultimately results in activation of the kinase.  
The structure of mammalian γ1 identified highly conserved aspartic acid residues that are 
present in each of the three CBS domains bound to nucleotides and absent from the empty 
pocket (Xiao et al., 2007). Figure 3.1 shows the conservation of these residues between 
mammals and yeast and shows their interaction with the three nucleotides bound to the γ 
subunit. These aspartic acid residues coordinate to the ribose of the nucleotide and potentially 
play an important role in binding to nucleotides. In order to investigate more thoroughly the 
roles of these residues in binding AMP, and to potentially elucidate the contributions of each 
AMP binding site in the regulation of AMPK, complexes harbouring mutations of these 
aspartic acids to alanine were generated by site-directed mutagenesis. The effects of the loss 
of these residues were assessed on the regulation of AMPK complexes both cell-free and in 
cell-based studies. 
In this chapter it is shown that these aspartic acid residues play an important role in the 
regulation of nucleotide effects on AMPK activity, although it is also clear that these 
mutations not only influence the nucleotide with which they directly coordinate but also the 
other nucleotides in the γ as well, preventing their use to effectively study isolated CBS 
domain function. However, this study has identified a mutation that, in a cellular 
environment, results in a constitutively active complex, a potentially valuable research tool.  
91 
 
 Chapter 3 – Investigating the regulation of AMPK by the γ subunit 
3.2 Results from in vitro studies 
3.2.1 Expression of recombinant AMPK complexes 
Expression of recombinant protein complexes in bacteria is a well characterised system and it 
was optimised several years ago for the expression of AMPK heterotrimers (Neumann et al., 
2003a). The complete AMPK complex can be co-expressed using a tricistronic vector (see 
Appendix 1) and Neumann et al. optimised this protocol for the expression of γ1 containing 
complexes. Unfortunately the γ2 and γ3 isoforms do not express well in this system, 
precluding their use in these studies. In this system competent E. coli cells are transformed 
with the tricistronic AMPK vector and expression induced by IPTG. A His-tag on the α 
subunit enables purification of the AMPK complexes from bacterial lysate through 
Ni2+sepharose affinity chromatography, yielding about 1 mg AMPK/litre bacterial culture. 
Figure 3.2A shows the product of expression of α1β1γ1 AMPK resolved using SDS-PAGE, 
showing the α-subunit (63kDa including the His-tag), the β-subunit (30kDa) and the γ-
subunit (36kDa). These data also illustrates the slightly anomalous migration of the β subunit 
that has been described previously (Gao et al., 1996; Woods et al., 1996a).  
AMPK complexes expressed in E. coli are essentially inactive, lacking phosphorylation of 
T172, shown in Figure 3.2B and Figure 3.2C (Sanders et al., 2007b; Suter et al., 2006). It is 
only upon incubation with either CaMKKβ or LKB1 and ATP that the complex is activated. 
Kinase activity can be assessed by SAMS peptide assay and the degree of T172 
phosphorylation determined by western blotting (Davies et al., 1989). Phosphorylation of 
inactive AMPK with CaMKKβ and ATP results in more than a 100-fold increase in the 
AMPK activity, correlating with increased T172 phosphorylation (Figure 3.2B, Figure 3.2C). 
A further 2-fold activation, from ~0.4 to 0.7 nmol/min/μg, is observed in the presence of 150 
μM AMP (Figure 3.2B). 
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C. An aliquot of the reaction described above was also subjected to western blot analysis for
phospho-Thr172 (P-T172) and total α1. 
B. Recombinant AMPK was incubated in the presence or absence of CaMKKβ (25 ng) for 20
min at 37°C. An aliquot of this was assayed for activity using the SAMS peptide assay in the
absence (white) or presence (black) of 150 μM AMP. Activities are given as mean values ±
S.E.M. from four independent experiments and are plotted as specific activity (nmole
phosphate incorporated per minute per microgram of protein, nmol/min/μg). * Indicates a
significant increase in activation with AMP relative to the control (without AMP) as judged
by a student’s t-test (P<0.05). 
A. The purified protein was resolved on a 10% SDS-PAGE Novex gel and stained with
Simply Blue stain. The molecular weight markers are indicated on the left (kDa) and the
identity of the bands is indicated on the right. 
Recombinant AMPK was purified from whole cell extract of E. coli competent cells
transformed with the tricistronic vector and induced with IPTG. After purification by Ni2+-
sepharose affinity chromatography the protein was concentrated.  
Figure 3.2 Expression and activation of recombinant AMPK (α1β1γ1) 
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3.2.2 Expression and characterisation of γ mutations 
In order to investigate the roles of the conserved aspartic acids in nucleotide regulation site-
directed mutagenesis was used to mutate each of the residues from an aspartic acid to an 
alanine residue, a small uncharged amino acid (aspartic acid residues 89, 244 and 316 from 
sites-1, -3, and -4 respectively). Mutated complexes are identified by the following 
nomenclature: D89A, D244A and D316A. Expression and stability of these complexes was 
comparable to wild-type (Figure 3.3A), and circular dichroism was used to assess if their 
secondary structures remained unaffected by these mutations (Figure 3.3B). All of these 
proteins expressed well although the γ subunit of the D89A complex showed a slight mobility 
shift relative to the other complexes. Despite this the complex appeared to have a comparable 
secondary structure and basal activity relative to WT (Figure 3.5). For several of the studies 
described in this section a well characterised WPW mutation was investigated for 
comparative purposes; the R298G mutation (equivalent to R531G in human γ2) has been 
extensively investigated and is one of the more severe mutations that has been characterised, 
completely negating nucleotide regulation (discussed in section 1.1.4). 
To first investigate the tertiary structure of these complexes the non-exchangeable AMP was 
investigated. In wild-type AMPK complexes one AMP is bound very tightly in site-4 and is 
present in the complex following expression in bacteria. Figure 3.4 shows that extraction of 
nucleotides from the recombinant complexes revealed that all of the mutant complexes, not 
just mutation of the aspartic acid directly coordinating to this residue (D316A), did not co-
purify with AMP. The inclusion of ADP as an internal standard in the recombinant AMPK 
solutions prior to nucleotide extraction revealed that the lack of nucleotide signal in these 
complexes was not due to loss of the nucleotide during the extraction process. Further 
analysis of AMPK complexes harbouring mutations associated with WPW syndrome 
revealed that the non-exchangeable AMP was lacking in all of the complexes tested, 
summarised in Table 7. Analysis of an AMPK complex harbouring a mutation in the γ 
subunit unrelated to a regulatory or disease phenotype (F60A/F61A double mutation) 
retained the presence of the non-exchangeable AMP, indicating that this phenomenon was 
not purely the result of the mutagenesis process. 
94 
 
 Chapter 3 – Investigating the regulation of AMPK by the γ subunit 
95 
 
D
24
4A
 
D
31
6A
 
D
89
A
 
W
T 
kDa 
95 
72 
55 
α1
β1
γ136 
28 
2
1
0
-1
-2
-3
190
-4
200 210 220 230 240
wavelength (nm)
Δε
m
rw
 (M
-1
cm
-1
)
250 260
A. 
B. 
Figure 3.3 Expression and verification of γ subunit mutant complexes 
A. As with WT recombinant AMPK complexes, vectors harbouring mutations in the γ
subunit of the indicated aspartic acids to alanine residues were expressed in E. coli and 
purified by Ni2+-separose affinity chromatography before SDS-PAGE analysis. 
B. Samples of the recombinant complexes were subjected to circular dichroism to compare
their secondary structures.  
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Figure 3.4 Analysis of adenine nucleotides present in recombinant AMPK complexes. 
The effect of different mutations on the non-exchangeable AMP in the γ subunit of AMPK
was investigated by analysing adenine nucleotides present in perchloric acid extracts of
recombinant protein using ion-exchange chromatography. For each sample extraction was
conducted on recombinant complexes alone (data not shown) and with an additional 4 nmol
ADP to control for efficiency of the extraction process. For a range of complexes a
representative trace is shown in the presence of 4 nmol ADP as well as a trace showing the
positions of standard AMP, ADP and ATP samples and ADP alone. 
AMP
Non-exchangeable AMP 
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Table 7 Effects γ subunit mutations on the non-exchangeable AMP 
 
All of the complexes were expressed as inactive proteins and could be activated by LKB1 or 
CaMKKβ. Two of the complexes, D89A and D316A, could be phosphorylated by either 
CaMKKβ or LKB1 to levels comparable to that seen in wild-type and also had similar basal 
kinase activities (Figure 3.5). The D244A complex showed a reduction in both the level of 
T172 phosphorylation and basal activity, present with both upstream kinases, although this 
was not a statistically significant decrease. These data confirm that the point mutations in the 
γ subunit do not disrupt formation of functional complexes and also that the complexes are 
substrates for either upstream kinase. 
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Figure 3.5 Effects of CBS domain mutations on phosphorylation and activation of
α1β1γ1 by CaMKKβ or LKB1 
Recombinant wild-type (WT) AMPK or complexes harbouring point mutations in the γ
subunit were activated by phosphorylation using either CaMKKβ (A and B) or LKB1 (C
and D) for 20 min at 37°C.  A and C Following phosphorylation AMPK activity of the
complexes was determined using the SAMS peptide assay (in the absence of AMP).
Results shown are the mean ± S.E.M. (n=4, independent experiments) and are plotted as
the specific activity of the kinase complex (nmol of phosphate incorporated/min per µg
complex). The phosphorylation statuses of these complexes were determined by western
blot analysis (B and D). A representative blot is shown for each upstream kinase. In each
case lane 1 is a negative control showing wild-type AMPK that has not been incubated
with either of the upstream kinases. 
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3.2.3 Effects of AMP binding site mutation on allosteric activation 
Having confirmed that all of the complexes were expressed and activated their regulation was 
investigated. The first mode of AMPK activation to be characterised fully was AMP 
allosteric activation (described in section 1.1.2). To investigate the disruption of AMP 
regulation a control for non-specific disruption of AMPK activity in general was used. A-
769662 is a compound developed by Abbott which is known to directly activate AMPK via a 
mechanism that is independent of AMP regulation (Sanders et al., 2007a).  
Allosteric activation of complexes by either AMP or A-769662 was assessed in the SAMS 
peptide assay. Wild-type AMPK was allosterically activated by AMP and A-769662 2.0- and 
2.2-fold respectively, consistent with other studies (Sanders et al., 2007b). In contrast, the 
CBS domain mutations had reduced AMP activation but all retained allosteric activation by 
A-769662 at levels comparable to that of wild-type (Figure 3.6A). The activities of the 
mutant complexes mirrored that seen in the basal activities and although the activity of the 
D244A complex was low the fold-activation with A-769662 was comparable to both the 
other mutants and wild-type complexes. The D89A and D244A complexes were the most 
severely affected, showing almost no AMP activation (1.2- and 1.1-fold respectively) (Figure 
3.6B). The effects of the D316A mutant, coordinating to the non-exchangeable AMP in site-
4, on allosteric activation by AMP were less severe, retaining about 50% of the AMP 
activation observed in wild-type.  
Allosteric activation by AMP was also studied over a range of concentrations, saturating 
around 100 μM AMP in wild-type AMPK (Figure 3.7). This showed that at high 
concentrations (>300 μM AMP) the D316A mutant is activated to a level comparable to wild-
type whereas the other mutants remain considerably less activated. Of the D89A and D244A 
mutations the latter was the most severe, with no AMP activation at the highest 
concentrations tested. 
99 
 
 Chapter 3 – Investigating the regulation of AMPK by the γ subunit 
100 
 
A. 
 
WT D89A D244A D316A
0.0
0.5
1.0
1.5
2.0
2.5
Fo
ld
 A
ct
iv
at
io
n
B. 
WT D89A D244A D316A
0.0
0.2
0.4
0.6
0.8 Control
+ AMP
+ A-769662
*
ns
ns
ns
*
*
*
*
Sp
ec
ifi
c 
A
ct
iv
ity
 (n
m
ol
/m
in
/μ g
)
Recombinant wild-type (WT) AMPK or complexes harbouring point mutations in the γ
subunit were activated by phosphorylation with CaMKKβ for 20 min at 37°C. AMPK
activity of the complexes was determined using the SAMS peptide assay in the presence or
absence of 150 μM AMP or 10 μM A-769662 compound as indicated. Results shown are the
mean ± SEM of four independent experiments and are either plotted as the specific activity of
the kinase complex (nmol/min/μg)(A) or as the fold activation relative to each unstimulated
control (as indicated by dashed line)(B). Figure legends in B are as in A. * indicates a
statistically significant increase in activity of the AMPK complexes treated with AMP or A-
769662 relative to the control (p<0.05 with one-way ANOVA and a Dunnett’s post test). ns
indicate that any increase is not statistically significant.  
Figure 3.6 Effects of CBS domain mutations on allosteric activation of α1β1γ1 
 Chapter 3 – Investigating the regulation of AMPK by the γ subunit 
101 
 
 
 
1 10 100 1000
1.0
1.5
2.0
2.5
WT
D89A
D244A
D316A
*
*
* *
*
[log AMP] (μM)
Fo
ld
 A
ct
iv
at
io
n
Figure 3.7 Effect of varying concentrations of AMP on activities of α1β1γ1 with D→A
mutations 
Wild-type (WT) α1β1γ1 or complexes harbouring DA γ mutations were activated in the
presence of recombinant CaMKKβ for 20 min at 37°C and aliquots used in a SAMS peptide
assay containing varying concentrations of AMP. Results shown are the mean (±S.E.M. of
four independent experiments) of the specific activity of the kinase complex (nmol of
phosphate incorporated/min per μg complex) and are plotted as the fold activation relative to
the no AMP control against the log-concentration of AMP. * indicates a statistically
significant increase in fold activation relative to the no AMP control (p<0.05 with one-way
ANOVA and a Dunnett’s post test).  
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3.2.4 Effects of AMP binding site mutation on dephosphorylation 
The second mechanism through which AMP regulates AMPK activity is through the 
prevention of dephosphorylation of T172; active complexes incubated in the presence of a 
phosphatase in addition to AMP retain their activity over a much longer time period. 
Phosphorylated AMPK complexes, both wild-type and those harbouring each of the CBS 
domain mutations, were used as a substrate for dephosphorylation by recombinant 
mammalian PP2Cα. The level of T172 phosphorylation retained was determined via Western 
blotting using an antibody specific to P-T172 and quantitated relative to the level of total α1 
in each sample.  
As shown in Figure 3.8, incubation with PP2Cα alone causes a ~75% reduction in the level of 
P-T172 relative to the control (in the absence of PP2Cα, not shown) and in wild-type 
complexes the presence of 150 µM AMP protects from this dephosphorylation (on average, 
2-fold relative to PP2C alone) and A-769662 shows and even greater protection (on average, 
3-fold). As seen in the allosteric data, each of the mutants shows a marked reduction in the 
level of protection in the presence of AMP, but not with A-769662, resulting in there being 
no significant difference in phosphorylation status in the presence of AMP relative to the 
phosphatase alone. This correlation between the allosteric and dephosphorylation regulation 
was strengthened by titration of either AMP or ADP in the dephosphorylation assay (Figure 
3.9). Our lab recently showed that in addition to AMP, ADP also regulates AMPK activity by 
preventing dephosphorylation of T172 (but has no allosteric effect); these data is discussed in 
section 4.2.1. These mutations equally affected regulation by both of these nucleotides and, 
mirroring the allosteric data, the D89A and D244A mutations eliminate protection at all 
concentrations tested whereas the D316A complexes show some protection at high 
concentrations. 
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Recombinant AMPK complexes were phosphorylated by CaMKKβ for 20 min at 37°C and
aliquots removed and incubated in the presence or absence of PP2C (26ng), AMP (150μM)
and A-769662 (10μM) for a further 20 min. The level of T172 phosphorylation was
determined by SDS/PAGE and western blot analysis for phospho-T172 (P-T172) and total
α1. Results shown are the mean ratio of P-T172:α1 (± S.E.M. of four independent
experiments) plotted as a percentage of the positive control (in the absence of PP2C, AMP
and A-769662). * indicates a statistically significant increase in % P-T172 in the presence of
AMP or A-769662 relative to PP2C treatment alone (p<0.05 with one-way ANOVA and
Dunnett’s post test).  
Figure 3.8 Effect of AMP and A-769662 on dephosphorylation of α1β1γ1 harbouring
D→A mutations 
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Figure 3.9 Effect of varying concentrations of AMP and ADP on dephosphorylation of
α1β1γ1 harbouring D→A mutations 
bed in Figure 3.8 were carried out using a range oThe same sets of experiments as descri
AMP or ADP concentrations.  
f
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3.2.5 Effects of amino acid choice on activity data 
ted on complexes with 
firm that these data 
s (D89R, D244R and D316R) expressed at slightly lower levels 
to wild-type AMPK and all showed a slight reduction in activity (and phosphorylation) after 
llosteric activation 
and AMP/ADP protection from T172 dephosphroylation. These effects are more pronounced 
 
The results presented in the previous sections are from studies conduc
conserved aspartic acids substituted for alanine residues. In order to con
are independent of the substituted residue and are the result of the loss of the conserved 
aspartic acid rather than the gain of an alanine at these sites, these experiments were repeated 
using a different substitution. The amino acid present in the same position in the CBS domain 
that does not bind an AMP is an arginine and this was used to substitute for the aspartic acid 
in the three remaining sites.  
All three new D→R mutation
incubation with CaMKKβ (Figure 3.10). Assessment of both allosteric activation and 
protection from dephosphorylation revealed that the effects of AMP were lost in all three 
mutant complexes while A-769662 activation was retained in both cases at levels comparable 
to wild-type (Figure 3.11). These results closely mirror those seen with the alanine mutations, 
indicating that these results are independent of the substituted amino acid. 
Loss of these highly conserved aspartic acids results in loss of both AMP a
in complexes harbouring mutations in the exchangeable binding sites, D89A (site-1) and 
D244A (site-3), and are independent of the upstream kinase and the substituted point 
mutation amino acid. 
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Figure 3.10 Impact of the amino acid substitution in CBS domain mutations on
expression and activation of α1β1γ1 
A. Recombinant wild-type (WT) AMPK or complexes harbouring point mutations of the
aspartic acids to arginines were expressed in E. coli as described in Figure 3.3. Samples of
each complex were subjected to SDS/PAGE and visualised using Simply Blue stain. 
B. These complexes were activated by phosphorylation by CaMKKβ for 20 min at 37°C. The
phosphorylation statuses of the complexes were determined by western blot analysis as
described before. A representative blot is shown accompanied by a graph showing the
relative quantitation of P-T172: total α1 from four independent experiments (mean ± S.E.M.). 
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Figure 3.11 Impact of the amino acid substitution in CBS domain mutation effects on
regulation of α1β1γ1 
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Recombinant wild-type (WT) AMPK or complexes harbouring point mutations of the
aspartic acids to arginines were activated by incubating with recombinant CaMKKβ for 20
min at 37°C. A. AMPK allosteric activity of the complexes was determined using the SAMS
peptide assay in the presence or absence of 150 μM AMP or 10 μM A-769662 compound as
indicated. Results shown are the mean ± SEM (n=4, independent experiments) and are
plotted as the specific activity of the kinase complex (nmol/min/µg complex). B. Aliquots of
active complex were incubated in the presence or absence of PP2C (26 ng), AMP (150 μM)
and A-769662 (10 μM) for 20 min at 37°C and the reaction terminated by the addition of
SDS sample buffer. The level of T172 phosphorylation was determined by western blot
analysis and analysed as described previously. * indicates a statistically significant increase
in activity or % P-T172 in the presence of AMP or A-769662 relative to untreated controls
(p<0.05 with one-way ANOVA and Dunnett’s post test). 
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3.2.6 Effects of CBS domain mutation on nucleotide binding 
In order to assess if the effects of these mutations on AMPK activity are due to disruption of 
nucleotide binding or disrupted relay of the nucleotide signal to the α subunit a series of 
binding studies were conducted. Unlike AMPK activity assays, measuring binding by 
spectrographic methods requires significant concentrations of highly purified protein and as 
illustrated in Figure 3.12A Ni2+-sepharose affinity chromatography alone on such large 
volumes is insufficient to produce a pure preparation and complexes were further purified by 
gel filtration. Initial studies were carried out using mant-labelled AXPs, as described in Xiao 
et al., which allow monitoring of nucleotide binding through changes in their fluorescence 
spectrum (Xiao et al., 2007). This technique was used to show that wild-type AMPK 
contained two exchangeable nucleotide binding sites with Kds of ~12 and ~24μM. However, 
preliminary data (see Appendix 3) indicated that binding at site-3 (the D244A mutation site) 
was accountable for almost the entire fluorescent signal upon mant binding whereas site-1 
(D89A) contributed very little fluorescence. This meant that not only could this method not 
be used to monitor both of these binding sites, but also that the analysis of the binding 
constants in the Xiao et al. study, which assumed equal fluorescence contribution from the 
two binding sites, was likely to be inaccurate.  
It was subsequently discovered by the Gamblin and Carling groups that the dinucleotides 
NADH and NADPH, which structurally resemble ADP with a nicotinamide substituent, 
specifically bind to AMPK with 1:1 stoichometry (Figure 3.12B, analysis of fluorescent 
binding studies are outline in Appendix 4). This interaction appears to be relatively specific 
to the reduced forms in that binding of either NAD+ or NADP+ to AMPK is barely detectable. 
NADH (and NADPH) undergo a significant change in fluorescence following binding to 
AMPK, interacting with a single exchangeable binding site on the enzyme which competes 
for binding with AXPs (see schematic on Figure 3.12C and Figure 3.12D). Using NADPH as 
a reporter for binding at one of these exchangeable sites the binding of AMP, ADP and ATP 
was determined for each of the mutant complexes (Table 8). The D316A mutation in the non-
exchangeable binding site and to a lesser degree the R298G, have increased Kds for the 
nucleotides relative to wild-type complexes but the error in this data set allows only limited 
interpretation. These data show that overall none of these mutations, or the WPW mutation, 
completely eliminates nucleotide binding at this site. This indicates that the effects on activity 
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Figure 3.12 Principles of NADH binding to AMPK 
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A. For binding experiments large scale highly purified preparations of the AMPK complexes
were necessary. Following Ni2+-sepharose purification complex expression was determined
for each fraction using SDS/PAGE and visualisation by Simply Blue safe stain. Peak
fractions were combined and subjected to gel filtration. SDS/PAGE and visualisation of the
peak fractions was conducted prior to concentration. B. The structure of NADH. C.
Uncomplexed NADH has an emission maximum at 465nm and in the presence of AMPK its
fluorescence emission intensity is increased and shifted to 438nm. Increasing concentrations
of wild-type AMPK were incubated with a fixed concentration of NADH (10 μM) in a
cuvette at 20°C, the mixture excited at 340nm and the emission spectrum measured from 400
to 550 nm. This graph shows the spectra of free NADH and when fully bound to AMPK. D.
Once the AMPK reaches saturation the NADH can be competed off by AXP binding that are
titrated into the cuvette, maintaining constant levels of NADH and AMPK. The plot shows
the increasing fluorescence at a fixed wavelength as the protein concentration increases and
the subsequent decrease in NADH fluorescence as nucleotide is added.  
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are not due to total loss of nucleotide binding in the γ subunit, but rather that an alternative 
mechanism it being affected. 
 Kd vs NADPH (μM) 
WT D89A D244A D316A R298G 
AMP 
ADP 
ATP 
Mg-ATP 
4.1 (1.2) 
8.0 (2.5) 
4.9 (1.2) 
21 (5.0) 
2.7 (0.8) 
5.5 (1.2) 
4.3 (0.6) 
3.2 (0.8)    
 
3.9 (0.9) 
24 (12) 
 
12.5 (3.5) 
6.8 (2.2) 
17.2 (7.0) 
9.0 (1.5) 
Table 8 Nucleotide binding to WT and mutated AMPK complexes 
Highly purified unphosphorylated wild-type (WT) AMPK or complexes harbouring the 
indicated mutations in the γ subunit were used to assess the dissociation constants for 
nucleotide binding using the fluorescent change in NADPH (S.D. of three independent 
experiments). NADPH was used as a reporter as under these conditions it gave a greater 
change in fluorescence intensity compared to NADH. These experiments were conducted in 
the presence of 300mM NaCl at room temperature.  
These data also clearly show a difference in the wild-type AMPK affinity for ATP relative to 
Mg-ATP. Under physiological conditions the majority of ATP will be in complex with 
magnesium and this appears to weaken its affinity for binding, increasing the Kd from ~5µM 
up to ~21µM. This shows that in the unphosphorylated complex both AMP and ADP have 
affinities for the complex that are ~5x or ~2.5x stronger respectively than Mg-ATP. 
Following the work described in this section nucleotide binding to full length phosphorylated 
AMPK was assessed using coumarin-labelled nucleotides (which have a higher affinity than 
the mant-derivatives and were verified to fluoresce equally at both binding sites) as well as 
using NADH. This data is shown in Table 11. This comprehensive analysis of nucleotide 
binding to active AMPK elucidated that all three nucleotides bind to two exchangeable sites 
which have very different affinities and these studies showed that NADH (and NADPH) 
interacts with the tighter of the two exchangeable sites. Although the dissociation constants 
were lower in the active complexes relative to the unphosphorylated AMPK in my studies, 
both data sets agree that all three nucleotides bind with similar Kds. These data also confirm 
that the affinity of Mg-ATP is significantly lower than the other nucleotides, an effect that is 
accentuated in the active complex. These data are discussed in section 4.2.2.  
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3.3 Results from cell-based studies 
In order to assess the effects of these mutations in a cellular environment wild-type or mutant 
forms of the γ subunit were co-expressed with wild-type α and β subunits in mammalian 
cells.  
3.3.1 Expression and characterisation of mammalian complexes 
All three AMPK subunits were transfected into a mammalian cell line expressing endogenous 
LKB1, COS7 cells. These were myc-tagged α1, untagged β1 and flag-tagged γ1 harbouring 
the D89A, D244A or D316A mutations. Western blotting of total protein cell lysates shows 
expression of all three subunits (Figure 3.13) and the level of endogenous β subunit (apparent 
in the untransfected, UT, lane) is much lower than in the cells transfected with additional β1. 
These blots also show that the presence of the mutations in the γ subunit does not adversely 
affect expression of the γ constructs and all are expressed at similar levels.  
In order to compare their tertiary structures of the mammalian expressed AMPK complexes 
to the recombinant complexes, occupancy of the non-exchangeable AMP was assessed. This 
very tightly bound AMP was initially identified from the crystal structure of bacterially 
expressed AMPK and in section 3.2.2 it was shown that a number of disease causing 
mutations, as well as these aspartic acid mutations, weaken binding at this site, abolishing its 
co-purification with the AMPK complex. In order to ascertain that this result, or the presence 
of a non-exchangeable AMP, is not an artefact of recombinant expression, AMPK purified 
from mammalian cells was analysed. Cells transfected with the indicated complexes were 
harvested and following Western blotting to judge expression levels, ~100µg AMPK was 
immunoprecipitated, and the immune-complex thoroughly washed. Complete 
immunoprecipitation was verified by blotting for unbound complex, and this ensured a 
constant level of AMPK was present in each sample. Adenine nucleotides in these immune 
complexes were extracted by perchloric acid and assessed by mass spectroscopy. AMP was 
clearly present in the extract of wild-type AMPK complexes, verifying the observation first 
made in protein from a bacterially expressed system (Figure 3.14, top trace). As with 
recombinant AMPK complexes, AMP was absent from all three of the AMPK complexes 
harbouring the aspartic acid mutations, as well as complexes harbouring the R298G mutation. 
This result indicates that the effects of these mutations on the non-exchangeable AMP are 
similar between the bacterially expressed and mammalian expressed complexes. 
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Myc-α 
β 
Flag-γ 
UT WT D316A D89A D244A
COS7 cells were transfected with myc-α1, untagged β1 and Flag-γ1 harbouring either the
D89A, D244A or D316A mutations or an untransfected (UT) control. Cells were rapidly
lysed and 60 µg of total protein analysed by western blotting for myc-tagged proteins (α1),
AMPK β (also present in the UT lane) and flag-tagged proteins (γ1). Loading judged by
coomassie stain of blots (not shown). Vertical line in blots indicates separate gels 
Figure 3.13 Transfection of COS7 cells with complexes harbouring mutations in flag-
tagged γ1 
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Figure 3.14 Mass spectroscopy analysis of the non-exchangeable AMP co-purified from
mammalian expressed WT or mutated α1β1γ1 complexes 
COS7 cells were transfected with wild-type α1-myc, β1 and either wild-type γ1-flag or γ1-
flag harbouring D89A, D244A, D316A or R298G mutations. Following transfection cells
were harvested and rapidly lysed and the level of transfection assessed by western blotting
alongside recombinant AMPK standards. 100 μg of AMPK was immunoprecipitated with
flag-agarose and extensively washed in buffer containing 100 mM NaCl. Adenine nucleotides
remaining bound to the immune complexes were assessed by mass spectroscopy of perchloric
acid extracts. A representative trace is shown for each complex (note the differences in scale
on the y-axis) and the results summarised in the table on the right.  
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3.3.2 Effect of CBS domain mutations on AMPK activity 
In recombinant AMPK complexes the aspartic acid mutants showed significantly reduced 
nucleotide regulation although they retained regulation by the compound A-769662 (Figure 
3.6 and Figure 3.8). In mammalian cells these mutations appear to have much more profound 
effects on the activity levels compared to that seen in these in vitro studies. 
Under basal conditions, when wild-type AMPK is relatively inactive (with a specific activity 
of ~0.016 nmol/min/mg lysate), the D89A and D244A complexes showed even lower levels 
of activity (0.006 and 0.007 nmol/min/mg respectively) while the activity of the D316A 
mutant was over ten times that of the wild-type (0.187 nmol/min/mg) (Figure 3.15). Western 
blot analysis of the AMPK complexes present in the lysates revealed similar levels of 
expression of the complexes, indicating that the changes in activity were not due to 
differences in the level of expression or association of the different γ subunits. Furthermore, 
the level of T172 phosphorylation, as judged by Western blotting, closely correlated with the 
observed levels of activity in the complexes. This indicates that the variations in basal 
activities of the mutant complexes are due to changes in the level of T172 phosphorylation. 
Furthermore, this pattern of phosphorylation was observed in the level of phosphorylated 
ACC, a downstream target of AMPK, indicating that these variations were transmitted 
downstream of AMPK. 
To further investigate this effect, the R298G mutation was examined in this system as it has 
previously been show to have increased basal activity (Sanders et al., 2007b). Under the 
conditions examined here the R298G mutant also has a significantly higher level of basal 
activity relative to wild-type, although this is still only 50% of the activity seen in the D316A 
mutant complexes. Data presented in Figure 3.16A shows comparative experiments 
conducted on the D244A and D316A complexes in a cell line that doesn’t express LKB1 
(CCL13) as the upstream kinase. This shows duplication of the pattern of basal activities, low 
(D244A) or very high (D316A) respectively, eliminating the possibility of a cell-line specific 
anomaly.  
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COS7 cells were transfected with wild-type α1-myc, β1 and either wild-type γ1-flag or γ1-
flag harbouring either the D89A, D244A, D316A or R298G mutations. Following
transfection cells were treated with either 1 mM H2O2 for 15 min or 200 μM A-769662 for 1
hour. AMPK complexes with the flag-tag were immunoprecipitated from 100μg total protein
using an anti-flag antibody, and were either Western blotted or the activity of the immune
complexes was measured using the SAMS peptide assay in the absence of AMP. P-ACC was
blotted in the unbound fraction post-immunopreceiption. Results shown are the mean ±
S.E.M. of four independent experiments and are plotted as nmol/min/mg lysate with
accompanying western blots. $ Indicates a statistically significant increase in basal (control)
specific activities relative to WT levels, * indicates a statistically significant increase in
treated cells relative to the untreated control for each complex (p<0.05 with two-way
ANOVA and Dunnett’s post test).  
Figure 3.15 Effect of D→A mutations in mammalian cells expressing LKB1 
115 
 
 Chapter 3 – Investigating the regulation of AMPK by the γ subunit 
 
WT D244A D316A
0.0
0.1
0.2
0.3
0.4 Control
+ H2O2
+ A-769662
*
*
*
*
$
Sp
ec
ifi
c 
A
ct
iv
ity
(n
m
ol
/m
in
/m
g 
ly
sa
te
)
WT D244A D316A
0.0
0.2
0.4
0.6
0.8
Control
+ Sorbitol
+ Metformin
*
*
$
Sp
ec
ifi
c 
A
ct
iv
ity
(n
m
ol
/m
in
/m
g 
ly
sa
te
)
B. 
A. 
Figure 3.16 Effect of D→A mutations in cells not expressing LKB1 and with
pharmacological activators 
A. The same set of experiments as described for Figure 3.15 were carried out in a cell line
(CCL13) that doesn’t express LKB1.  
B. The same set of experiments as described for Figure 3.15 were carried out in COS7 cells
and treated with either 600 mM sorbitol for 30 min or 3 mM Metformin for 180 min prior to
harvesting. Results were generated by Dr Nell Marty. 
$ Indicates a statistically significant increase in basal (control) specific activities relative to
WT levels, * indicates a statistically significant increase in treated cells relative to the
untreated control for each complex (p<0.05 with two-way ANOVA and Dunnett’s post test).
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Cells transfected with each of the complexes were subject to a range of treatments: hydrogen 
peroxide (H2O2) which causes oxidative stress and ultimately leads to ATP depletion; A-
769662, a direct activator of AMPK (both in Figure 3.15 and Figure 3.16A); sorbitol which 
induces osmotic stress; and metformin, an anti-diabetic drug which can activate AMPK 
independently of ATP depletion (both in Figure 3.16B). The D89A and D244A complexes, 
despite their low basal activities, showed significant activation by A-769662 and although the 
other activators showed some stimulation of activity, in only one case, the D89A treated with 
H2O2, did this reach statistical significance. The D316A appeared to be almost maximally 
activated under basal conditions in COS7 cells with little additional activation by any of the 
treatments. However, this mutation did show some activation in CCL13 cells, with CaMKKβ 
as the upstream kinase, and there is also a smaller difference in basal activities between wild-
type and the D316A, only a 4.5-fold increase in this cell line compared to the 11-fold increase 
in the cell line with LKB1. These data indicate that there is a difference in the basal activity 
states of the complexes dependent on which upstream kinase is present. This discrepancy is 
likely to be attributable to the fact that LKB1 is constitutively active, resulting in higher basal 
activities. Under the conditions in CCL13 cells the lower basal activity of the D316A mutant 
allows some further activation by the stresses investigated here, indicating that this complex 
may not be incapable of activation but simply that its basal activity is so high it cannot be 
further activated. This is investigated in the next section. 
 
3.3.3 D316A mutation constitutively activates AMPK 
Previous studies have shown that several of the WPW mutations cause increased basal 
activity, an intermediate phenotype in comparison to the basal level of D316A activity 
(reviewed in Arad et al., 2007). This mutation in the non-exchangeable AMP site appears to 
maximally activate the AMPK complex and is incapable of further activation by the direct 
activator A-769662. Conversely, the D89A and D244A complexes, harbouring mutations in 
the exchangeable binding sites, result in significantly reduced basal activity.  
To see if these complexes were capable of being activated to levels comparable to wild-type 
and to see if the D316A complexes could be further activated their activity was assessed in 
vitro. After isolation from cell lysates by immunoprecipitation the complexes were incubated 
with LKB1 in vitro before their activity was determined using the SAMS peptide assay. 
117 
 
 Chapter 3 – Investigating the regulation of AMPK by the γ subunit 
Figure 3.17 shows comparison of untreated complexes with those that were incubated with 
LKB1. The wild-type, D89A and D244A complexes are all capable of being activated to 
comparable levels (specific activities around 0.39 nmol/min/mg lysate in each case). The 
maximum level of activity reached by these three complexes was similar to the basal level 
observed in the D316A complex (0.40 nmol/min/mg lysate), which could not be significantly 
activated any further. This confirms firstly, that the two mutations in the exchangeable sites 
do not prevent activation of the complex by upstream kinases, indicating that this is not the 
cause of the reduced basal activities, and secondly that the D316A mutation appears to result 
in a maximally activated complex even under basal conditions.  
 
3.3.4 Aspartic acid mutants are not allosterically activated by 
AMP 
In vitro studies on these mutations (see sections 3.2.3 and 3.2.4) indicated that they were 
insensitive to regulation by AMP, either allosterically or to prevent dephosphorylation. 
However, data from these cell-based experiments show that the D89A and D244A complexes 
still show some activation in response to H2O2 treatment, which acts by increasing AMP 
levels, as well as with sorbitol and metformin (Figure 3.15 and Figure 3.16).  
To clarify if these mammalian complexes still retain some regulation by AMP they were 
immunoprecipitated from cell lysates and used in the SAMS peptide assay in the presence or 
absence of 150μM AMP. Figure 3.18 shows that wild-type complexes are capable of being 
allosterically activated by AMP 3-fold. However, none of the complexes harbouring 
mutations in their CBS domains showed a significant level of activation in the presence of 
this concentration of AMP. It can therefore be assumed that the activation apparent in the 
cells treated with these stresses, and particularly H2O2, is not due to detecting increased AMP 
levels. 
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Figure 3.17 D316A mutant complexes are maximally activated  
COS7 cells transfected with wild-type AMPK or complexes with D→A mutations in the γ
subunit were rapidly lysed and the AMPK complexes immunoprecipitated from 100 μg total
protein using an anti-FLAG resin. Immune complexes were subsequently incubated with
recombinant LKB1 and kinase buffer for 30 min at 37°C. The activity was measured using
the SAMS peptide assay (in the absence of AMP). Results shown are the mean ± S.E.M. of
three independent experiments and are plotted as nmol/min/mg lysate (A) or as the fold
activation relative to the un-reactivated control (-LKB1)(B).  
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As described in the legend for Figure 3.15 cells were transfected with WT or mutant AMPK
complexes and treated with 1 mM H2O2 for 15 min. These complexes were immuno
precipitated from 100 μg total protein and their activity measured using the SAMS peptide
assay in the presence or absence of 150 μM AMP. Results shown are the mean ± S.E.M. of
three independent experiments and are plotted as the fold activation in the presence of AMP
relative to in the absence of AMP. 
Figure 3.18 Mutated AMPK complexes expressed in cells are not allosterically activated
by AMP in vitro  
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3.3.5 In vitro characterisation of activity regulation 
Taken together the data from these cell-based studies first confirm that, as in the recombinant 
system, these mutations disrupt the tight non-exchangeable AMP binding site as well as 
eliminating regulation by AMP through allosteric activation. However, these studies 
highlighted significant differences in the basal activities between the mutations in the 
exchangeable binding sites and the non-exchangeable site. In order to investigate the 
potential causes of this variation in the basal activities in cells recombinant AMPK was again 
used. These changes are likely to be due to either variation in the complex activation by the 
upstream kinases or the level and/or rate of dephosphorylation.  
Prior in vitro data indicated that these complexes had some variation in their level of 
phosphorylation by either LKB1 or CaMKKβ but under the conditions tested these change 
were minimal (Figure 3.5). By analysing the level of T172 phosphorylation following 
incubation with a range of concentrations of CaMKKβ it is clear that there is some variation 
between the activity levels of the three complexes (Figure 3.19). Although these changes are 
not significant there is a definite trend: the D316A complexes appear to be phosphorylated 
more readily and more fully than their wild-type counterparts whereas the D89A and D244A 
complexes tend to be slightly less phosphorylated under the conditions tested. At higher 
concentration of CaMKKβ this effect is less pronounced, accounting for the mild differences 
observed in the initial studies.  
Dephosphorylation of these complexes was also investigated in greater detail in vitro, testing 
the level of T172 phosphorylation over a range of PP2C concentrations (Figure 3.20). These 
data, as seen in the CaMKKβ titrations, also show some variation between the mutant 
complexes and wild-type although the two exchangeable mutations (D89A and D244A) show 
little deviation from the pattern of dephosphorylation observed in the wild-type complexes. 
The D316A complexes however, show a trend of being less susceptible to dephosphorylation 
relative to the other three complexes, showing 15-20% higher P-T172 levels at low 
phosphatase concentrations. 
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Figure 3.19 Effect of D→A mutations within the γ subunit on phosphorylation of
α1β1γ1 by CaMKKβ 
Recombinant wild-type (WT) α1β1γ1 complexes or those harbouring point mutations in the γ
subunit were activated by phosphorylation using varying concentrations of recombinant
CaMKKβ for 20 min at 37ºC. The level of T172 phosphorylation was determined by
SDS/PAGE and western blot analysis for phospho-T172 (P-T172) and total α1. Results
shown are the mean ± S.E.M. of three independent experiments and are plotted as the ratio of
P-T172:α1, accompanied by representative blots. 
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Figure 3.20 Effect of D→A mutations within the γ subunit on dephosphorylation of
α1β1γ1 by PP2Cα 
Recombinant wild-type (WT) AMPK (α1β1γ1) or complexes harbouring point mutations in
the γ subunit were activated by phosphorylation using recombinant CaMKKβ for 20 min at
37ºC and aliquots were removed and incubated with increasing concentrations of PP2Cα for a
further 20 min. The level of T172 phosphorylation was determined by SDS/PAGE and
western blot analysis for phospho-Thr172 (P-T172) and total α1. Results shown are the mean
± S.E.M. of three independent experiments and are plotted as the ratio of P-T172:α1 as a
percentage of the positive control (in the absence of PP2C).  
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These data could provide an explanation for the variation of the cell-based basal activities. 
The D316A-containing complexes appeared to be a slightly better substrate for the upstream 
kinase and a worse substrate for the phosphatase, accounting for its high basal activity, while 
the opposite is true of the mutations in the exchangeable binding sites. These slight variations 
in the regulation of the complexes, independent of any nucleotide effects, could be sufficient 
to account for the differences in basal activities of these mutations in the cell. These effects 
appear to be particularly pronounced in the presence of the constitutively active LKB1. 
However, the data presented here does not provide an explanation as to how these differences 
between mutations either in exchangeable or non-exchangeable sites result in differential 
regulation of P-T172 levels.  
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3.4 Discussion 
Although the mechanism of nucleotide regulation of AMPK has been extensively 
investigated in the 20 years since it was first characterised the detailed process through which 
binding in the γ subunit is transmitted to the level of phosphorylation of T172 on the α 
subunit remains a mystery. Previous studies have utilised a wide spectrum of techniques to 
study AMP binding and its effects on the activity of AMPK but it was only with the 
crystallisation of the complete γ subunit that definitive insights were drawn (Xiao et al., 
2007). This structure identified not two as was previously thought, but three nucleotide 
binding sites, one of which appeared to bind AMP in a non-exchangeable manner. This 
structure was used to identify residues within these three binding pockets that are highly 
conserved and appeared to interact with the ribose group of the nucleotide, potentially 
making an important contribution to nucleotide binding and signal transduction. Mutation of 
these residues was investigated to shed light on the contributions of each of these binding 
sites and to have a greater understanding of the different mechanisms through which 
nucleotides influence AMPK. 
Data presented in this study show that the presence of these aspartic acid residues is critical 
for nucleotide regulation, highlighting the importance of not just the exchangeable binding 
sites but also the non-exchangeable site. As has been previously shown with disease causing 
mutations, interference in these binding sites results in loss of nucleotide regulation of 
activity both in vitro and in cell-based systems as well as influencing factors such as 
phosphorylation and dephosphorylation (summarised in Table 9). However, this study 
highlighted the fact that these mutations do not appear to be having isolated effects on the 
complex and they disrupt binding of nucleotides with which they do not directly coordinate 
(i.e. the non-exchangeable site). Although this finding precludes the use of these mutations to 
study the roles of the separate binding sites they have identified useful tools for ongoing 
research into AMPK regulation.  
Recombinant AMPK can be expressed and purified from bacteria as an inactive complex. As 
previously described phosphorylation of T172 in the purified complex, is below the detection 
limit of the P-T172 antibody. AMPK activity, although detectable in the SAMS peptide 
assay, is very low and values increase only slightly upon addition of AMP at saturating 
concentrations (Figure 3.2) (Suter et al., 2006). Furthermore the specific activities of these 
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Table 9 Summary of effects of conserved aspartic acid mutation 
Results for the previous section are summarised in the above table from the cell-free and 
cell-based assays as well as effects on binding. 
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recombinant complexes after incubation with either CaMKKβ or LKB1, resulted in over 100-
fold activation of the complex, comparable to levels shown previously (Woods et al., 2005). 
These complexes can then be allosterically activated by AMP or A-769662, an average of 
2.0-fold and 2.2-fold respectively, comparable to other studies carried out in this manner 
(Sanders et al., 2007a; Suter et al., 2006). Suter et al. suggest that these values for allosteric 
activation could be underestimating the true stimulatory potential of AMP due to AMP 
generated from ATP by non-enzymatic decay that will always be present in the ‘no AMP’ 
measurements and the auto-phosphorylation status of the complex, extrapolating that AMP 
could increase AMPK activity by 10-fold or more (Suter et al., 2006). The complexes 
harbouring aspartic acid mutations expressed well and did not disrupt the structure or 
formation of the complex as judged by circular dichroism. However, they did show some 
variation in their basal activities, reflecting their ability to be phosphorylated in vitro, with the 
D244A mutation having a slightly lower activity (corresponding to a lower level of T172 
phosphorylation). However, this difference was not significant and previous studies 
investigating the effects of WPW mutations in AMPK show some variation in their 
expression and basal activity levels, similar to that seen with these mutations (reviewed in 
chapter 1.1.4).  
All three aspartic acid mutations resulted in complexes that were less sensitive to both 
allosteric activation by AMP and protection from dephosphorylation, even the D316A mutant 
which corresponds to the non-exchangeable AMP binding site. However, as has also been 
observed with the WPW mutations, the three mutants exhibited different sensitivity to AMP. 
Mutation in the exchangeable binding sites, D89A and D244A, had the most severe effects on 
nucleotide regulation, rendering the complexes almost completely insensitive to either 
allosteric activation or prevention of dephosphorylation at even the highest concentrations 
tested (Figure 3.7 and Figure 3.9). On the other hand, the D316A mutation, although causing 
a significant reduction in the effects of AMP, was capable of allosteric activation by much 
higher concentrations of this nucleotide to levels comparable to wild-type. As judged by 
titration of AMP in the allosteric assay the wild-type complex is half-maximally activated 
around 30 μM whereas for the D316A complex this is around 100 μM, a pattern that is 
mirrored in the dephosphorylation assays (Figure 3.7 and Figure 3.9). As this site is 
permanently bound to AMP in the wild-type complex it can be assumed that it does not play 
a role in sensing nucleotide levels and instead may play a role in stabilising the complex. It 
can therefore be hypothesised that this mutation either weakens the binding affinity at the 
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regulatory binding sites (i.e. the exchangeable sites) or it inhibits the mechanism of signal 
transduction following nucleotide binding.   
Importantly, mutation of any of these three residues had no effect on activation of AMPK by 
A-769662, indicating that the changes in the AMP sensitivity are unlikely to be due to gross 
functional changes in the complex that render it inactive. Furthermore, use of alternative 
mutations, converting the aspartic acids to arginines, shows that this dysregulation is also not 
due to the gain of an alanine in these sites. 
This loss of nucleotide regulation with all three mutations in itself is perhaps not unexpected; 
WPW mutations which disrupt AMP regulation have been mapped to all four of the CBS 
domains, even the ‘empty’ site and to residues that do not directly interact with a nucleotide 
(Figure 1.10) (Xiao et al., 2007). Studies investigating the severity of these mutations 
generally concur that those directly interacting with nucleotides (R531G, T400N, R302Q and 
the H383R) result in more severe phenotypes and furthermore that these mutations are 
predominantly clustered around the exchangeable binding sites, correlating with the findings 
presented here (Daniel and Carling, 2002b; Scott et al., 2004). 
In order to delineate between weakened nucleotide binding and disruption of the regulatory 
mechanism binding studies were carried on the mutant complexes. Towards this end the non-
exchangeable binding site in CBS4 was investigated, in which an AMP molecule is co-
purified from the bacterial expression system in the wild-type complex. Contrary to 
expectations, not only was this tightly bound AMP absent from this site in the D316A 
mutant, but it was also missing from complexes harbouring mutations in the exchangeable 
binding sites as well as in a number of WPW complexes (Figure 3.4 and Figure 3.14). 
However, this does not seem to be a non-specific result from mutating residues anywhere 
within the γ subunit as an unrelated mutation near the surface of the subunit did not disrupt 
this AMP. Despite this, some of the WPW mutations that had lost their non-exchangeable 
AMPs also lie far from the nucleotide binding pockets (Y254H and E273K) and do not 
interact directly with any nucleotides. This result raises a number of points. Firstly, it draws a 
parallel between these target mutations and the disease causing mutations, which appear to 
have similar effects on the complex regardless of the spatial location, indicative of an 
important functional role for this AMP. Secondly, this result indicates that point mutations in 
one CBS domain do not have isolated effects, and given the unique arrangement of the CBS 
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domains in the γ subunit of AMPK with only one side chain separating each face of the 
subunit it is not unlikely that an individual amino acid could disrupt interactions within 
different CBS domains.  
In order to investigate these effects on binding further, experiments were undertaken to assess 
exchangeable binding at the other two sites. Initially mant-labelled nucleotides were used to 
assess binding by monitoring changes in their fluorescent profiles upon binding as previously 
described (Xiao et al., 2007). However, preliminary data indicated that this would not yield 
interpretable data; in order for data collected in this manner to be analysed it is assumed that 
binding at both sites contribute equally to the fluorescence signal and this was not the case. 
Preliminary studies suggested that mutation of site-3 (D244A) eliminated almost the entire 
fluorescence signal but that binding at this site was very weak, whereas binding at site-1 
(D89A) contributed little to the mant fluorescent signal but that this binding was very tight 
(Appendix 3). This is one of the few scenarios that would result in these discrepancies not 
becoming apparent during the extensive optimisation with the wild-type complexes and as 
such it could not be used. An alternative had to be found and this presented itself in the form 
of NADH and NADPH. These nucleotides were found to specifically bind to one of the 
exchangeable binding sites on AMPKγ with a 1:1 stoichiometry and they undergo significant 
changes to their fluorescent profiles upon binding. The implications of NADH interacting 
with AMPK are discussed in section 4.3.  
Previous methods that have assessed the impact of WPW mutations on binding have shown 
dramatic reductions in the binding affinities for AMP in R531G mutant complexes, perhaps 
the most severe of the WPW mutations, which increased the Kd for AMP from 61 μM up to 
2800 μM, nearly a 50-fold difference (Scott et al., 2004). The data generated here using 
NADPH as a readout revealed much more subtle differences in AMP binding in either the 
three aspartic acid mutants or the R298G mutation and even binding of AMP to the wild-type 
complex was much tighter with a Kd of ~4.1μM (Table 8). The D316A and R298G mutations 
did appear to slightly weaken the dissociation constants for the nucleotides tested, weakening 
AMP binding 5.8- and 1.7-fold respectively. Conversely, the mutations in the exchangeable 
binding sites appeared to slightly reduce the Kds for both AMP and ATP. Unfortunately the 
variability of these data makes it difficult to interpret definitively although it indicates that the 
differences are very subtle and do not support dramatic effects on nucleotide binding. 
However, this result does highlight the fact that in the wild-type complex chelating of ATP 
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with magnesium, as it would predominantly exist in a cellular environment, considerably 
reduced the affinity for this nucleotide at this site, increasing the Kd from ~5μM up to 
~21μM. This difference will impact upon the ability of ADP and AMP to compete with ATP 
for AMPK activation. 
These results are significantly different to that publish previously and do not correlate with 
the significant changes observed in the activity data (Scott et al., 2004). There are several 
factors to consider that could contribute to these variations. Firstly it is important to note that 
by using NADPH only one of the exchangeable binding sites will be monitored. Secondly, a 
key difference between these studies and those described previously is the nature of the 
complex in which binding was assessed. The studies carried out by Scott et al. were 
conducted on isolated CBS domains as opposed to a full-length complex, potentially 
accounting for the more severe effects due to reduced stability of the truncated complexes. 
Ideally these studies should be repeated with active, phosphorylated complexes to conclude 
whether binding is unaffected by these mutations under more physiological conditions. 
Another important factor that limits the interpretation of these binding studies is the fact that 
all of the mutations also disrupt the non-exchangeable AMP binding site, potentially 
weakening binding enough to convert this site to an exchangeable binding site. If this is true 
it is possible that mutation in one of the exchangeable binding sites may well eliminate 
nucleotide binding at that site but also could generate a new binding site at the same time, 
potentially also capable of binding NADPH. As such the only way forward to address this 
problem would be to find a method to assess binding at specific sites or to perhaps try and 
crystallise these mutations in the presence of nucleotides to try and judge if the targeted site is 
empty. 
In order to investigate the effects of these mutations under physiological conditions their 
effects were investigated in cell-based systems. Initially the non-exchangeable AMP was 
investigated as this has only been indentified in recombinant AMPK and its presence in 
mammalian-expressed AMPK had not previously been verified. The presence of a non-
exchangeable AMP in wild-type complexes following expression in mammalian cells was 
confirmed in complexes isolated from COS7 cells (Figure 3.14). Furthermore, this non-
exchangeable AMP was absent from preparations of either the aspartic acid or the R298G 
mutant complexes, as was seen with the recombinant complexes.  
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The most striking observation from these studies was the significant variation in basal 
activities of the complexes. Mutation of either of the exchangeable binding sites resulted in 
decreased basal activity whereas mutation in the non-exchangeable binding site appears to 
result in a maximally activated complex under basal conditions. This highlights a potentially 
important difference in the roles of these sites. It has previously been shown that a number of 
WPW mutations result in increased basal activities, although they were initially thought to be 
constitutively active this is now attributed to their reduced affinity for ATP (in addition to 
AMP) and this results in an overall more active AMPK complex (Arad et al., 2003; Zou et 
al., 2005). When the R298G mutation was compared to the D316A mutation in this system it 
was clear that the R298G mutation does increase the basal activity, about 6-fold higher than 
wild-type (comparable to published effects of this mutation), but it still only reaches half the 
level of activity seen with the D316A mutant complexes.  
These differences indicate that the initial in vitro characterisation of these complexes was not 
sufficient to detect subtle differences in their regulation, an important observation that must 
be taken into consideration when conducting work on recombinant proteins in vitro in the 
future. Further characterisation of these complexes revealed that the low basal activities of 
the D89A and D244A complexes were not due to reduced capacity to be activated, but also 
that the D316A was maximally activated. Further in vitro characterisation revealed that this 
effect may be due to a slight reduction in the susceptibility of D316A complexes to 
dephosphorylation and increased phosphorylation by the upstream kinases whereas the 
reduced basal activities of the D89A and D244A are due to their being slightly worse 
substrates for the upstream kinases (Figure 3.19 and Figure 3.20). These data raise a number 
of questions. Most significant is that while all three of these mutations abolish binding of the 
non-exchangeable AMP, only the D316A mutation results in the dramatic increase in T172 
phosphorylation under basal conditions. These variations could be due to the difference 
between total loss of binding at this site, in the case of the D316A, and a reduction in the 
tightness of the binding, in the case of the D89A and D244A which could just weaken 
binding at this site. Under physiological conditions there is likely to a much more complex 
balance of signals beyond just phosphorylation and dephosphorylation in addition to 
nucleotide binding contributing to these variations.  
The effects of different stimuli were also tested on these complexes in cells. As in the 
recombinant system all of the complexes examined retained activation by the A-769662 
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compound but exhibited considerable, but not complete, reduction in activation by H2O2, 
osmotic stress and metformin (Figure 3.15 and Figure 3.16). The mutant complexes were 
insensitive to allosteric activation by AMP, but despite this some still exhibited varying levels 
of activation in response to stimuli that are known to decrease ATP levels, for example, 
biguanides inhibit complex 1 of the mitochondrial respiratory chain, resulting in a decrease in 
cellular ATP (El-Mir et al., 2000; Hawley et al., 2010; Owen et al., 2000). This means that 
the activation of these complexes must be due to AMP-independent mechanisms and recent 
studies have proposed alternative mechanisms for AMPK activation by both hydrogen 
peroxide and metformin. Zmijewski et al., sought to characterise why AMPK activation was 
observed in the presence of reactive oxygen species in the absence of a decrease in cellular 
levels of ATP (Zmijewski et al., 2010). This study demonstrated that hydrogen peroxide can 
directly activate AMPK in vitro and in vivo, and it is associated with enhanced oxidative 
modification of the AMPKα subunit (cysteine residue oxidation or S-glutathionylation), 
illustrating that this mechanism could be sufficient to result in significant activation of AMP-
insensitive complexes (Zmijewski et al., 2010). However, this study does not rule out other 
side-effects that could impact on AMPK activity or address the relative importance of this 
activation under cellular conditions when alterations in the AMP/ATP ratio would also 
regulate activity. An alternative mechanism of metformin activation was also identified 
recently in a paper that showed HEK293 cells treated with this anti-diabetic compound had 
decreased PPM-like phosphatase activities (Voss et al., 2011). This indicates that metformin 
could stimulate AMPK activity not only by inhibiting mitochondrial complex I (and thus 
increasing AMP levels) as was previously described (Hawley et al., 2010) but also by 
decreasing dephosphorylation and inactivation of the complex by PPM phosphatases. 
Together these data highlight the fact that AMPK is not simply regulated by nucleotides but 
is subject to a plethora of cellular signals. 
A paper that was published during the course of this work also studied the effects of mutating 
these aspartic acids in AMPK to alanine residues (Oakhill et al., 2010). These mutations were 
generated in human γ1 and expressed and isolated from COS7 cells. Unfortunately, due to the 
fact that this study was investigating the phosphorylation of these complexes, they were first 
dephosphorylated with PP2C prior to re-activation and consequently there is no data 
presented on the basal activities of these complexes. In the study by Oakhill et al. all three 
mutant complexes have reduced allosteric activation by AMP and they also show reduced 
activation by CaMKKβ in the presence of AMP. This data mirrors that described in this 
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thesis, showing loss of regulation by AMP by all three mutant complexes and also that the 
mutations in the exchangeable binding sites had a more severe effect on regulation than that 
of the mutation in the non-exchangeable binding site. However, one difference between the 
Oakhill et al. study and the data presented here is that the basal rates of CaMKKβ 
phosphorylation of the mutant complexes are all comparable to wild-type. This variation 
could be due to a number of factors; mode of analysis (western blot versus SAMS assay), 
recombinant complexes versus mammalian expressed complexes, or the fact that these 
complexes were dephosphorylated prior to activation. Furthermore, these data only show 
phosphorylation at a single time point and CaMKKβ concentration, potentially missing subtle 
differences in their regulation as was the case in the initial characterisation in this study. 
In summary, the results presented here have shown the importance of conserved aspartic 
acids in nucleotide regulation of AMPK activity. However, it is clear that mutation of sites 
within the binding pockets do not have isolated effects, highlighted by the loss of the non-
exchangeable AMP, and as such cannot be used to delineate the roles of the different binding 
sites. Although all three mutations resulted in loss of both allosteric regulation and protection 
from dephosphorylation it cannot be concluded from these data that the different binding sites 
are not responsible for different roles. However, cell-based data has identified subtle 
differences in the basal activities between mutations in the exchangeable and non-
exchangeable binding sites. Despite this it is still not clear how these mutations, which all 
negate nucleotide regulation, alter phosphorylation levels in the α subunit. Furthermore this 
study has identified the absence of the non-exchangeable AMP from all of the WPW 
complexes that were characterised here, identifying a unifying factor despite their varied 
effects on regulation and disease progression.  
One of the most significant finding to come out of this research is the identification of 
mutations in AMPK that result in either very low or very high basal activities. As such they 
could provide a valuable research tool with which to investigate the consequences of long-
term changes in AMPK activity and the outcome of potential pharmacological manipulation 
of this pathway. The current tools available to address this problem include the constitutively 
active kinase domain, the use of which is impeded by the absence of the accessory regulatory 
subunits, potentially affecting factors such as correct localisation and target interaction. 
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4 Structural insights into the regulation of 
AMPK 
4.1 Introduction 
The central role of AMPK in regulating energy metabolism makes it a key target for 
therapeutic intervention in metabolic disease and consequently understanding its regulation 
could provide invaluable insight. Nearly 30 years ago a number of studies looking at the 
regulation of HMG-CoA reductase and ACC activity, likely to be due to AMPK activity, 
reported activation by ADP (Harwood et al., 1984; Yeh et al., 1980). However, the activating 
signal of AMPK was attributed to AMP and since then AMPK has been shown to be 
allosterically activated by this nucleotide but primarily regulated by protection against 
dephosphorylation of T172.  
Results presented in the previous section showed the effects of mutating conserved aspartic 
acid residues in each of the mammalian γ subunit nucleotide binding pockets. Unfortunately 
these studies revealed that these mutations were not only disrupting binding to the nucleotide 
with which they directly coordinate; instead they appeared to disrupt binding at all three of 
the pockets to varying extents, precluding their use to study the different roles of each 
binding site. Structures of the regulatory cores (primarily full length γ subunits and varying 
fragments from the α and β subunits) from both mammalian AMPK and yeast homologues in 
S. cerevisiae and S. pombe, have identified several nucleotide binding sites (Amodeo et al., 
2007; Jin et al., 2007; Townley and Shapiro, 2007). In particular a recent S. pombe structure 
identified two nucleotide binding sites; site-4, equivalent to the non-exchangeable AMP 
binding site in AMPK, which bound all three AXPs; and the other in site-2, the unoccupied 
site in mammalian AMPK, which only bound ADP. Further insights from these data have 
been limited by the lack of characterisation of AMPK in S. pombe. Recently some work 
conducted in our group identified a new, and potentially critical, activator of AMPK, ADP. 
Furthermore, a more complete structure of AMPK containing the majority of the α subunit, as 
well as the γ subunit, was elucidated, shedding light on potential novel modes of interaction 
within the complex. In this section the regulation of wild-type AMPK by ADP is 
characterised and the novel interactions between the different subunits investigated in order 
to try and address some of the unanswered questions outlined in chapter 3. Data presented in 
this section identifies ADP as an important physiological regulator of AMPK and also 
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delineates the functions of the nucleotide binding sites, identifying the sites responsible for 
either allosteric regulation or protection against dephosophorylation.  
4.2 Results 
4.2.1 ADP protects AMPK against dephosphorylation 
Unlike AMP, ADP had been previously shown to have no significant allosteric effect on 
AMPK isolated from rat liver, and this was confirmed using recombinant AMPK complexes 
(Figure 4.1A) (Carling et al., 1989). Under these conditions AMP shows maximal allosteric 
activation around 30 μM whereas there is no activation in the presence of ADP up to 200 μM. 
Furthermore, the presence of ADP in the allosteric assay with AMP significantly reduced its 
activation, effectively competing with AMP for this function (Figure 4.1B). Under conditions 
when the ADP concentration is double that of AMP (100 μM AMP allosteric activation in the 
presence of 200 μM ADP) any activation by AMP is eliminated. This indicates that although 
both nucleotides are likely to be binding at the site responsible for allosteric activation of the 
complex, only AMP is able to affect a response. 
Importantly however, studies in our group revealed that ADP protects AMPK from 
dephosphorylation at similar concentrations as AMP (Xiao et al., 2011). Results from my 
own work confirms this effect, shown in Figure 4.2A. Both nucleotides protect 
dephosphorylation over similar concentration ranges with the half-maximal effect of AMP at 
~10μM while ADP is slightly higher at ~20 μM although the maximum protection by both 
nucleotides is around 60%. These studies also showed that the same effect is apparent using 
AMPK purified from rat liver (Xiao et al., 2011). While Mg-ATP does not protect AMPK 
from dephosphorylation it plays an essential role in the inactivation of the complex following 
restoration of nucleotide levels by competing with AMP for binding. This mode of regulation 
is also apparent with ADP as seen in Figure 4.2B. ATP effectively competes with ADP for 
protection of dephosphorylation, almost completely eliminating the effects of 30 μM ADP at 
800 μM, indicating that the binding of Mg-ATP at this site is much weaker than that of ADP. 
This correlates with binding constants observed for ATP and Mg-ATP at one of the 
exchangeable binding sites assessed by a different technique in section 3.2.6, Table 8. 
Furthermore both AMP and ADP effects on dephosphorylation are equally disrupted by 
mutation of critical residues in the γ-subunit described in the previous section (Figure 3.9). 
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Figure 4.1 Role of ADP in allosteric activation of AMPK  
A. Recombinant AMPK complex (α1β1γ1) was phosphorylated with CaMKKβ and its
activity measured in the presence or absence of varying concentrations of AMP or ADP.
Results are the mean ± S.E.M (n=4) and are plotted as fold activation relative to the activity
in the absence of added nucleotide. This data was generated by Dr. M. J. Sanders. B.  Active
recombinant AMPK (α1β1γ1) was used in the SAMS peptide assay in the absence (Ctl) or
presence of 100μM AMP (present in all samples apart from Ctl) and increasing
concentrations of ADP (as indicated on the figure). Results are plotted as specific activity of
the AMPK complex (nmol/min/μg) and are the average ± S.E.M. for 3 independent
experiments. * indicates a statistically significant increase in treated cells relative to the
untreated control for each complex (p<0.05 with one-way ANOVA and Dunnett’s post test). 
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Figure 4.2 Role of ADP in regulation of AMPK dephosphorylation  
A. Phosphorylated AMPK was incubated at 37°C for 20 min in the presence or absence of
PP2C, and in the presence or absence of varying concentrations of AMP or ADP. The
reactions were diluted 1:40 in ice-cold buffer (50 mM Hepes, pH 7.4, 1 mM EDTA, 1 mM
dithiothreitol, 10% glycerol) and varying amounts of AMP or ADP were added to the diluted
samples to bring the final concentration of AMP and ADP to 1.5 μM in all of the samples.
AMPK activity was measured using the SAMS peptide assay. The results are plotted as a
percentage of the activity measured in the absence of PP2C. Results are the mean ± S.E.M.
for 4 independent experiments. B. AMPK was incubated at 37°C with PP2C alone or in the
presence of ADP (30 μM) alone or with increasing concentrations of ATP (as indicated on
the figure). Data shown is the average ±SEM from 4 independent experiments. * indicates a
statistically significant increase in treated cells relative to the untreated control for each
complex (p<0.05 with one-way ANOVA and Dunnett’s post test).
0 10 20 30 40 50 60
0
20
40
60
80
AMP
ADP
nucleotide (μM)
A
M
PK
 A
ct
iv
ity
(%
 n
o 
PP
2C
)
 Chapter 4 – Structural insights into the regulation of AMPK 
These data show that although only AMP is capable of allosterically activating AMPK both 
AMP and ADP are capable of protecting T172 from dephosphorylation. Regulation by these 
nucleotides appears to be equally disrupted by either competition with ATP or mutations in 
the γ subunit, indicating that they are likely to exerting their effects via a similar mechanism 
at the same binding site.  
4.2.2 AMPK has two exchangeable binding sites, one tight and 
one weak 
In order to further characterise the binding of all three nucleotides to full length, active 
(phosphorylated) AMPK, detailed binding analysis was carried out by our collaborators (see 
Appendix 4 and Appendix 5). Recombinant AMPK was stoichiometrically phosphorylated on 
T172 before re-purification of the active complex for analysis. Initial studies were conducted 
using ATP and ADP labelled with the fluorescent reporter coumarin which binds with a much 
higher affinity relative to mant adducts which had been used previously (limitations of using 
mant are discussed in section 3.2.6). Prior to characterisation, the binding of these labelled 
nucleotides compared to their unlabelled counterparts was verified by determining the crystal 
structure of the full length γ subunit with either coumarin-ADP or cold ADP, showing that 
they both make similar interactions. Binding analysis revealed that all three nucleotides bind 
to two sites on AMPK and that these two sites have very different affinities (Table 11 in 
Appendix 5). Binding at the tighter of the two sites was over 30-times stronger than the other 
site with Kds for ADP at 1.5 μM and 50 μM respectively.  
Under physiological conditions the majority of ATP will be coordinated to magnesium and 
comparison of the binding of Mg-ATP with ATP showed that it bound nearly 10-fold weaker 
when in complex with magnesium. Again this data is similar to that seen when assessing 
NADPH binding with inactive wild-type AMPK (Table 8). Furthermore, the affinity of the 
active form of AMPK for Mg-ATP was three-fold weaker than the inactive form as assessed 
by coumarin binding (data not shown). Taken together these data indicate that active AMPK 
will bind AMP and ADP with a much higher affinity than it does Mg-ATP at both of the 
binding sites. 
Comparison of this binding data with dose response curves for AMP- and ADP-mediated 
protection from dephosphorylation shows that the functional concentration ranges are 
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comparable to binding at the weaker, rather than the stronger, of the two exchangeable 
binding sites.  This phenomenon was further explored in the next section. 
 
4.2.3 NADH binds to one of the nucleotide binding sites 
As briefly discussed in section 3.2.6, NADH and NADPH competitively bind to one of the 
exchangeable nucleotide binding sites in the γ subunit of AMPK. Upon binding NADH 
undergoes a significant change in its fluorescence, allowing monitoring of competition for its 
binding with AMP, ADP or ATP (see schematic in Figure 3.12). The binding data for NADH 
to active full length AMPK is shown in Table 11. These results show that NADH competes 
with all three nucleotides at concentrations that indicate it is binding at the tighter of the two 
binding sites identified using coumarin-adducts. 
To investigate this competition on regulation of activity, NADH was included in assays for 
AMP allosteric activation or AMP/ADP protection from dephosphorylation. These data show 
there are no effects of NADH alone (at concentrations up to 1mM) on either allosteric 
activation (Figure 4.3A) or dephosphorylation (Figure 4.3B) of AMPK. Figure 4.3A shows 
that when NADH was competed with AMP for allosteric activation there was a reduction in 
activity, from a 1.9-fold activation with 10 μM AMP alone, down to a 1.3-fold activation in 
the presence of an additional 800 μM NADH. Conversely, Figure 4.3B shows no apparent 
competition of NADH with either AMP or ADP at the same concentrations in the 
dephosphorylation assay. These observations indicate that NADH, binding at the stronger of 
the two exchangeable binding sites, is capable of competing for allosteric activation of 
AMPK but not protection from dephosphorylation, providing the first evidence for 
delineation of functions of the γ subunit binding sites. Furthermore these data confirm the 
speculation that it is the weaker of the two binding sites, which does not bind NADH, which 
accounts for the protection against dephosphorylation by AMP and ADP. Interestingly this 
highlights the fact that NADH alone has no influence on AMPK activity under these 
conditions, despite its structural similarity to ADP. However, this does not rule out the 
possibility of other roles for this interaction in a cellular environment in addition to 
competing with AMP for allosteric activation.  
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Figure 4.3 Effects of NADH on allosteric activation and dephosphorylation of AMPK 
Recombinant AMPK (α1β1γ1) was activated by phosphorylation with CaMKKβ. A. Its
activity was assayed in the presence of AMP (10 μM) or NADH (800 μM) alone or in
combination. Results are plotted as specific activity (nmol/min/μg) and are the average ±
S.E.M. for 3 independent experiments. * indicates a statistically significant increase in treated
samples relative to the untreated control (p<0.05 with one-way ANOVA and Dunnett’s post
test). B. Active recombinant AMPK incubated for 20 min at 37°C with or without PP2C and
in the absence or presence of either 800 μM NADH, 10 μM AMP or 10 μM ADP alone or in
combination as indicated. After incubation samples were diluted as described in Figure 4.2
and the activity measured by SAMS peptide assay. Results are shown as AMPK (as a % of
the untreated control) and are the average ± S.E.M. for 3 independent experiments. 
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Crystallisation studies by our collaborators with NADH and AMPK were unsuccessful so in 
order to try and establish the identity of the two binding sites ADP was investigated instead. 
One molar equivalent of ADP was co-crystallised with the regulatory fragment of AMPK and 
this resulted in a structure with full occupancy of ADP at site-1 but no detectable electron 
density in site-3 (structure not shown). This disparity is likely to be due to the significant 
differences in affinity between the two sites and under conditions of limited nucleotide ADP 
bound in the tighter site, site-1. This allows the tentative assignment of the tighter allosteric 
site as site-1 and the weaker site responsible for prevention of dephosphorylation at site-3. 
This hypothesis is further investigated in the next section. 
 
 
4.2.4 Crystal structure of an active AMPK complex 
To elucidate the mechanism through which nucleotide binding at the γ subunit is conferred to 
the activation status of T172 in the kinase domain our collaborators determined the crystal 
structure of an active form of the enzyme. This structure is shown in Figure 4.4. The 
crystallised complex consists of the complete γ1 subunit, a largely intact α subunit lacking a 
loop region from the C-terminal region, and a highly truncated β subunit, summarised in 
Figure 4.4A. This complex was fully phosphorylated by CaMKKβ to activate it and ensure 
homogenous auto-phosphorylation and it was further stabilised by incubation with the kinase 
inhibitor staurosporine. This yielded a data set to 3.3Å Bragg spacing although due to the size 
some parts of the molecule are better defined than others (Figure 4.4B). 
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A. 
B. 
Figure 4.4 Crystal structure of active mammalian AMPK 
A. Schematic representation of the components of the heterotrimer; the parts of the complex
missing from the crystallized protein are depicted in grey. The domains, including the
activation loop (pink) and α-hook (dark blue), are coloured the same in both panels.  
B. Ribbon representation of the crystallized complex with two bound AMPs, staurosporine
and phospho Thr-172 shown in stick representation. The α-hook and activation loop of the
kinase domain are shown in heavier lines and coloured dark blue and pink respectively. 
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4.2.5 Stabilisation of the activation loop 
This new structure identified a number of original interactions between the different subunits 
and prompted investigation of these factors. As shown in Figure 4.5A a significant area of the 
kinase domain interacts with different regions of the complex, in particular the activation 
loop of the kinase interacts with the C-terminus of the β subunit. Unlike previous structures 
of the inactive kinase domain the activation loop with phosphorylated T172 is well ordered 
and it clearly enables this phosphorylated side chain to bind in a pocket created by other 
regions of the kinase. Under these conditions the T172 appeaers to be protected from access 
by phosphatases. 
To investigate the importance of this apparent interaction between the activation loop and the 
β subunit site-directed mutagenesis was carried out on a residue contributing to this interface 
with the kinase domain. The residue His233 (equivalent to His235 in β2) was mutated to 
alanine in a full length α1β1γ1 complex to examine its effects on stability and regulation of 
the kinase (Figure 4.5A). Results in Figure 4.5B show that mutation of this residue results in 
a complex that is more susceptible to dephosphorylation, inactivating at a more rapid rate 
than that seen in wild-type complexes. However, this mutation did not disrupt nucleotide 
regulation and there is a reduction in the rate of dephosphorylation in the presence of fixed 
concentrations of AMP, ADP or A-769662 (Figure 4.5C). Interestingly, mutation of an 
equivalent neighbouring histidine residue in SNF1 (the S. cerevisiae AMPK homologue) 
significantly reduced the activity of the complex independently of activation loop 
phosphorylation (Figure 5.13). These data indicate an important role for this interaction 
between the β subunit and the activation loop in the stabilisation of the active conformation 
of the complex, with an inaccessible T172. The impact of this interface on activity is 
enhanced by nucleotide binding and it is likely to play an important role in stabilising the 
activation loop not only such that T172 is inaccessible to phosphatases, but also to maintain 
the kinase domain’s activity.  
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Figure 4.5 Analysis of the β subunit interaction with the T-loop in AMPK regulation  
A. The interface between the activation loop and the regulatory fragment of the β subunit are
shown in more detail in a similar orientation as the complete structure, potential electrostatic
interactions are indicated by dashed lines with residues of interest highlighted. 
B. Phosphorylated AMPK (α1β1γ1) wild-type (WT) or β His-233 to alanine mutant (H233A,
corresponding to H235A in β2) were incubated at 37ºC in the presence of PP2C for various
time points. An aliquot of this reaction was diluted into a SAMS assay and activity of the
AMPK determined. C. WT or H233A mutant complexes were incubated with PP2C in the
presence or absence of AMP (30 μM) or ADP (30 μM). Following incubation for 5 min at
37°C the samples were diluted 1:40 in ice-cold buffer supplemented to a final concentration
of 0.75 μM in all of the samples (as previously described). AMPK activity was measured
using the SAMS peptide assay and the results are plotted as a percentage of the activity
measured in the absence of PP2C. Data shown is the average ± S.E.M. from ≥3 independent
experiments.   
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4.2.6 Interaction of the α and γ subunits 
A second component in the α subunit that appears to be responsible for interaction with other 
subunits is part of the segment linking the N-terminal kinase domain to the C-terminal 
regulatory fragment between residues α373 and α382. This region forms a hook structure, 
termed the ‘α-hook’, which appears to interact with one of the exchangeable nucleotide 
binding sites, site-3, on the γ subunit (highlighted in Figure 4.6A). In this structure AMP is 
bound in this site, proposed to be the weaker of the two sites, and the hook appears to make a 
lid over the binding site. Although this structure only shows AMP bound at this and the non-
exchangeable AMP site, higher concentrations in the crystallisation process yielded data with 
site-1 also occupied. This discrepancy is likely to be due to the increased protection afforded 
to the nucleotide in site-3 due to the α-hook region. This structural data suggests a role for the 
α-hook in transduction of the nucleotide signal from the γ to α subunit.  
To test this and the hypothesis that site-3, and consequently the α-hook, is the site responsible 
for regulation of dephosphorylation, a series of mutations in this region were generated. Poor 
resolution of this region of the structure prevented identification of the precise residues 
interacting with the γ subunit so in an otherwise complete α1β1γ1 complex four residues, 
R375Q, T377A, D380A and E381A, within α1 were mutated and the complex expressed and 
phosphorylated by CaMKKβ. The results shown in Figure 4.6B firstly show that the resulting 
enzyme was still allosterically activated by AMP and the AMPK activator A-769662, both 
~1.6-fold, only slightly lower than the 2-fold seen with wild-type AMPK. Conversely this 
complex was not subject to protection against dephosphorylation by either AMP or ADP 
(Figure 4.6C) although it did retain significant protection with the A-769662 compound, 
indicating that the complex was capable of regulation in this manner.  
Thus mutations in this hook region of AMPK α only appear to disrupt nucleotide regulation 
of dephosphorylation, leaving either the allosteric or A-769662-mediated regulation intact. 
This is the first evidence of separate functions of the nucleotide binding sites and further 
evidence of the differences in the modes of activation between nucleotides and the A-769662 
compound. 
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A. The interface between the α-hook region and one of the AMP-binding sites in the γ subunit
is shown in more detail in two orientations and in close-up with residues of interest
highlighted. Phosphorylated wild-type (WT) α1β1γ1 or mutant AMPK (harboring mutation of
residues R375Q, T377A, D380A and E381A within α1) were activated by phosphorylation
with CaMKKβ. B. Allosteric activation was determined in the presence of absence of 10μM
AMP or A-769662 by the SAMS peptide assay. Results are plotted as the fold activation by
AMP (mean ± S.E.M. of three independent experiments). C. Aliquots of active AMPK were
incubated for 20 min at 37ºC with PP2C in the presence or absence of AMP (30μM), ADP
(30μM) or A-769662 (5μM). Samples were diluted and assayed as in Figure 4.5. Data shown
is the average ± S.E.M. from three independent experiments. 
Figure 4.6 Mutational analysis of α subunit interaction with the AMP-binding pocket in
AMPK regulation  
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4.3 Discussion 
Given the limitations of using mutations to investigate the roles of each nucleotide binding 
site discussed in the previous chapter, a way to investigate regulation of wild-type AMPK 
had to be addressed. Around this time the observation was made in our group that ADP, like 
AMP, was capable of protecting T172 from dephosphorylation but did not have any allosteric 
effect. This provided a potential avenue down which to investigate the differing roles of the 
binding sites and to ascertain if the different binding sites were responsible for either 
allosteric activation or prevention from dephosphorylation or both. Consequently the 
biochemical studies described in this chapter were conducted alongside our collaborators who 
investigated nucleotide binding to the active AMPK complex and carried out crystallisation 
studies.  
In this chapter I have presented evidence illustrating a new role of ADP in AMPK regulation 
under physiological conditions and, using insights from a new structure of AMPK, identified 
unique regulatory mechanisms of both T172 phosphorylation and nucleotide regulation. 
Furthermore, these data indicate separate roles for the exchangeable binding sites with one 
responsible for allosteric activation and the other for the regulation of dephosphorylation.  
Although ADP was in fact likely to have been the first activator of AMPK to be identified it 
was concluded at the time that the activation was caused by contaminating AMP. Since then 
AMPK has been characterised by its allosteric activation by AMP and, as it does not have 
this effect, ADP has been largely overlooked until now. These data confirm that ADP is not 
capable of allosteric activation of recombinant AMPK complexes, even at very high 
concentrations (Figure 4.1A). However, ADP is clearly capable of protecting AMPK from 
dephosphorylation over a similar concentration range as AMP (Figure 4.1B). Data from the 
previous chapter also showed that mutations that disrupt AMP protection of 
dephosphorylation equally affect ADP regulation (Figure 3.9).  
It is known that Mg-ATP alone has no effect on AMPK activity and it has been shown that 
high concentrations of ATP antagonise allosteric activation by AMP by competing for 
binding at the regulatory site (Corton et al., 1995). Consequently ATP plays an important role 
in regulation by competing with AMP for its binding and activation, a mechanism that is 
apparent with both the allosteric and dephosphorylation effects, thus promoting the 
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inactivation of the complex when in excess. This mode of regulation is also apparent with 
ADP and ATP effectively competes for its protection from dephosphorylation (Figure 4.2B). 
Interestingly, high concentrations of ADP compete with AMP for its allosteric activation of 
AMPK, indicating that despite its lack of regulatory action at this site ADP is still capable of 
binding (Figure 4.1B). These data indicate that the rate of AMPK inactivation will be 
dependent on the balance of these three nucleotides with a dynamic equilibrium accounting 
for variations in the rate of dephosphorylation (or allosteric activation). 
Nearly all previous studies have focussed on AMP regulation of AMPK and a range of 
theories have been proposed to account for the apparent disparity between the balance of 
nucleotides and AMP’s ability to activate the enzyme. Absolute levels of nucleotides in 
mammalian cells are likely to be cell type and compartment dependent and there is significant 
variation in data collected by different methods. Typical concentrations of free nucleotides 
are 3000-8000μM for ATP, 50-200μM for ADP and 0.5-5μM AMP (Chen et al., 2000; 
Hellsten et al., 1999; McConell et al., 2005; Moyer and Henderson, 1985; Veech et al., 1979). 
When considering these values it is important to note that although the free concentrations of 
the nucleotides were calculated based on estimates from the creatine kinase (or similar) 
equilibria reactions many of these measurements were made from human biopsies and as 
such may be less accurate than cell-based measurements (Kennedy et al., 1999). Despite this, 
it is difficult to imagine a situation when the levels of AMP would reach levels that would 
effectively compete with ATP. Although the actions of adenylate kinase in the cell which, 
when at equilibrium cause the AMP:ATP ratio to vary as the square of the ADP:ATP ratio, 
resulting in dramatic variation in AMP concentrations following stress, it is still clear that at 
any one time AMP would activate only a tiny pool of the available AMPK (Hardie and 
Hawley, 2001). Since the free concentration of ADP (depending on cell type) is 10- to 400- 
fold higher than that of AMP, ADP will be more successful at competing with Mg-ATP in 
spite of the actions of adenylate kinase. Therefore, the fact that ADP protects AMPK from 
dephosphorylation is likely to represent an important physiological mechanism for its 
regulation. 
Given that all three of the nucleotides appear to bind at the same sites, illustrated by the 
competition between AMP and ADP or ATP for allosteric activation or between ATP and the 
other two nucleotides for dephosphorylation, our collaborators undertook binding studies on 
full length, active (phosphorylated) AMPK. These studies were carried out using either 
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coumarin-labelled ADP or ATP, which had been verified to bind at the exchangeable binding 
sites in a similar manner to unlabelled nucleotides, or using NADH. Several studies 
previously had identified binding at two exchangeable sites in either the phosphorylated or 
non-phosphorylated forms and this was verified with the coumarin studies (Scott et al., 2004; 
Xiao et al., 2007). These results showed a striking 30-fold difference in the binding affinities 
of the two sites as had been hypothesised from preliminary mant-nucleotide studies described 
in the previous results chapter. As was illustrated in the binding studies in the previous 
chapter the formation of the Mg-ATP complex significantly weakens the affinity of the 
nucleotide at both binding sites, an effect that is accentuated in the active complex. This 
indicates that active AMPK preferentially binds to AMP/ADP over Mg-ATP at both of these 
exchangeable binding sites. 
These data also showed that NADH and NADPH bind to AMPK, as was briefly highlighted 
in the previous chapter. NADH (and NADPH) is essentially an ADP molecule bound to 
nicotinamide and they were found to bind a single site on AMPK and compete with 
nucleotides for binding at one of the exchangeable sites. Interestingly binding of NAD+ and 
NADP+ to the AMPK complex was barely detectable, indicating a degree of specificity for 
the reduced forms of the cofactor. Analysis of NADH and nucleotide competition in the 
binding assay revealed binding constants for the nucleotides that closely correlate with the 
values of the tighter binding site, indicating that this is where NADH binds.  
Rafaeloff-Phail et al. studied the effects of NAD+ and NADH on allosteric activation of 
AMPK and showed data indicating that NAD+ appeared to activate AMPK whereas NADH 
had the opposite effect (Rafaeloff-Phail et al., 2004). However, a subsequent study showed 
that commercial preparations of NAD+ were contaminated with AMP, and further 
purification by HPLC was used to show that neither NAD+ nor NADH had any direct effect 
on AMPK activity at concentrations up to 300 μM (Suter et al., 2006). Since NAD+ does not 
appear to bind AMPK and due to its relative instability resulting in AMP generation we 
decided to only clarify the biochemical effects of the interaction between NADH and AMPK. 
NADH was tested over a range of concentrations in either the allosteric or dephosphorylation 
assay but there was no evidence of it having any direct effects on AMPK activity, correlating 
with the data presented by Suter et al. (Suter et al., 2006). When the dephosphorylation assay 
was repeated with either ADP or AMP in the presence of high concentrations of NADH there 
was also no indication of any competition for this regulation. However, when NADH was 
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included in an assay for the allosteric activation by AMP there was a marked reduction in this 
activation, indicating that NADH, like ADP and ATP, is capable of competing at this site. 
However, it is unlikely that NADH would be bound at this site under basal conditions as it 
binds much more weakly than AXPs (NADH Kd ~ 65μM versus ~1.5μM for nucleotides) and 
only under conditions when it was elevated would it be able to displace any bound 
nucleotide. This observation indicated that since NADH only binds at the tighter of the two 
exchangeable binding sites, and it also only competes for allosteric activation of the enzyme, 
that this site is responsible for allosteric activation alone and the weaker exchangeable site is 
responsible for prevention of dephosphorylation. Further crystallisation experiments on the 
regulatory fragment of AMPK with one molar equivalent revealed nucleotide bound at site-1 
but no detectable density at site-3, indicating that this is likely to be the tighter of the two 
binding sites. This designation concurred with the preliminary mant-binding data described in 
the previous chapter which indicated that binding at the D244A site (site-3) was weak in 
comparison to the D89A site (site-1). Therefore each of the binding sites could tentatively be 
assigned; site-1 as the tighter binding site, responsible for allosteric activation by AMP and 
NADH binding and site-3 as the weaker binding site responsible for protection from 
dephosphorylation by AMP and ADP. 
The novel finding that NADH not only binds to AMPK but also competes with AMP for 
allosteric activation identifies a potentially important link between this cofactor and 
regulation of AMPK activity. NADH plays an essential role in energy production in the cell 
and NADH produced during glycolysis and the citric acid cycle goes on to be used to 
generate ATP. The NAD+/NADH ratio is an essential component of the redox state of a cell 
which affects the metabolic state and health of the cell, not only acting as a coenzyme in 
redox reactions but also controlling the activity of several key enzymes and acting as an 
ADP-ribose donor in ADP-ribosylation reactions and generating cyclic ADP-ribose 
(reviewed in Belenky et al., 2007; Lin and Guarente, 2003). In order to maintain this ratio to 
favour oxidative reaction NADH can be converted into NADPH which is about 10-times less 
abundant in cells and acts as a coenzyme for biosynthetic pathways including cholesterol 
synthesis.  
Recently there has been growing interest in the link between AMPK and sirtuins, NAD+-
dependent histone/protein deacetylases, which have also been termed ‘fuel-sensors’ and 
detect variations in nutrient availability and expenditure due to changes in the NAD+/NADH 
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ratio (Kelly, 2010a; Kelly, 2010b). Consequently both AMPK and SIRT1, the best 
characterised of the sirtuins, detect changes in energy availability and mediate biological 
responses in cells via changes in metabolism and gene expression, often sharing common 
downstream targets (reviewed in Ruderman et al., 2010). However, there is some debate as to 
whether AMPK regulates SIRT1 or vice versa (reviewed in Fulco and Sartorelli, 2008). One 
of the first papers to highlight a potential link showed that under high glucose conditions in 
rat muscle there is a decrease in AMPK activity, in the absence of a change in the energy 
state of the cell, and this correlated with a decrease in the NAD+/NADH ratio and SIRT1 
activity, an effect that was subsequently illustrated in HepG2 cells (Itani et al., 2003; 
Suchankova et al., 2009; Zang et al., 2004). Subsequently numerous studies have shown both 
correlating and opposing activities of AMPK and SIRT1 and it remains unclear whether 
SIRT1 is a positive or negative regulator of AMPK (Fulco et al., 2008; Hou et al., 2008; 
Narala et al., 2008; To et al., 2007). Interestingly several studies propose that SIRT1 
regulates AMPK by deacetylating LKB1 either playing a role in determining its localisation 
or ubiquitination and turnover (Lan et al., 2008; Zu et al., 2010). Conversely, several studies 
have shown that treatment with AMPK activators results in increased NAD+/NADH ratios, as 
well as increased transcription of Nampt by AMPK which also leads to increased NAD+ 
levels and SIRT1 activation (Canto et al., 2009; Fulco et al., 2008). 
Together these data indicate that depending on the stimulus and target tissue AMPK and 
SIRT1 display different regulatory functions and the balance of ATP and NAD+ sensing in 
the cell could result in different stress responses. Recently a model of coordinated and 
sequential actions of AMPK and SIRT1 was proposed by Canto et al., suggesting that AMPK 
could play a role in targeting SIRT1 deacetylation by first phosphorylating substrates (Canto 
and Auwerx, 2009). Taken together these findings indicate that a common regulator of 
AMPK and SIRT1 activity could play an important role in the modulation of this pathway. 
NADH, in addition to competing for allosteric activation of AMPK, has also been shown to 
inhibit SIRT1 activity, making it a likely candidate for linking these regulatory pathways 
(Chaudhary and Pfluger, 2009; Hayashida et al., 2010). 
The crystal structure of a more complete AMPK complex has also helped dissect the 
relationship between the binding sites and regulation of activity. An AMPK complex 
consisting of nearly the full length α subunit (lacking a disordered loop region), a short 
scaffold region of the β subunit and the complete γ subunit was crystallised and this identified 
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several unique interactions between the different subunits. This structure enabled 
investigation of the putative ‘auto-inhibitory’ domain. This region has been characterised 
predominantly in yeast and is a short sequence in the α subunit (residues α300-330 in S. 
pombe) has been shown to inhibit the complex and exert an auto-inhibitory function, although 
the helical structure of this region does not appear to be conserved between truncated kinase 
domains of S. pombe and S. cerevisiae (Chen et al., 2009; Littler et al., 2010). Other groups 
have investigated the role of this region in AMPK regulation. Studies on truncated α subunits 
have shown that the presence of this region reduces AMPK activity of the isolated kinase 
domain, although what implication this has on regulation of a full length complex remains 
unclear (Goransson et al., 2007; Pang et al., 2007). The structure of the active AMPK shown 
in Figure 4.4 does not retain a region correlating to this proposed auto-inhibitory helix, 
although this does not rule out a role for this region in regulation of either the inactive 
complex or the isolated α subunit. It is also feasible that under conditions that favour 
inactivation of the complex the linker region between the kinase domain and the C-terminal 
region could form a structure that could mediate an auto-inhibitory function. Comparison of 
the structure of the kinase domain of this active structure with a previously published isolated 
unphosphorylated kinase domain shows that the small lobe of the kinase domain is in a 
closed conformation, usually required for kinase function (Johnson et al., 1996; Littler et al., 
2010). 
This new structure also highlighted a considerable interaction between the well ordered 
activation loop of the kinase domain and the C-terminus of the β subunit. The T-loop region 
surrounding the phosphorylated T172 binds in a pocket and in this conformation this 
threonine appears to be protected from access by phosphatases. The ability of this interaction 
to stabilise the activation loop and prevent its dephosphorylation was investigated by 
mutagenesis of one of the interacting residues present in the β subunit, β1 His233. This 
disruption of the interface resulted in an AMPK complex that was more readily 
dephosphorylated but did not appear to impact significantly on the ability of nucleotides (or 
A-769662) to reduce the rate of dephosphorylation. Given that this mutation probably only 
weakens the interaction between the kinase domain and the regulatory β fragment, it is not 
surprising that ADP binding is still able to stabilise this interaction. This interaction between 
the kinase loop and the β subunit appears to play an important role in the protection of the 
T172 against dephosphorylation and may be involved in translation of the nucleotide signal 
in the regulation of AMPK activity.  
152 
 
 Chapter 4 – Structural insights into the regulation of AMPK 
153 
 
A. B. 
P 
1 2
34
β
α
α 
Weak Binding site 
Non-exchangeable 
AMP 
dephosphorylation 
AMP, ADP, ATP 
Tight Binding site
allosteric effect 
AMP, ADP, ATP, 
NADH
C. 
LKB1/CaMKKβ 
PPase 
↑ADP/AMP 
↑ATP 
P 
? 
AMP AMP AMP 
ATP 
ATP 
ATP 
ATP 
AMP/ 
ADP 
AMP/ 
ADP 
Maximally 
active 
Partially 
active Inactive 
Figure 4.7 Model for the regulation of AMPK activity by nucleotides 
A. Schematic representation of the components of the heterotrimer. The domains, including
the activation loop (pink) and α-hook (dark blue), are coloured the same in all panels. 
B. Schematic diagram of the location of each of the subunits in the crystal structure with the
location and roles and binding partners of each of the binding sites in the γ subunit identified.
C. The left panel represents the inactive complex without phosphorylation of T172 and with
ATP bound in the exchangeable sites of the γ subunit. In this form the T-loop region is
accessible to phosphorylation by upstream kinases. This allows the kinase domain to
interaction with the regulatory β subunit and slightly stabilise the active conformation
(middle panel). The weak nature of this interaction means that it will be transient and the
T172 is still accessible for dephosphorylation by phosphatases. The panel on the right shows
that under conditions when AMP or ADP increase and these nucleotides occupy site-3, as
shown occupied by ADP, and the absence of the γ-phosphate of ATP allows interaction with
the α-hook, increasing the stability of the interaction of the T-loop with the regulation region
and reducing the rate of dephosphorylation. AMP bound to site-1 allosterically activates the
complex via an unknown mechanism (indicated by the ?). 
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A second inter-subunit interaction was identified from this structure between a section of the 
α subunit which links the N-terminal kinase domain to the C-terminal regulatory fragment 
and a nucleotide binding pocket in the γ subunit. This region, residues α1 373-382, is largely 
conserved between the two α isoforms and it appears to form a loop structure, termed the ‘α-
hook’, which interacts with the exchangeable binding site-3 when AMP is bound, forming a 
lid over this nucleotide. This binding site had been tentatively assigned as the weaker of the 
two exchangeable binding sites that is responsible for protection from dephosphorylation. 
Although the crystal structure shown in Figure 4.4 only shows one nucleotide bound higher 
concentrations of the nucleotides during crystallisation resulted in good occupancy of site-1. 
Comparison of the nucleotide binding site when an AMP is interacting with the α-hook with 
the binding site when Mg-ATP is bound (structures obtained with the isolated regulatory 
fragment) indicates that the hook cannot interact with site-3 when Mg-ATP is present; this is 
due to a change in the conformation of γ1 Arg-69 which would cause a steric clash. In order 
to investigate if the role of the hook region was involved in nucleotide regulation a mutant of 
this region (R375Q, T377A, D380A, and E381A) was generated and its regulation assessed. 
The resulting complex retained allosteric activation by AMP but was not protected from 
dephosphorylation by either AMP or ADP (Figure 4.6). The integrity of this complex was 
verified by the fact that A-679662 was still capable of protecting it from dephosphorylation 
as well as allosteric activation.  
Taking into consideration both the functional data presented here and the structural data 
generated by our collaborators this study allows the proposal of a new model of AMPK 
regulation (summarised in Figure 4.7). This study illustrates that both AMP and ADP are 
capable of reducing the rate of T172 dephosphorylation through binding to the weaker of the 
two exchangeable binding sites, identified as site-3. This regulation is affected by interaction 
with the α-hook region in the presence of either of these nucleotides, but not Mg-ATP, which 
could stabilise this region and promote the interaction between the kinase domain and the 
regulatory fragment. This interaction, predominantly between the activation loop and the β 
subunit, acts to protect this region from dephosphorylation. Since the interactions described 
here are relatively small it is likely that in solution this would be a dynamic, interchangeable 
interaction with AMP/ADP favouring a protected conformation whereas Mg-ATP would 
favour the less stable exposed conformation. The second, tighter, exchangeable binding site 
would modulate allosteric activation by AMP although the studies shown here do not reveal a 
mechanism through which this activation is mediated. Given the competition for AMP 
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regulation at this site not only by ATP but also ADP and NADH, it is perhaps likely that 
AMPK would be subject to very limited allosteric activation under normal physiological 
conditions. This mode of activation could function as a ‘last resort’ to activate AMPK up to a 
further 2-5-fold when AMP levels are high. 
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5 Investigating the regulation of SNF1 
5.1 Introduction 
SNF1 is the S. cerevisiae homologue of AMPK and a significant amount of research has 
pursued the roles and regulation of this complex under conditions of glucose limitation when 
the complex is activated (see section 1.2.2). Despite yielding may critical insights into 
regulation of the AMPK family critical factors in its regulation remain a mystery. 
SNF1, like AMPK, also exists as a heterotrimeric complex, activated by phosphorylation of a 
threonine residue in the activation loop of the kinase domain. When yeast undergo stress 
following transfer to a less favourable carbon course SNF1 is essential for adaption and 
survival to occur. When this close homology between AMPK and SNF1 was first discovered 
it was thought that the regulatory mechanisms by AMP would also be conserved. However, it 
was found that SNF1 is not regulated by AMP, despite a correlation between its activity and 
AMP levels (Wilson et al., 1996). The recent determination of the Snf4 (γ) subunit structures 
of SNF1 from both S. cerevisiae and S. pombe further emphasises the structural conservation 
between these species and also illustrates that both homologues are capable of binding 
nucleotides (Figure 5.15) (Amodeo et al., 2007; Jin et al., 2007; Townley and Shapiro, 2007). 
Despite these findings the trigger for SNF1 activation following glucose depletion remained 
elusive. 
Recently our group showed that AMPK activity is regulated by ADP, discussed in chapter 4, 
and this prompted an investigation into whether ADP could be the elusive signal activating 
SNF1. In this chapter the regulation of SNF1 is investigated and evidence is presented that 
SNF1 is activated by ADP which binds to the Snf4 (γ) subunit at two key exchangeable sites, 
preventing dephosphorylation of T210. The nature of this regulation is investigated and 
parallels with the regulation of AMPK are highlighted. 
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5.2 Results 
5.2.1 Activation of SNF1 by nucleotides 
For these studies recombinant heterotrimeric SNF1 complexes (Snf1, Gal83, Snf4, unless 
otherwise stated, which represents the predominant form of SNF1 in vivo) were expressed 
and purified from E. coli using the endogenous 13-His sequence at the N-terminal of the Snf1 
subunit (see schematic in Figure 1.12). The close functional conservation between AMPK 
and SNF1 is emphasised by the cross-species functionality between the yeast and mammalian 
upstream kinases and phosphatases (Hong et al., 2005; Woods et al., 2005). This allows the 
activation of recombinant SNF1 complexes by CaMKKβ phosphorylation of T210. Figure 
5.1 shows the 100-fold activation of SNF1, and the accompanying phosphorylation of T210, 
following incubation with the mammalian kinase. This shows that, like AMPK, SNF1 is 
expressed as an inactive heterotrimer and in the presence of mammalian CaMKKβ it is 
phosphorylation on T210 and activated, consistent with a previous study (Sanders et al., 
2007b).  
A study investigating the regulation of AMPK by AMP also looked at the role of this 
nucleotide in SNF1 regulation on both allosteric activity and on protection from 
dephosphorylation (Sanders et al., 2007b). As was shown in this and other studies AMP had 
no effect on allosteric activation as judged by SAMS peptide assay, as did ADP or ATP (see 
Appendix 6). However, little work has been conducted on the regulation of 
dephosphorylation of SNF1 using the techniques described in this thesis. Although the 
Sanders et al. paper (Sanders et al., 2007b) had investigated the role of AMP in SNF1 
dephosphorylation only a single concentration was tested so for this study a wider range of 
nucleotide concentrations were investigated. This is especially important as AMP and ADP 
concentrations in yeast are thought to be much higher than in mammalian cells (discussed in 
section 5.3).  
In order to assess dephosphorylation of SNF1 the complexes were first activated by 
CaMKKβ and subsequently incubated in the presence of the mammalian phosphatase PP2C 
in the presence or absence of the molecule of interest. Residual activity following 
dephosphorylation was judged either by Western blotting for T210 phosphorylation or 
assessing activity levels in the SAMS peptide assay. The data in Figure 5.2 clearly shows that  
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Figure 5.1 Expression and activation of recombinant SNF1 
Recombinant SNF1 (Snf1, Gal83, Snf4) was expressed and purified from whole cell extract
of E. coli by Ni2+-sepharose affinity chromatography the protein was concentrated.  
A. The purified protein was resolved on a 12% SDS-PAGE Novex gel and stained with
Simply Blue stain. The molecular weight markers are indicated on the left (kDa) and the
identity of the bands is indicated on the right. Dashed line indicates intervening lanes have
been removed. 
B. Recombinant SNF1 was incubated in the presence or absence of CaMKKβ for 20 min at
37°C and an aliquot of this was assayed for activity in the SAMS peptide assay. Activities are
given as mean specific activity (nmol/min/mg)(± S.E.M., n=3 independent experiments). An
aliquot of the reaction described above was used to assess the level of T210 phosphorylation
by western blot analysis with anti-phospho-T172 (to detect P-T210 in Snf1) and anti-His
antibodies (to detect total Snf1). * Indicates a significant increase in activation with
CaMKKβ relative to the unincubated control as judged by a student’s t-test (P<0.05). 
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Recombinant SNF1 (snf1, gal83, snf4) was phosphorylated by CaMKKβ for 20 min at 37°C
and aliquots were removed and incubated in the presence or absence of PP2C, and varying
concentrations (30, 100, 300, 500, 800, 1000 or 1500 μM) of either AMP, ADP or ATP for a
further 10 min at 37°C. Results shown are the mean ratio of P-T210:total Snf1 (±S.E.M., of
four independent experiments) and are plotted as a percentage of the positive control (in the
absence of PP2C) with representative P-T210 blots for each of the nucleotides and an
example loading control (total His-Snf1). * indicates a statistically significant increase in
treated cells relative to the untreated control (0 μM nucleotide) for each complex (p<0.05
with one-way ANOVA and Dunnett’s post test). 
Figure 5.2 Effects of varying concentrations of nucleotides on dephosphorylation of
SNF1 
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incubation of active SNF1 with PP2C in the presence of increasing concentrations of ADP, 
but not AMP or ATP, significantly protected T210 from dephosphorylation. These data show 
that the half-maximal effect of ADP is relatively high, >500 μM, when compared with 
AMPK (~10-20 µM, Figure 4.2). This effect plateaus at around 50% protection of the T210 
signal at high ADP concentrations, indicating a significant effect on the activity of the 
complex under these conditions. This effect was further characterised in a time course 
experiment. ADP protection of T210 is apparent over the range of time points tested when 
dephosphorylated in the presence of a constant ADP concentration of 800 μM (Figure 5.3), 
consistently about 20% higher signal over the linear range. Data for AMP (not shown) again 
was no different to control data. 
 
5.2.2 Characterisation of the ADP effect 
To determine if the effects of ADP are unique to SNF1 complexes containing the Gal83 
isoform as the β subunit, SNF1 complexes containing the Sip2 isoform (with a short N-
terminal truncation) were compared. Unfortunately complexes containing the Sip1 subunit 
were not stable and could not be used for comparison. Figure 5.4 shows the comparison of 
these complexes on both dephosphorylation and protection by ADP. Both the Gal83- and 
Sip2- containing complexes are dephosphorylated to comparable levels, ~20% P-T210 
relative to the untreated control, and furthermore ADP produces an almost identical degree of 
protection for either of these β isoforms, increasing P-T210 to ~57%.  This finding strongly 
indicates that ADP protection of T210 dephosphorylation is independent of the β subunit 
present in the complex. Furthermore, the extent of dephosphorylation of T210 also appears to 
be very similar for both complexes, indicating that this too occurs independently of the 
complex isoform under the conditions tested in this assay. This was further characterised by 
assessing the dephosphorylation of the Sip2-containing complexes over a range of ADP or 
AMP concentrations which closely mirrors data seen with Gal83 complexes (Appendix 7). 
Crystal structures of yeast SNF1 have highlighted interactions between the β and γ subunits 
which could be important to complex stability and/or transduction of the glucose signal. In 
order to investigate the importance of different functional domains of SNF1 in its regulation 
recombinant complexes were expressed with either truncation of the β subunit such that the 
GBD was absent or mutation of an ATP-binding residue (D194A) in the Snf1 kinase domain  
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Figure 5.3 Time course of SNF1 T210 dephosphorylation in the presence or absence of
ADP 
Full length recombinant SNF1 complex (Snf1, Gal83, Snf4) was activated by incubation with
CaMKKβ for 20 min at 37°C and aliquots incubated with PP2C in the presence or absence of
ADP (800 μM) for varying periods of time. The level of T210 phosphorylation was
determined by western blot analysis. Intensity of P-T210 signal was quantitated relative to the
total Snf1 signal and expressed as a percentage of the 0 min time point. The graphed results
are the mean ± S.E.M., n>3 independent experiments. Representative P-T210 blots either in
the absence or presence of 800 μM ADP are shown with an example loading control (total
His-Snf1). Data for AMP (800 µM) (not shown) overlays that of the control timecourse. 
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which eliminates kinase activity of the complex. Both of these complexes were 
dephosphorylated to levels comparable to that seen with the wild-type full length complexes 
in the assay, retaining about 20% phosphorylation under the conditions tested. Truncation 
analysis of the GBD in Sip2-containing complexes revealed a complete loss of protection by 
ADP, an effect that was also seen following loss of kinase activity (Figure 5.4). Disruption of 
SNF1 regulation by these structural and functional alterations is also seen following similar 
alterations to AMPK (unpublished communication by M. J. Sanders). This dramatic effect on 
SNF1 regulation highlights the importance of both the GBD and kinase activity upon 
nucleotide regulation, not only of SNF1 but also mammalian AMPK. Although these two 
alterations both result in the same loss of regulation it is not clear from these data if this is 
due to disruption of the same mechanism or due to completely separate effects. One factor 
that could potentially account for this effect could be loss of auto-phosphorylation as a result 
of no kinase activity, in the case of the kinase dead mutant, or the loss of the β subunit where 
many sites are known to be located. Some of the auto-phosphorylation sites in the β subunit 
N-terminal region have been proposed to play a role in AMPK regulation although as yet 
little is known of their role in SNF1 regulation.  
Finally, mutagenesis was conducted on the Snf4 subunit to try and identify the CBS domain 
responsible for ADP binding and regulation. In AMPK it was found that loss of highly 
conserved aspartic acids present in the three CBS domains capable of binding nucleotides, or 
WPW mutations, resulted in loss of protection from dephosphorylation by both AMP and 
ADP (see section 3.2.4). These aspartic acids are conserved in yeast (see Figure 3.1A) and 
site-directed mutagenesis was used to generate these mutations in Snf4. The Western blots 
and graph in Figure 5.5A show the effects of mutation of the Snf4 aspartic acid residues, 
D83, D240 and D312 to an alanine or the WPW mutation R294G (equivalent to the R531G in 
human γ2), on ADP regulation. These data show that some of these mutations appear to 
effect stability or activity of the complex, such as the low expression of the D83A complexes 
or the low level of T210 phosphorylation of the D240A complex prior to dephosphorylation. 
Despite these effects on basal activities none of these mutations abolished protection of T210 
dephosphorylation by ADP. This is consistent with work carried out using growth assays 
showing that a number of WPW mutations do not significantly disrupt the yeasts ability to 
adapt to alternative carbon sources (Momcilovic et al., 2008). This negative result suggests 
that either the residues selected for mutagenesis do not make an essential contribution to 
nucleotide regulation as seen with AMPK or regulation occurs in site-2 which lacks a 
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Recombinant proteins were expressed of the following complexes: full length SNF1 (Snf1,
Gal83, Snf4); complexes with a truncated N-terminus of the β subunit (Snf1, Sip2154-415,
Snf4); complexes lacking the GBD of the β subunit (Snf1, Sip2296-415, Snf4); and a full length
complex (Snf1, Gal83, Snf4) harbouring the D194A mutation in the ATP-binding pocket of
the kinase domain. Complexes were activated with CaMKKβ for 20 min at 37°C before
incubation with or without PP2C and 800 μM ADP for a further 10 min. Reactions were
terminated by addition of sample buffer and the phosphorylation status determined by
western blot analysis. The bar chart shows the protection relative to the positive control for
each complex as the mean ± S.E.M. for four independent experiments with a representative
blot. * Indicates a significant difference in T210 phosphorylation with 800 μM ADP relative
to the –ADP sample as judged by a student’s t-test (P<0.05). 
Figure 5.4 ADP protection of dephosphorylation of SNF1 complexes 
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Figure 5.5 Effects of mutations in the Snf4 subunit on ADP regulation 
A. Since mutation of conserved aspartic acids were shown to have functional effects in
AMPK the equivalent mutations were made in SNF1 (an amino acid alignment of Snf4 and
AMPKγ with these residues highlighted is shown in Figure 3.1A). Recombinant WT SNF1
(Snf1, Gal83, Snf4) and SNF1 harbouring mutations in the Snf4 subunit as indicated were
expressed and activated as previously described. Aliquots were incubated with or without
PP2C and 800μM ADP for 10 min at 37°C. Reactions were terminated by addition of sample
buffer and the phosphorylation status determined by Western blot analysis. The bar chart
shows the protection relative to the positive control for each complex as the mean ± S.E.M.
for three independent experiments with a representative blots (dashed line indicates
intervening lanes have been removed). * Indicates a significant difference in T210
phosphorylation with 800 μM ADP relative to the –ADP sample as judged by a student’s t-
test (P<0.05). 
B. This structure highlights the rationale for mutagenesis of valine residues into bulky
tryptophan to cause a steric clash with the nucleotide, illustrated in site-4 with NADH bound.
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conserved aspartic acid, highlighting potential differences in the regulatory mechanism. Since 
the mutation of these conserved aspartic acids did not appear to be sufficient to eliminate 
nucleotide binding to Snf4 an alternative approach was investigated. Residues were identified 
from the Snf4 crystal structure that pointed into the nucleotide binding pocket, either from the 
same CBS domain or a residue from the opposing domain, and these were mutated into bulky 
tryptophan residues in the hope of displacing the nucleotides (Figure 5.5B). Unfortunately 
none of these mutations showed any effects on either ADP regulation of SNF1 activity or on 
nucleotide binding (see Appendix 8). 
 
5.2.3 ATP competition for ADP regulation 
Regulation of AMPK activity is tightly controlled by the balance of activating nucleotides 
(AMP and ADP) and inhibitory ATP, which all compete for binding at the same 
exchangeable sites in the γ subunit. This competition means that under basal conditions, 
when ATP levels are high, AMP and ADP are prevented from binding and activating AMPK. 
This can be demonstrated by competition for the regulation of AMPK by the different 
nucleotides for either allosteric activation or prevention of dephosphorylation, as discussed in 
section 4.2.1. Since ADP is the only nucleotide that activates SNF1, AMP and ATP binding 
to the same site should limit activation, as seen in the mammalian system, playing an 
essential role in the inactivation of SNF1. 
To investigate this effect ADP was titrated in the dephosphorylation assay as described in 
Figure 5.2 but fixed concentrations of ATP were also included in the assay (Figure 5.6). 
Under these conditions any competition between ADP and ATP would cause a right-shift in 
the protection by ADP, with higher concentrations required to achieve the same effects. 
Instead of observing a competition for activation as seen in AMPK (resulting in reduced 
protection by ADP) these data show that the presence of both nucleotides in the assay has an 
additive effect which increases with higher ATP concentrations. Over the range of ADP 
concentrations tested the presence of 400μM ATP increased the level of T210 
phosphorylation ~10% with a further 5% increase in the presence of 800μM ATP.  
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Figure 5.6 Effects of ATP on SNF1 dephosphorylation in the presence of ADP 
Full length SNF1 complex (Snf1, Gal83, Snf4) was activated by phosphorylation with
recombinant CaMKKβ for 20 min at 37°C. In each case SNF1 was incubated with PP2C over
a range of ADP concentrations and in the presence or absence of fixed concentrations of ATP
for 10 min at 37°C. Reactions were terminated by the addition of sample buffer and SNF1
activity determined by SDS-PAGE and western blot analysis. Results shown are the mean ±
S.E.M. for three independent experiments with accompanying western blots. 
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Figure 5.7 Effects of ADP and ATP on SNF1 dephosphorylation over a range of time
points. 
The same set of experiments as described for Figure 5.3 were carried out with either no
nucleotide, 800 μM ADP or a combination of 800 μM ADP and ATP. Results shown are the
mean ± S.E.M. of four independent experiments accompanied by representative P-T210 blots
and a single total His-Snf1 blot. Data for 800 µM ATP alone is identical to the control data
set. 
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Given that ATP alone has no effect on T210 dephosphorylation under these concentrations it 
is unexpected that there should be increased protection with both ADP and ATP. However, 
this additive effect on T210 phosphorylation does not appear to be an artefact of the time 
point assessed and an additional 20% P-T210 signal on top of the protection afforded by ADP 
is apparent over a range of time points with fixed ADP and ATP concentrations (both 800 
μM) (Figure 5.7). The cause of this effect was further investigated and results are discussed in 
Appendix 9. 
 
5.2.4 AMP competes for ADP regulation 
Due to the limitations of using ATP to investigate competition for regulation in this assay, 
AMP was investigated. Using the methods described in the previous section, preliminary data 
was generated by competing constant concentrations of AMP with ADP over a range of 
concentrations. This indicated that competition was only apparent with much lower 
concentrations of ADP relative to AMP, and also that at concentrations >1mM AMP 
appeared to have adverse effects in the assay, protecting the AMPK kinase domain from 
dephosphorylation under these conditions (see Appendix 10). Subsequent assays focussed on 
testing competition within this range, limiting the starting concentration of ADP (and thus the 
level of protection) that could be monitored. Figure 5.8 shows that under the altered assay 
conditions at 200 μM ADP, there is a 1.8-fold increase in protection of SNF1 activity relative 
to PP2C alone. There is a downward trend in the level of ADP protection (and a loss of 
significant effect) when in competition with increasing concentrations of AMP, reducing the 
level to a 1.2-fold activation in the presence of 4× concentrations of AMP relative to ADP. 
This suggests that AMP binds to the ADP regulatory site with a much lower affinity than 
ADP, indicating that AMP concentrations in a cell would have to significantly outweigh 
those of ADP in order to contribute significantly to the inhibition of SNF1. Binding data is 
discussed in section 5.2.6. 
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Figure 5.8 AMP competes with ADP for its effects on SNF1 dephosphorylation 
Activated full length SNF1 complex (Snf1, Gal83, Snf4) was incubated with PP2C (39 ng) in
the presence of 200 µM ADP alone or with increasing concentrations of AMP as indicated
for 5 min at 37°C. The reaction was terminated by dilution in ice-cold buffer (50 mM Hepes,
pH 7.4, 1 mM EDTA, 1 mM dithiothreitol, 10% glycerol) supplemented with ADP and AMP
to final concentrations of 5 µM and 20 µM respectively. Activities were determined by the
SAMS peptide assay and the results shown are the mean S.E.M., n=3 independent
experiments. * indicates a statistically significant increase in treated cells relative to the
control (PP2C alone) (p<0.05 with one-way ANOVA and Dunnett’s post test). 
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5.2.5 Regulation of endogenous SNF1 by ADP 
In order to confirm that this ADP regulation was not an artefact of recombinant expression of 
SNF1, or the use of mammalian kinases and phosphatases, a set of experiments were 
conducted by our collaborators on endogenous SNF1. A TAP-tagged form of Snf1 was 
expressed in yeast cells and was subsequently grown on sucrose medium, conditions under 
which SNF1 is phosphorylated and activated by one of its three upstream kinases, Sak1, Tos3 
or Elm1. Active SNF1 complexes were purified from these cells which will consist of a 
mixture of the different β-isoforms available with Gal83 being the predominant form. 
Incubation of the endogenous SNF1 with mammalian PP2C in the presence or absence of 
AMP or ADP showed that this complex was efficiently dephosphorylated by this phosphatase 
and, consistent with the results obtained with recombinant SNF1, titration of ADP in the 
assay resulted in significant protection of T210 phosphorylation (Figure 5.9A). Moreover, 
protection by ADP occurred over a similar concentration range to that seen with recombinant 
complexes, maximally activating the complex at concentrations >500μM. Finally, to verify 
that these effects are independent of the phosphatase this experiment was repeated at a single 
ADP concentration using either mammalian PP1 (Figure 5.9C) or the endogenous SNF1 PP1 
phosphatase complex (Figure 5.9C). Glc7-Reg1 was purified from yeast in a partially active 
form and was capable of dephosphorylating T210 about 30% under the conditions tested 
(Figure 5.9D). Despite this small decrease in P-T210 following dephosphorylation with Glc7-
Reg1, ADP still showed significant protection of dephosphorylation, as was also seen with 
the mammalian PP1, indicating that this regulatory mechanism is independent of the 
phosphatase and enforcing the likelihood of this nucleotide playing a physiological role in 
yeast regulation. 
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Figure 5.9 ADP protects against dephosphorylation of endogenous SNF1 
SNF1 complexes were purified from yeast grown in the presence of sucrose as the carbon
source. A. These complexes were incubated with PP2C in the presence of increasing
concentrations (0-800 μM) of either AMP or ADP as described in Figure 5.2. The results of a
representative experiment are shown together with the corresponding blots (B). The level of
T210 phosphorylation in a control incubation lacking PP2C is shown in each case, and the
dashed line indicates the removal of intervening lanes from samples run on the same gel.
Similar experiments were carried out using either rabbit PP1 (C) or purified Glc7
phosphatases (D) with a single ADP concentration (800 µM). n=3 ± S.E.M. This data was
generated by M. Schmidt. 
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5.2.6 Nucleotide binding to SNF1 
In order to better understand the regulation of SNF1 by ADP a series of binding studies were 
carried out on the phosphorylated, active form of Gal83-containing complexes. Initially the 
presence of a non-exchangeable nucleotide binding site, as is seen in AMPK, was 
investigated. Recombinant SNF1 complexes were subjected to perchloric acid extraction and 
any soluble extract analysed by HPLC as described in section 3.2.2. This did not identify the 
presence of any non-exchangeable nucleotides in SNF1 complexes, showing that this non-
exchangeable binding site is not conserved between these homologues (data not shown). 
These results are in agreement with crystallographic studies of SNF1 from both budding and 
fission yeast which did not identify any co-purifying nucleotides (Amodeo et al., 2007; 
Townley and Shapiro, 2007).  
Exchangeable binding was examined by the Gamblin group. Initially analogues of ADP and 
ATP tagged with a coumarin fluorescent-reporter group were used and the affinity for un-
labelled nucleotides determined by competition analysis (discussed in Appendix 4). These 
experiments revealed two exchangeable nucleotide-binding sites with very different binding 
affinities, summarised in Table 12 (in Appendix 5). All three nucleotides bind to one 
relatively tight high-affinity site (Kd for ADP ~80μM) and to a second, much weaker site (Kd 
for ADP ~800μM). This binding pattern is comparable to that seen in AMPK, shown in Table 
11. 
As with AMPK, SNF1 was also found to bind NADH with a stoichiometry of 1:1, with a Kd 
of approximately 12 μM whereas binding of NAD+ was virtually undetectable (Kd >250 μM). 
Binding analysis with NADH revealed that it binds at a single site and competes with AMP, 
ADP and ATP to give binding constants comparable to those determined for the stronger of 
the two binding sites identified by coumarin-labelled nucleotides (Table 12).   
Figure 5.10 shows a crystal structure of the SNF1 regulatory core (full-length Snf4 with C-
terminal regions of Snf1 and Sip2, see schematic diagram in Figure 5.10A) with a single 
molecule of NADH, AMP or ADP soaked into site-4.  Consistent with the binding studies 
this shows a site-specific interaction of NADH with SNF1 and that AMP and ADP also bind 
strongly at this site. This site is equivalent to the non-exchangeable AMP-binding site in 
mammalian AMPK and has also been shown to bind all three nucleotides in the structure of 
the SNF1 homologue from S. pombe (Jin et al., 2007; Townley and Shapiro, 2007).  
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A. 
B. 
Figure 5.10 Structure of S. cerevisiae SNF1 in complex with AMP, ADP and NADH 
A. Diagram representation of the three components of the SNF1 heterotrimer: the constructs
used for crystallisation are shown hatched. B. Ribbon representation of the crystallized
complex with one molecule of AMP (pink), ADP (white) or NADH (yellow) bound at site-4.
The three domains are coloured according to (A) and the nucleotides are shown in ball-and-
stick representation. The Snf4 subunit comprises of four CBS domains, each contributing to a
potential nucleotide binding site. In this structure only one site is occupied by nucleotides,
site-4 is shown in more detail with AMP, ADP or NADH. This structure was generated by
the Gamblin group. 
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As in AMPK, NADH does not have a direct effect on SNF1 activity (Figure 5.11, allosteric 
data shown in Appendix 6). Given that NADH competes for binding with ADP at one of the 
Snf4 binding sites, identified as site-4 in the crystal structure, it was investigated whether it 
could also compete for the ability of ADP to protect against dephosphorylation. Even at the 
highest concentration investigated, shown in Figure 5.11, there was no evidence that NADH 
had any effect on this regulation. Given the comparative dissociation constants for ADP 
(either ~80 μM or 800 μM) and NADH (Kd ~ 12 μM) these concentrations would be expected 
to show competition if the site which binds NADH is also responsible for regulation. 
Comparison of this binding data with the half-maximal effect of ADP on dephosphorylation 
(>500 μM for recombinant SNF1), indicates that this correlates with concentrations seen at 
the weaker of the two binding sites (Kd ~ 800 μM). Furthermore, the site which binds NADH, 
the only site apparent in the crystal structure, is not the site responsible for ADP’s actions on 
SNF1 activity, illustrated by its lack of competition. Taken together these data strongly 
indicate that of the two exchangeable binding sites only one, the weaker of the two, is 
responsible for ADP regulation of dephosphorylation. However, a lack of convincing electron 
density in a second site in the crystal structure (or in the published S. cerevisiae structure) the 
identity of the regulatory site remains unknown.  
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Figure 5.11 Effect of NADH on SNF1 activity and regulation by ADP 
Recombinant SNF1 was activated by incubation with CaMKKβ. Aliquots of the active
complex were incubated for a further 10 min at 37°C in the presence of PP2C (26 ng) and
with increasing concentrations of either ADP or NADH alone or with increasing
concentrations of ADP and in the presence of 0.5 mM NADH. The reactions were terminated
by dilution and the activity determined by SAMS peptide assay as described in Figure 5.8.
Results shown are mean ± S.E.M. (n≥3) and are expressed as a percentage of the positive
control (untreated with PP2C). 
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5.2.7 Insights into SNF1 regulation 
Recently a crystal structure of the active form of mammalian AMPK was obtained by our 
collaborators (Figure 4.4). In AMPK the role of a loop region of the α subunit, termed the α-
hook, was investigated and found to be essential for the transmission of the nucleotide signal 
for the protection from dephosphorylation from the γ subunit to T172 (Figure 4.6). 
Unfortunately a lack of sequence similarity around this region between AMPK and SNF1 
prevents the identification of a putative hook region in Snf1 which could be responsible for 
transmission of the ADP signal. However, this structure also identified a region of the β 
subunit that made close interactions with the activation loop and potentially played a role in 
stabilising the active conformation of the complex (section 4.2.5). Mutagenesis of residues in 
this region of AMPKβ showed that the interaction does play an important role in regulation 
of activity (Figure 4.5) and fortunately this region of the Snf1 is highly conserved, allowing 
comparison of function of this region (Figure 5.12).  
Two conserved histidine residues identified from the β subunit of AMPK, His379 and His384 
(corresponding to His375 and His380 in Sip2) were mutated to an alanine in Gal83-
containing complexes and expressed in the recombinant system. Interestingly one of these 
mutations, H384A, caused an almost complete loss of kinase activity, as judged by the SAMS 
peptide assay, despite being phosphorylated to levels comparable to that seen in either the 
other His mutation or wild-type complexes (Figure 5.13A and B). The reason for this almost 
complete loss of activity with just one of these histidine mutations remains unclear but this 
result indicates that this interaction is important for normal functioning of the kinase domain. 
The mutant complex that displayed normal kinase activity (H379A)  was further 
characterised in the dephosphorylation assay and it has a slight increase in the rate of T210 
dephosphorylation relative to the wild-type complex, and was almost completely inactivated 
after five minutes compared to ten minutes for the WT (Figure 5.13C). This indicates that this 
residue is likely to be involved in stabilising the activation loop in a conformation in which 
T210 is sheltered from dephosphorylation as was seen with mammalian AMPK. However, 
this mutation did not significantly affect the ability of ADP to reduce the rate of 
dephosphorylation, indicating that the function of this interaction in independent of 
nucleotide binding but that signal transduction from the Snf4 subunit enhances this 
stabilisation (Figure 5.13D).  
176 
 
 Chapter 5 – Investigating the regulation of SNF1 
177 
 
A. 
B. 
Figure 5.12 Conservation of Histidine residues which interact with the T-loop of the
kinase domain 
A. An amino acid alignment of the C-terminal regions of Gal83, Sip2 and the AMPK and S.
pombe β subunits with conserved residues highlighted in grey and the two histidine residues
(which appear to play an important role in T-loop stabilisation of AMPK) are highlighted in
black. 
B. A partial ribbons representation of the structure of SNF1 determined for this study (see
Figure 5.10) is shown with the active kinase domain of AMPK (coloured in grey) docked on
to the complex. The enlarged panel shows a closer view of the loop region of the kinase
domain and the two histidine residues from Sip2 (H375 and H380, equivalent to H379 and
H384 in Gal83).  
 Chapter 5 – Investigating the regulation of SNF1 
178 
 
A. 
CaMKKβ (ng) 
B. 
WT H379A 
β mutant
800μM ADP 
0 2 4 6 8 10
0
25
50
75
100
WT
H379A
Time (min)
SN
F1
A
ct
iv
ity
 (%
 a
ct
iv
ity
, 0
 m
in
)
His-Snf1 
Control 
H379A 
mutant 
P-T210 
His-Snf1 
P-T210 
His-Snf1 
P-T210 H384A 
mutant 
6      12      24 
C. D. 
Figure 5.13 Mutational analysis of Gal83 interaction with the T-loop in SNF1 regulation
A. WT or SNF1 complexes harboring His-379 or His-384 to alanine mutants in the Gal83
subunits were incubated with increasing concentrations of CaMKKB for 20 min at 37ºC and
their activity judged by SAMS peptide assay. Data shown is the average ± S.E.M. from 3
independent experiments.  B. Accompanying Western blots for P-T210 and total Snf1 are
shown for each complex. C. Phosphorylated wild-type SNF1 (WT) or H379A mutant
complexes were incubated at 37ºC in the presence of PP2C for various time points. An
aliquot of this reaction was diluted into a SAMS assay and activity of the SNF1 determined
as described in Figure 5.8. D. The same assays were carried out as in C but in the presence or
absence of 800uM ADP and the activity determined after a 10 minute incubation. Data shown
is the average ± S.E.M. from 3 independent experiments. 
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These data closely mirror those seen with the comparative mutations in AMPKβ. Although 
this does not prove that there is conservation of regulatory mechanisms between AMPK and 
SNF1 it does suggest that they are likely to share aspects of their regulation, not only kinase 
domain stabilisation but potentially translocation of the nucleotide message between the 
different subunits. These data, illustrating the conservation of this regulatory mechanism, 
indicates that it is possible that cellular ADP levels could be communicated to the Snf1 
subunit by a similar mechanism to that seen in AMPK, potentially by a loop region. 
However, it will require further investigation of SNF1 to clarify the precise mechanism by 
which ADP binding in the Snf4 subunit confers protection from dephosphorylation of T210 
in the Snf1 subunit.  
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5.3 Discussion 
Nutrient-induced signalling networks allow rapid adaption of cellular metabolism to changes 
in environmental conditions that are crucial for survival. The yeast Saccharomyces 
cerevisiae, like mammals, has evolved to assess the amount and nature of available nutrients 
and to adapt its metabolic regulation accordingly and over 40% of its genes rapidly alter their 
expression depending on the availability of glucose (Wang et al., 2004). 30 years ago the 
sucrose non-fermenting-1 (SNF-1) gene was identified in a screen of mutants unable to adapt 
to alternative carbon sources; encoding a serine/threonine protein kinase, SNF1 was to be a 
founding member of the AMPK family (Carlson et al., 1981; Celenza and Carlson, 1984, 
1986). SNF1 is activated under conditions of low glucose and plays a central role in the 
transcription of glucose-repressed genes as well as several adaptive mechanisms including 
aging, meiosis, pseudohyphal growth and glycogen storage (reviewed in Zaman et al., 2008). 
Unlike AMPK, the intracellular signal/s that activate SNF1 remain unidentified and although 
genetic approaches have enabled significant understanding of its physiological roles, aspects 
of its regulation and biochemical properties remain unknown. Consequently identifying the 
signal that communicates glucose availability as well as understanding the regulation of 
SNF1 by either the β subunit or by nucleotide binding (or indeed another metabolite) via the 
Snf4 subunit will be essential. 
Following the research described in the previous chapter detailing the physiological 
regulation of AMPK by ADP, taken together with the fact that ADP had been shown to co-
crystallise with the S. pombe homologue of Snf4, SNF1 activity was investigated in order to 
elucidate what role this nucleotide could have on its regulation. The data presented in this 
chapter identifies an important role for ADP in the regulation of SNF1. Overall, ADP, as with 
AMPK, activates SNF1 indirectly by reducing the rate of dephosphorylation of T210, an 
effect which is apparent in both recombinant and endogenous complexes and is independent 
of the phosphatase present. How ADP mediates these effects was also investigated, and 
although I was not able to fully characterise its mode of action, parallels with AMPK 
regulation have been identified. The novel modes of SNF1 regulation identified in this study 
are summarised in Figure 5.14 along with known factors influencing SNF1 activity. 
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Figure 5.14 Summary of the roles of the SNF1 subunits in its regulation 
This schematic diagram summarises the contributions of each of the subunits in SNF1
regulation, these published roles are summarised in Table 3, Table 4, Table 5, and Table 6.
The novel modes of regulation identified in this thesis are highlighted in yellow. 
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Several studies have shown that AMP does not activate the SNF1 complex either 
allosterically or by protection from dephosphorylation (Mitchelhill et al., 1994; Sanders et al., 
2007b; Woods et al., 1994). To date there have been no reports of the effects of other 
nucleotides on regulation of SNF1 and this was initially addressed using a recombinant 
expression system. Heterotrimeric complexes consisting of Snf1, Gal83 (unless otherwise 
stated), and Snf4, which represents the predominant form of the complex in vivo, were 
expressed in E. coli and the ability of the complex to be activated assessed by 
phosphorylation with CaMKKβ and either Western blotting for phosphorylated T210 or by 
measuring the complex activity in the SAMS peptide assay. Following verification of the 
complexes the effects of AMP, ADP and ATP were assessed on both their ability to 
allosterically activate or protect the complex from dephosphorylation. As described 
previously AMP had no effect on either of these modes of regulation (Mitchelhill et al., 1994; 
Sanders et al., 2007b; Woods et al., 1994). However, while ADP did not allosterically 
regulate SNF1 activity it did significantly protect T210 from dephosphorylation, activating 
SNF1 under these conditions (Figure 5.2).  The half-maximal effect of ADP under these 
conditions was >500μM and this protection is apparent over a range of time-points in the 
assay, significantly reducing the rate of dephosphorylation. 
Numerous studies have investigated different roles of the β subunit in SNF1 regulation and 
there is evidence that the different isoforms show differential regulation in response to 
stresses and upstream kinases, summarised in Table 4 (Mangat et al., 2010; McCartney et al., 
2005; Momcilovic et al., 2008; Nath et al., 2002; Vyas et al., 2003; Wiatrowski et al., 2004; 
Zhang et al., 2010). The regulation of SNF1 was further characterised by comparison of the 
ADP regulation with different isoforms of the β subunit as well as truncations and mutations. 
As had been previously described, comparison of the Gal83 complex with Sip2-containing 
complexes (with a short N-terminal truncation) showed firstly that both isoforms of the β 
subunit conferred comparable levels of activity to the complex (Nath et al., 2002). 
Furthermore these data show that these β isoforms do not appear to differentially impact on 
the rate of dephosphorylation in the absence of ADP with both complexes being 
dephosphorylated to comparable levels. Finally, both complexes also showed a similar degree 
of protection in the presence of ADP (Figure 5.4). Unfortunately these experiments could not 
be repeated with Sip1-containing complexes as the recombinant protein appeared to be 
unstable. This finding mirrors data collected in vivo indicating that this isoform is very 
unstable and present at relatively low levels in yeast cells (Nath et al., 2002). A recent paper 
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proposed that this instability may be due to the long N-terminal extension that is absent from 
the other isoforms (Mangat et al., 2010).  
The effects of the GBD and kinase activity on the regulation of SNF1 by ADP were also 
investigated as both of these alterations affect nucleotide regulation in AMPK (a personal 
communication from M. J. Sanders) and also play important roles in regulating SNF1 
activity. Truncation of the GBD or mutation of the Snf1 subunit to produce a catalytically 
inactive complex both completely abolished protection by ADP (Figure 5.4). Several studies 
that have been conducted in vivo also show that either truncation of the GBD or mutation of 
residues in the GBD which interact with the Snf4 subunit disrupt SNF1 regulation (Mangat et 
al., 2010; Momcilovic et al., 2008). One factor which could account for this loss of normal 
regulation could be due to loss of autophosphorylation of the complex, many sites of which 
are present in the GBD (Yang et al., 1994). However, this hypothesis would contradict the in 
vivo observation that mutation of these phosphorylation sites or deletion of the GBD appears 
to have no effect on function and regulation of the SNF1 complex (Mangat et al., 2010; Yang 
et al., 1994). Data from the study by Mangat et al. also contradicts the finding that truncation 
of the GBD from Sip2 eliminates ADP regulation as they observed little effect in response to 
growth on alternative carbon sources with loss of the GBD in Sip1 or Sip2 (Mangat et al., 
2010). This result is surprising although it could indicate that despite structural conservation 
of this domain its role in the regulation of SNF1 could be dependent on the isoform in which 
it is present (i.e. the complex composition) and also the type of stress the yeast is subject to. 
There is also some data emerging into the role of the regulatory subunit of the phosphatase, 
Reg1, which has separately been shown to interact with both Snf1 and the GBD of the β 
subunits (Elbing et al., 2006a; Ludin et al., 1998; Mangat et al., 2010). Although the data 
presented here shows that ADP regulation of dephosphorylation is independent of the 
phosphatase and occurs in the absence of Reg1 it will be interesting to see if also plays a role 
in mediating this interaction in vivo to further regulate the complex activity. 
Mutagenesis was carried out on the Snf4 subunit to try and identify the site of ADP 
regulation. Initially equivalent aspartic acid residues to those mutated in chapter 3 were 
investigated, bearing in mind that in the mammalian system these did not have CBS-specific 
effects. However, none of these mutations resulted in loss of regulation by ADP as did 
mutation of the corresponding residue to the R298G (R294G). Interestingly this WPW 
mutation had been previously indicated to have little effect on the ability of yeast to respond 
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to glucose limitation (Daniel and Carling, 2002a). The lack of effect of these mutations 
suggests that either of these residues, which have been shown to be important for activation 
of AMPK by nucleotides, do not have conserved roles in SNF1 or that loss of a single residue 
in the binding pocket is insufficient to eliminate binding, possibly due to the lower binding 
constants in SNF1. To tackle this problem an alternative approach was investigated, targeting 
residues that point into the binding pockets and mutating these into bulky tryptophan 
residues. Again these mutations were found to have little effect on the binding or the ability 
of ADP to protect SNF1 from dephosphorylation and it is possible that these mutations did 
not efficiently block nucleotide binding at the target site. If the hypothesis that no single 
residue contributes an essential interaction for ADP binding to SNF1 is correct this 
mutagenesis approach may not yield useable data. These data highlight the difficulties of 
using a mutagenesis approach to identify regulatory sites, further to the reservations 
highlighted in chapter 3.4.  
Previous studies on AMPK have highlighted the important role that ATP plays in inactivating 
the kinase when energy levels are more favourable, a process which occurs by competing 
with AMP (or ADP as illustrated in the previous chapter) to eliminate allosteric activation 
and increase the rate of dephosphorylation (Adams et al., 2004; Corton et al., 1995; Hardie et 
al., 1999). Upon repeating these assays in the SNF1 assay system it was clear that ATP and 
ADP appeared to have an additive effect despite that fact that ATP alone had no effect on 
activity. It is possible that this side effect of having both ATP and an activating nucleotide is 
not apparent in the assay with AMPK due to the much lower concentrations of nucleotides 
required in this system. Due to these limitations, AMP was investigated in competition with 
ADP. This clearly shows a reduction in the activation by ADP in the presence of 3-4x 
concentrations of AMP, indicating that these nucleotides are indeed binding at the same site 
and also that AMP binds much more weakly than ADP.  
Studies using endogenous SNF1 were used to assess the effects of ADP in a non-recombinant 
system by our collaborators. Data presented here shows that active SNF1 purified from yeast 
can be effectively dephosphorylated by treatment with recombinant mammalian PP2C or PP1 
and consistent with my recombinant data, the inclusion of ADP but not AMP results in 
significant protection from dephosphorylation. Moreover, this protection occurred over a 
similar concentration range. Importantly, ADP was also shown to protect against the 
dephosphorylation of SNF1 using the physiologically relevant phosphatase, Glc7. 
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Analysis of nucleotide binding to phosphorylated active SNF1 revealed a similar pattern of 
binding to that seen with AMPK. Two sites were identified; a tight site (Kd for ADP ~80 μM) 
which also binds NADH (but not NAD+) and does not appear to be responsible for protection 
from dephosphorylation, and a weak site (Kd for ADP ~800 μM) which correlates with 
concentrations seen with the activity data. Given that the dissociation constant for NADH is 
nearly 7-fold tighter than the nucleotides, and considering the relative concentrations of these 
factors in yeast (Canelas et al., 2008), it is likely that this tight site will be bound to NADH 
under most conditions. However, competition analysis with NADH revealed that this 
nucleotide does not bind at the site responsible for mediating ADP protection from 
dephosphorylation and did not have any direct effects on SNF1 activity in these assays. 
Crystal soaking experiments identified NADH in site-4, effectively ruling out this site as the 
one responsible for ADP regulation. The presence of this tight NADH binding site, at the 
equivalent site to the non-exchangeable AMP in AMPK, highlights a parallel between these 
systems in which the same site is permanently occupied, suggesting that this site may play an 
important conserved role. Unfortunately due to the lack of a second ADP present in the S. 
cerevisiae crystals, likely to be due to the low binding constants, and the absence of 
interpretable data from mutagenesis studies the site responsible for mediating the ADP effect 
remains a mystery.  
The studies described in this thesis into the regulation of AMPK identified a hook region of 
the α subunit that interacts with the γ subunit. The interaction of this region with either AMP 
or ADP in site-3 is proposed to be responsible for transmitting the protection from 
dephosphorylation signal (but not allosteric activation) in the mammalian system. This loop 
region is not conserved in the SNF1 sequence and so it is not possible to identify an 
equivalent region in Snf1. Several studies have identified regions of Snf1 which interact with 
Snf4 and play an important role in activating the complex (Jiang and Carlson, 1997) and it 
remains possible that this interaction could also play an equivalent role to the α-hook, 
communicating of the nucleotide signal between the subunits and stabilising the kinase 
domain. In order to confirm if this mechanism is conserved a more complete structure of the 
kinases will be necessary. Histidine residues present in the β subunit of AMPK were found to 
play an important role in stabilisation of the T-loop region and due to their conservation in 
Snf1 the roles of these residues could be compared. These data showed that mutations of 
these histidines in Gal83 resulted in similar effects on the SNF1 complex, increasing the rate 
of dephosphorylation but not disrupting regulation by ADP. The stability provided by this 
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Site 4 Site 3 
AXP and NADH in S. 
cerevisiae and ADP in S. 
pombe, non-exchangeable 
AMP in mammalian 
AMPK 
Weaker 
(dephosphorylation) AXP 
binding site in mammalian 
AMPK 
Site 2 Site 1 ADP in S. pombe 
Tighter (allosteric) AXP 
and NADH binding site in 
mammalian AMPK.  
Figure 5.15 Structural overlap of S. cerevisiae Snf4 and the mammalian and S. pombe γ
subunits 
The Snf4 subunit is shown in green, AMPKγ in red and the S. pombe structure in blue with
the bound nucleotides in the same colours. The structures are shown from two orthogonal
views with the known roles of each site identified in the bottom panel.  
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interaction is clearly enhanced by nucleotide binding to the Snf4 subunit and this finding 
highlights parallels in the regulation of these complexes. 
The asymmetrical orientation of the kinase domain on a single face of the γ subunit strongly 
indicates that the ADP binding site mediating these effects will be on this face of Snf4 (site-2 
or site-3). In the AMPK system we have shown that it is site-3 which is responsible for the 
regulation of dephosphorylation (see Chapter 4). However, the crystal structure available for 
the S. pombe γ subunit shows ADP present in site-2 (as well as site-4), equivalent to the 
empty site in mammalian AMPK (Jin et al., 2007; Xiao et al., 2007). Site-2 lies on the same 
face of Snf4 as site-3, correlating with the structural data implicating this face of the subunit 
as key in this regulation (Figure 5.15).  
Following glucose limitation the ATP levels in yeast fall dramatically and this results in a 
rapid increase in ADP (Wilson et al., 1996). The findings described in this chapter suggest 
that ADP is the elusive metabolic signal that leads to activation of SNF1 under conditions 
that result in elevated nucleotide levels in budding yeast, representing a ‘unifying activator’ 
for the activation of AMPK in both yeast and mammals. One clear difference between these 
systems is in the concentrations of ADP required to protect the complexes from 
dephosphorylation, reflecting the major differences in energy metabolism between these 
organisms. This raises the question of what are typical nucleotide concentrations in S. 
cerevisiae. Unfortunately there is little consistent data on nucleotide levels in yeast and 
different extraction processes in addition to variations in culture conditions seem to 
significantly impact on the values obtained, summarised in Table 10 (reviewed in Canelas et 
al., 2009; Gonzalez et al., 1997; Richard et al., 1996; Saez and Lagunas, 1976).  Techniques 
available for measuring free nucleotides in intact cells include in situ NMR which can 
measure free ATP but unfortunately this cannot be used to measure AMP or ADP levels in 
yeast (Shanks, 2001). Recently a new technique that could be used to give time-resolved 
measurements of intracellular adenine nucleotides has been described which uses a novel 
type of nano-biosensor and could be used to assess metabolite levels under different growth 
conditions (Nielsen et al., 2010; Ozalp et al., 2010). Most of these papers have measured 
nucleotides under glucose limiting conditions and give average values for ATP of ~2mM and 
ADP ~1mM, indicating that ADP levels are likely to exceed the levels required for activation 
of SNF1 under these conditions. Hopefully these advances in metabolite sensing will allow 
187 
 
 Chapter 5 – Investigating the regulation of SNF1 
accurate determination of nucleotide levels under a range of time points and growth 
conditions. 
 Glucose-excess Glucose-limited 
 ADP ATP ADP:ATP ADP ATP ADP:ATP
(Saez and 
Lagunas, 1976) 0.3 mM 1.25 mM 0.24    
(Larsson et al., 
1997) 1.5 µmol/g 8.6 µmol/g 0.17 1.2 µmol/g 7.2 µmol/g 0.17 
(Gonzalez et al., 
1997)    5.9 µmol/g 6.7 µmol/g 0.88 
(Theobald et al., 
1997) 0.28 mM 2.52 mM 0.11 0.47 mM 3.36 mM 0.14 
(Teusink et al., 
2000) 1.32 mM 2.52 mM 0.52    
(Visser et al., 
2004)    0.72 mM 2.65 mM 0.27 
(Canelas et al., 
2008)    0.72 mM 3.06 mM 0.24 
(Canelas et al., 
2009) 1.7 µmol/g 7.0 µmol/g 0.24 1.4 µmol/g 3.8 µmol/g 0.37 
(Ozalp et al., 
2010)  2.0 mM   1.0 mM  
Average   0.26   0.35 
Table 10 Summary of ADP and ATP levels and the ADP:ATP ratios in S. cerevisiae 
under glucose-excess or –limiting conditions 
The data presented in this chapter show that like AMPK, SNF1 also has two exchangeable 
nucleotide binding sites with significantly different affinities and also intriguingly that it is 
the weaker of the two sites that appears to provide protection from dephosphorylation. 
Moreover, both complexes bind NADH at the tighter binding site but this cofactor appears to 
have no direct affect on activity (although in AMPK it competes for allosteric activation). 
Given that NADH binds to site-4 much more strongly than AXP’s in SNF1 it is likely that it 
would be bound at this site during growth on high glucose. Although the physiological 
significance of NADH binding at this site remains unclear it is tempting to speculate that it 
could play a conserved role in kinase regulation. As this binding site lies on the opposite face 
of the γ subunit relative to the weak binding site and, if subunit orientation is conserved, lies 
on the outside of the complex it could perhaps be involved in modulating interaction with 
other proteins. 
188 
 
 Chapter 5 – Investigating the regulation of SNF1 
189 
 
Based on the results presented in this chapter, a model for activation of SNF1 by ADP can be 
proposed. In this model ADP binding, but not AMP or ATP, stabilises a conformation of the 
complex that is resistant to dephosphorylation of T210 by a range of protein phosphatases. 
The ability of ADP to stabilise the complex may involve a region from the Snf1 subunit, as 
seen with AMPK, but also clearly requires the presence of the GBD and kinase activity for 
this stabilisation to occur. The binding site responsible for this regulation in the Snf4 subunit 
was not identified in this study but recent structures of AMPK and S. pombe indicate that it is 
likely to be either site-2 or site-3. Another key question raised by this model is why ADP and 
not AMP. With AMPK the disruption of protection by ATP is likely to be due to the 
conformation change of γ1Arg69 in the nucleotide binding site, absent when AMP or ADP is 
bound, which may generate a steric clash with the α-hook, thus preventing its interaction and 
destabilising the complex. Unfortunately the lack of either the identity or structure of the 
binding site responsible for this regulation in SNF1 makes it impossible to draw any firm 
conclusions as to whether a similar mechanism is present in the yeast complex. One 
possibility could be that due to the low binding constants at this site the β-phosphate of the 
ADP makes a critical contribution, and is the reason why AMP has much weaker binding 
constants.
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6 Summary and Future Work 
Maintenance of energy homeostasis plays a vital role at both a cellular and whole body level 
and many examples of when these systems have gone awry are apparent in the metabolic 
syndrome. AMPK plays a central role in this mechanism and dysregulation of AMPK results 
in WPW syndrome and cardiac dysfunction whereas activation of this kinase has displayed 
beneficial effects in the treatment of type 2 diabetes and the metabolic syndrome. 
Understanding how AMPK functions at a molecular level will facilitate research into 
treatments of diseases with underlying defects in energy homeostasis.  
The work presented in this thesis identified novel modes of regulation of AMPK and its yeast 
homologue, SNF1. Work conducted in vitro and in cells has identified unique roles for each 
of the nucleotide binding sites of AMPK and proposes a model for its regulation by 
nucleotides. Furthermore, a novel regulator of both AMPK and SNF1 activity has been 
identified, ADP, potentially the elusive ligand in yeast that translates glucose limitation into 
SNF1 activation. 
In chapter 3 the role of highly conserved aspartic acid residues in the nucleotide binding sites 
of the AMPKγ subunit were investigated. These residues were originally identified in the 
crystal structure of the regulatory core of AMPK which was surprisingly found to bind AMP 
at three sites (Xiao et al., 2007). Previous binding data had indicated the presence of two 
exchangeable nucleotide binding sites in the γ subunit and this was indeed the case although 
there was also a third, non-exchangeable AMP identified which was bound very tightly (Scott 
et al., 2004). In addition to comparing the effects of mutation of these conserved residues on 
the biochemical properties of the complex the presence of the non-exchangeable AMP was 
verified in mammalian expressed complexes. The main finding from this research is that all 
three of the mutations disrupt regulation of the complex, either via allosteric activation or 
dephosphorylation, and this result was confirmed in a recent publication (Oakhill et al., 
2010). Whether this dysregulation is due to complete loss of binding at a specific site or a 
more general effect on the γ subunit as a whole requires further investigation.  
More importantly these data highlighted the fact that these mutations do not have site-specific 
effects. Firstly, mutation in the non-exchangeable AMP binding site affects regulation of 
AMPK which occurs through nucleotide binding at the exchangeable sites and secondly, all 
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three mutations result in weakened binding at the non-exchangeable AMP site. Clearly these 
results indicate that point mutations in the γ subunit do not have isolated effects. This is 
perhaps not surprising as there is only a single side chain separating each face of the subunit 
and even though the residue appears to coordinate to a single nucleotide it could still disrupt 
interactions in different CBS domains. Numerous WPW mutations in the γ subunit have also 
been well characterised and have been shown to disrupt nucleotide regulation to varying 
extents (reviewed in Arad et al., 2007). The non-exchangeable AMP was also found to be 
absent in all of the WPW mutant complexes investigated in this study, including those which 
lie far from the nucleotide binding sites, identifying a common factor of these mutations that 
is absent from non-specific mutations in this subunit. In the future it will be important to 
determine to what extent the binding at the non-exchangeable site is weakened in each 
mutant, indeed it could be converted to a site able to bind nucleotides exchangeably like the 
other two binding sites, and understanding these factors may shed light on the effect/s γ 
mutations have in vivo.  
In cells these mutant complexes had very different characteristics: the mutations in the 
exchangeable binding sites (D89A in site-1 and D244A in site-3) resulted in decreased basal 
activity whereas mutation in the non-exchangeable site (D316A in site-4) resulted in maximal 
activation of the complex regardless of the upstream kinase present. This appears to be due to 
subtle differences in the rate of phosphorylation and dephosphorylation of the complexes that 
was not immediately apparent in the in vitro data. These differences indicate that the 
mutations may be having site-specific effects, i.e. exchangeable versus non-exchangeable 
mutation effects, despite the fact that the non-exchangeable AMP is absent from all three 
complexes. Taken together, unfortunately these data indicate that these mutations do not have 
site-specific effects and as such cannot be used to study the roles of each binding site 
separately. However, they indicate an important role for the non-exchangeable AMP in the 
regulation of basal complex activity and its ‘activatability’ and research in this area could 
shed light on the disruption present in the WPW mutations.  Furthermore, the identification of 
an AMPK complex that has very high basal activity will be a valuable research tool, for 
example to study the effects of long term activation of AMPK in vivo.  
With the benefit of hindsight, ADP is likely to have been the first regulator of AMPK activity 
to have been identified but it was only recently that its potential as an AMPK activator was 
recognised by our group. In chapter 4 the regulation of AMPK by ADP was further 
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investigated, identifying a key physiological regulator of AMPK activity. Unlike AMP, ADP 
does not allosterically activate the complex, as has been shown in previous studies, and in 
fact it competes with AMP in this respect (Mitchelhill et al., 1994; Sanders et al., 2007b; 
Woods et al., 1994). It does however protect the complex from dephosphorylation at 
concentrations similar to that of AMP and ATP competes for this protection. This indicates 
that both AMP and ADP are capable of binding at the same sites to affect these modes of 
regulation but yield different responses. Given that under most cellular stress conditions ADP 
concentrations will greatly outweigh those of AMP, it is likely to be a key factor in the 
activation of AMPK and this supports the argument that the protection from 
dephosphorylation is the predominant mechanism through which AMPK is regulated 
(Sanders et al., 2007b).  
Further characterisation of AMPK revealed that of the two exchangeable binding sites in the 
γ subunit one binds much more tightly than the other (Kd for ADP ~1 μM vs 60 μM). The 
tighter site, site-1, which also binds NADH was found to be responsible for allosteric 
activation of the complex via an unknown mechanism. The weaker site, site-3, is responsible 
for prevention of dephosphorylation via interaction with a hook region of the α subunit. This 
is the first published data showing that the two exchangeable binding sites play separate roles 
in the regulation of complex activity via two seemingly independent mechanisms. While the 
mutation in the α-hook region gives a complex lacking protection from dephosphorylation it 
will be important to identify the mechanisms through which the allosteric effect is regulated 
to try and delineate the contributions of these mechanisms in AMPK regulation. Further 
differences in these effects have been identified and truncation of the GBD from the β subunit 
of the complex has also been shown to disrupt the protection from dephosphorylation 
mechanism without disrupting allosteric activation of the complex (personal communication 
from M. J. Sanders). This study indentified another important role of the β subunit in 
stabilising the T-loop region of the catalytic subunit which protects T172 from 
dephosphorylation, an effect which is enhanced by nucleotide binding. Together these data 
highlight an important role for the β subunit in the regulation of AMPK activity and the 
precise roles it plays, together with the contributions on the phosphorylation sites and 
glycogen binding domain requires further investigation.  
In the final results chapter ADP was identified as a regulator of SNF1 activity, the first 
evidence of the signal that translates glucose limitation into activation. As seen in the 
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mammalian system ADP reduces the rate of SNF1 dephosphorylation and inactivation via a 
mechanism that is independent of the phosphatase present. Numerous studies have shown 
that AMP does not play a role in this regulation and binding studies showed that this 
nucleotide is capable of binding Snf4 and even competes for ADP activation. Indeed the 
pattern of the nucleotide binding site affinities was similar to that of AMPK with one much 
tighter than the other (Kds for ADP 80 μM versus 800 μM). Only one of these binding sites 
was identified and the mechanism for ADP regulation was not elucidated. Crystal structures 
similar to those published previously identified site-4, equivalent to the non-exchangeable 
binding site in AMPK, as the tight site which also binds NADH but does not appear to 
contribute to nucleotide regulation in this complex, raising the question as to which of the 
remaining sites is responsible for ADP regulation. Furthermore, although a role for the β 
subunit in stabilising the T-loop region of the Snf1 kinase domain was identified in SNF1 the 
identification of a mechanism responsible for nucleotide signal transmission was not possible. 
It could be through a similar mechanism to that seen in AMPK via the α subunit or in SNF1 
the β subunit plays a central role in stress response and the limited structures available show 
close interactions between the β subunit and the Snf4 subunit (Amodeo et al., 2007; Jin et al., 
2007). Obtaining a crystal structure of the active SNF1 complex with all of its domains 
present would provide support for elucidating the relative contributions of the Snf1 and β 
subunits in this regulation. 
Having shown that both AMPK and SNF1 are regulated by ADP it will be important to see if 
this activating ligand is conserved further, for example in the SNF1-related kinases (SnRKs) 
present in plants. SnRK1 was originally identified by its ability to compliment Snf1Δ 
mutations in yeast (Alderson et al., 1991) and Arabidopsis contains 38 protein kinases that 
are related to SNF1 (Hrabak et al., 2003). It has been proposed that the increased variety of 
complex isoforms available with this system affords greater flexibility of regulation relative 
to SNF1. However, it is the SnRK1 subgroup which is most closely related to SNF1 and this 
family of kinases was subsequently found to consist of either heterotrimeric complexes or 
dimeric complexes with β/γ fusion subunits (Polge and Thomas, 2007). Like its homologues 
the SnRK1s have been shown to play roles in starvation and metabolic stress responses in 
response to darkness and low sugar levels and a number of potential regulators have been 
identified (Baena-Gonzalez et al., 2007; Halford and Hardie, 1998; Halford and Hey, 2009). 
In addition to AMP reducing the rate of dephosphorylation of the SnRK1s (Sugden et al., 
1999), other regulators that have been proposed include glucose and sucrose (Baena-
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Gonzalez et al., 2007), glucose-6-phosphate (Toroser et al., 2000), and trehalose-6-phosphate 
(Harthill et al., 2006). Given that SnRK1 has been shown to be protected from 
dephosphorylation by AMP it is likely that ADP too will regulate its activity, however it will 
be important to confirm this hypothesis.  
A key observation in this thesis that will require further characterisation is that NADH and 
NADPH specifically bind to a single CBS domain of both AMPK and SNF1. In both cases 
this cofactor binds to the external face of the subunit, indicating that this interaction could 
potentially play an important role in targeting the kinase. Although the work presented in this 
thesis did not identify any direct effects of NADH binding to these kinases beyond competing 
with AMP for allosteric activation of AMPK it is tempting to speculate that this interaction 
could play a regulatory role and provide a link between the AMPK and other metabolic 
pathways, for example the sirtuins (discussed in section 4.3). Further characterisation of this 
interaction could provide valuable insights into manipulating these pathways which both play 
central roles in metabolic adaption and ageing. 
Within the last decade 12 AMPK-related kinases have been identified and many of these 
remain largely uncharacterised (reviewed in Bright et al., 2009; Manning et al., 2002). 
Although these kinases are closely related by sequence homology in their kinase domains and 
all but one are activated by LKB1 phosphorylation it is now becoming apparent that they may 
have very different structures and regulatory domains (Lizcano et al., 2004). Furthermore, 
these kinases do not appear to be activated by stresses that activate AMPK, for example 
phenformin, AICAR or muscle contraction (Lizcano et al., 2004; Sakamoto et al., 2004) with 
the exception of NUAK2 (Lefebvre et al., 2001), and as such are likely to be subject to 
different forms of regulation. Indeed, it is not yet clear if the regulation of dephosphorylation 
of these complexes plays an important role in determining their activity although components 
of phosphatase complexes have been identified as substrates (Sjostrom et al., 2007; 
Yamamoto et al., 2008). Factors that are important to AMPK-RK regulation include 
phosphorylation at a number of sites (Bright et al., 2008; Bright et al., 2009; Hutchison et al., 
1998), the presence of a regulatory UBA domain adjacent to the catalytic domain (Al-Hakim 
et al., 2008; Jaleel et al., 2006; Manning et al., 2002; Rider, 2006) as well as interaction with 
the 14-3-3 family of scaffolding proteins (Al-Hakim et al., 2005; Goransson et al., 2006). It 
would be interesting to see if there is any conservation of the regulatory mechanisms between 
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AMPK and the AMPK-RKs and further characterise the roles of these related kinases which 
may in itself shed light on the regulation of AMPK.  
Finally one of the key factors missing from the understanding of AMPK regulation is the 
identity of the protein phosphatase responsible for its dephosphorylation. As discussed in 
section 1.1.2 a number of studies have identified direct and indirect effects of several 
phosphatases on AMPK activity both in vitro and in vivo. Identification of the phosphatase/s 
responsible for regulation in various tissues and under different conditions could provide a 
valuable mode of manipulating AMPK activity to treat metabolic diseases. Indeed the finding 
that several factors modulate AMPK activity through manipulation of PP2C expression lends 
weight to the feasibility of this approach. 
AMPK activity is regulated at many levels: complex expression and localisation, subunit 
interactions, binding to regulatory ligands and regulation of activity levels. Some of the data 
presented in this thesis identifies an important physiological activator as well as unique 
insights into the regulatory mechanisms involved in this control. Furthermore, a valuable 
research tool was identified in the form of AMPK complexes with very high or low basal 
activities, allowing investigation of long-term alteration of AMPK activity with full length 
complexes. Studies not only into AMPK itself and its homologues but also understanding 
other facets of the pathway could all provide valuable insights and a key challenge for the 
future will be translating this understanding to its implications on regulation at a whole-body 
level. As our knowledge of these mechanisms increases so does our potential to manipulate 
this pathway in the treatment of metabolic diseases.  
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Appendix 1 The tricistronic vector 
A schematic diagram of the tricistronic vector for expression of AMPK complexes in E.coli. 
There are ribosomal binding sites for each of the subunits and the α subunit is expressed with 
an N-terminal histidine tag. Taken from (Neumann et al., 2003b).  
γ β His-α
promoter terminator 
Ribosomal binding sites
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Appendix 2 Table of oligonucleotides used in this study 
The following oligonucleotides were used in this study to introduce point mutations within 
the α1β1γ1 tricistronic vector. All mutations were generated within the γ1 subunit with the 
exception of the R375Q/T377A/D379A/E318A quadruple mutation within the α1 subunit and 
the H233A mutation within the β1 subunit. 
Mutation Direction Sequence (5’-3’) 
D89A Forward  CTGACCATCACTGCCTTCATCAATATT 
Reverse  AATATTGATGAAGGCAGTGATGGTCAG 
D244A Forward  TACTCCAAGTTTGCTGTGATTAATTTG 
Reverse  CAAATTAATCACAGCAAACTTGGAGTA 
D316A Forward  GTATCGCTGTCTGCCATCTTACAGGCT 
Reverse  AGCCTGTAAGATGGCAGACAGCGATAC 
D89R Forward  CTGACCATCACTCGCTTCATCAATATT 
Reverse  AATATTGATGAAGCGAGTGATGGTCAG 
D244R Forward  TACTCCAAGTTTCGTGTGATTAATTTG 
Reverse  CAAATTAATCACACGAAACTTGGAGTA 
D316R Forward  GTATCGCTGTCTCGCATCTTACAGGCT 
Reverse  AGCCTGTAAGATGCGAGACAGCGATAC 
R298G Forward  GCAGAGGTTCACGGTCTGGTGGTGGTG 
Reverse  CACCACCACCAGACCGTGAACCTCTGC 
R151T Forward  AATAAGATCCACACGCTTCCAGTTATT 
Reverse  AATAACTGGAAGCGTGTGGATCTTATT 
Y254H Forward  GCAGAAAAGACACACAACAACCTAGAT 
Reverse  ATCTAGGTTGTTGTGTGTCTTTTCTGC 
E273K Forward  TCACACTACTTCAAGGGTGTTCTCAAG 
Reverse  CTTGAGAACACCCTTGAAGTAGTGTGA 
F60A/F61A Forward  CGCTGCAGGTAAAGAAAGCCGCCGCTGCCCTGGTGACTAACGGTG 
Reverse  CACCGTTAGTCACCAGGGCAGCGGCGGCTTTCTTTACCTGCAGCG 
R375Q/T377A/
D379A/E318A 
Forward  ACACCAAGGGCCCAACACGCCCTAGCTGCATTAAACCCACAGAAATCC 
Reverse  GCTAGTTATTGCTCAGCGG 
H233A Forward  CCGGAGCCCAACGCCGTCATGCTGAAC 
Reverse  GTTCAGCATGACGGCGTTGGGCTCCGG 
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Appendix 3 Mant-AMP binding data 
Mant-labelled AMP was incubated in the presence of wild-type (WT) AMPK or complexes 
harbouring mutations in their γ subunits (D89A, D244A or D316A). Upon binding of the 
mant-AMP to the AMPK complex there is an increase in fluorescence and a left-shift of the 
signal, indicating that the mant-moiety is less solvent exposed, illustrated in A. when 
comparing the mant-AMP alone to the fully bound signal with each of the complexes. These 
data show that mant binding to the D89A mutant has the same fluorescence maximum as the 
wild-type complexes whereas the D244A complexes have a much lower fluorescence 
maximum. Binding of the D316A complex to the mant-AMP has a very different spectrum 
with little left-shift. From this, data binding can be examined by plotting the fluorescence at a 
fixed wavelength (420nm for WT and D89A and 432 for D244A and D316A) against the 
protein concentration (B.).  
A. B.
 
These data indicate that the D89A may bind nucleotides more strongly than WT where as the 
D244A does not appear to bind at all. The D316A mutation may also bind mant-AMP more 
weakly than WT. These data indicate two things. First, that the D316A mutation affects the 
optical properties of mant-AMP making it difficult to directly compare these data to WT. 
Second, assuming that mutation at one site does not affect the properties (either optical or 
affinity) of the other exchangeable binding site (i.e. a single site is being monitored) the 
majority of the fluorescence observed in the WT complex comes from the D244A binding 
site. Based on these assumptions these data indicate that of the two exchangeable binding 
sites the D89A site has low fluorescence, but bind nucleotides tightly whereas the D244A site 
has a very high fluoresce but binds nucleotides very weakly. 
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Appendix 4 Analysis of fluorescent binding studies 
The small sample requirements and rapid data collection make optical methods an ideal way 
of assessing interactions between small molecule ligands and proteins. Binding of a ligand to 
AMPK or SNF1 was analysed in two stages, first through titration of NAD(P)H (or 
fluorescent-tagged nucleotides) with AMPK and second by competition and displacement 
assays. Binding of the fluorescent ligand was monitored through titration of known 
concentrations of AMPK into a known concentration of the ligand and stoichiometry of the 
interaction was assessed (discussed below) and fitted using one of the following analysis. 
Subsequently the dissociation constant for the nucleotide of interest was calculated in 
competition with the fluorescent ligand. 
Binding studies on nucleotides were carried out in collaboration with S. Martin and E. 
Underwood on full length, active AMPK and SNF1 complexes through competition with 
either NADH or coumarin labelled AXPs. Binding of NADH to the complexes was recorded 
with an excitation wavelength of 340nm and emission scanned from 400-550 nm. Binding of 
NADH was monitored by titration of the protein complex into a NADH solution (8 µM). 
Because it is only possible to distinguish between one and two site binding models when a 
‘close to stoichiometric’ titration can be performed (under conditions where all the added 
AMPK binds to the NADH) additional measurements were made at 1oC in a salt free buffer. 
The stoichimetry best fitted a 1:1 model although it was not possible to exclude the 
possibility that NADH also binds with low affinity to a second site. However, two additional 
pieces of data suggest that a 1:1 model is appropriate. First, when a mixture of AMPK (32 
µM) and NADH (15 µM) is titrated with AXPs almost complete displacement of NADH 
occurs when just over one equivalent of AXP has been added. Second, NADH is only 
capable of partially displacing C-AXPs which bind to two sites on AMPK. The NADH 
binding data was therefore analysed using non-linear least squares fits to equation (1) (all 
equations shown below). 
Coumarin ADP and ATP have emission maxima at 479 nm with excitation at 430 nm. The 
stoichiometry of the interactions was confirmed as 2:1 using ‘close to stoichiometric’ 
titrations as with NADH. C-AXP binding data was therefore analysed using non-linear least 
squares fits to equation (3). In order to simplify analysis it was assumed that binding was 
non-cooperative (α=1) as this cannot be assessed in experiments using optical methods. 
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Binding of AMP, ADP and ATP were determined using displacement assays with NADH and 
C-AXP. NADH displacement data was analysed using non-linear least squares fits to 
equation (5) with the Kd for NADH binding fixed at the value determined in the direct 
titration. This site only monitors binding at the tighter of the two sites, ignoring any 
contribution from the weak site, but the constants were in good agreement with the C-AXP 
data.  
Displacement of C-AXPs by AXPs is a much more complicated analysis due to the 
multiplicity of the species formed and the fact that nucleotide displacement occurs over two 
distinct phases. In order to analyse the whole curve a new method was developed. The data 
was analysed using non-linear least squares fits to equation (8) with the Kds for C-AXP 
binding fixed at the value determined in the direct titrations. Concentrations were calculated 
using the method developed by Storer and Cornish-Bowden (Storer and Cornish-Bowden, 
1976) and the Kds calculated as described. 
 
Titration of a fluorescent ligand with the protein of interest 
1:1 interactions – The interaction of a protein (P) with a ligand (L) to form a 1:1 complex 
(PL) is represented by the following scheme: 
P L PL+
Kd
 where the dissociation constant, Kd = 
ሾPሿሾLሿ
ሾPLሿ
 
For any mixture of P and L the observed fluorescence signal (FOBS) is given by: 
FOBS = FP[P] + FL[L] + FPL[PL] = FP[P0] + FL[L0] + (FPL – FP – FL)[PL] (1) 
Where [X0], [X] and FX represent the total concentration, the equilibrium concentration, and 
the molar fluorescence coefficient of species X respectively. A non-linear least-squares fit to 
equation (1) with [PL] calculated using equation (2) yields the Kd for the interaction and the 
FX values (program written by S. Martin, NIMR). 
( ) ( )
2
]L][P[4]L[]P[K][L  ]P[K
]PL[ 00
2
00d00d −++−++=
   (2) 
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2:1 interactions – When a ligand (L) binds to two sites on a protein (P) the following scheme 
is appropriate: 
The dissociation constants for the two sites are defined as: 
]PL[
]L][P[K
I
I,d = ]PL[
]L][P[K
II
II,d =
                  
α is a ‘cooperativity factor’ which accounts for that fact 
that binding at one site may increase or decrease the 
affinity of the ligand at the other site.
 
 
For any mixture of P and L the observed fluorescent signal (FOBS) is given by: 
FOBS = FP[P] + FL[L] + FPLI [PLI] + FPLII [PLII] + FPLILII [PLILII]  (3) 
A non-linear least squares fit to equation (3) yields the Kd values for the interaction and the 
FX values. In this case the concentration of the protein [P] is known and free ligand [L] can 
be calculated (Storer and Cornish-Bowden, 1976) which means [PLI] and [PLII] can be 
obtained from the expression for the Kds and [PLILII] from equation (4). 
II,dI,d
2
III KK
]P[]L[]LPL[ α=         (4) 
Competition and displacement of the fluorescent ligand 
The values for the competition and displacement assays were determined according to an 
alternative model: a mixture of two competing ligands, in this case NAD(P)H or fluorescent-
tagged nucleotides (termed L) with the ligand of interest (AMP, ADP or ATP, termed N), is 
titrated with the protein and since the Kd of L is known the other can be determined. 
AMPK will interact with two ligands (N and L) according to the following scheme: 
The dissociation constants for the two ligands are 
defined as: 
]PL[
]L][P[K L,d = ]PN[
]N][P[K N,d =  
                 
For any mixture of P, L and N the observed fluorescent signal (FOBS) is given by: 
FOBS = FP[P] + FL[L] + FN[N] + FPL[PL] + FPN[PN]    (5) 
A non-linear least squares fit to equation (5) yields the Kd values for the interaction and the 
FX values. If both the protein and the displacing ligand are non-fluorescent, as in this case, 
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then FN = FPN = FP = 0. The free protein concentration can be calculated (equations not 
shown) as the starting concentrations of ligand are known and from this [PL] and [PN] can be 
calculated from the equations below (6 and 7) and the remaining values from the expression 
for the Kds or from conservation of mass (e.g. [L] = [L0] – [PL]). 
]P[K
]P][L[]PL[
L,d
0
+=   (6)  ]P[K
]P][N[]PN[
N,d
0
+=   (7)
 
Due to the fact that dissociation analysis using the C-AXPs yields a greater number of species 
a different method of analysis had to be developed. For any mixture of P (AMPK or SNF1), 
L (C-AXP) and X (AXP) the observed fluorescence signal (FOBS) is given by: 
]LPX[F]XPL[F]LPL[F]PL[F]PL[F]L[FF IIIPLIIIPLIIILPLIIPLIPLLOBS IIIIIIIII +++++=  (8) 
Because AMPK, SNF1 and AXP have no fluorescence contribution it was assumed FP = FPXI 
= FPXII = FPXIXII = 0 as well as FPLIXII = FPLI and FPXILII = FPLII. 
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Appendix 5 Binding studies on AMPK and SNF1 
Using the techniques described in Appendix 4 the binding of nucleotides was assessed with 
AMPK and SNF1. The figure below shows example data used to calculate the nucleotide 
dissociation constants using coumarin-tagged nucleotides or NADH. 
a. The binding of coumarin-ATP (inset) and its subsequent displacement by AXPs from 
the AMPK-(coumarin-ATP)2 complex was monitored at 470 nm. The solid lines 
represent the computational best fits with the Kd,I and Kd,II for C-AXP binding to AMPK 
fixed at 1.1 and 4.2 µM. b. The binding of NADH to AMPK (inset) and its subsequent 
displacement by AXPs from the AMPK-NADH complex was monitored using 
fluorescence at 435 nm. The solid line is the computational best fits with the Kd for 
NADH binding to AMPK fixed at 65 µM.   
Binding data for AMPK is summarised in the table below. 
 
Kd vs 
NADH 
(μM)
Kd vs Coumarin-ATP (μM) 
tight weak 
AMP 1.6 (0.5) 2.5 (0.6) 80 (25) 
ADP 1.3 (0.5) 1.5 (0.4) 50 (15) 
ATP 0.9 (0.3) 1.7 (0.5) 65 (15) 
Mg-ATP 32 (12) 18 (7.5) 230 (80) 
Table 11 Equilibrium dissociation constants for the binding of AXPs to phosphorylated 
full length AMPK 
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Dissociation constants for AMPK were determined at 20°C by competition against NADH or 
C-AXPs in 25 mM Tris, 1 mM TCEP, 100 mM NaCl (pH 8) with and without 5 mM MgCl2. 
The Kd values are reported as the mean (± SD) determined from at least three independent 
measurements. These data were generated by E. Underwood and S. Martin. 
Binding data for SNF1 is summarised below. 
 
Kd vs NADH (μM) Kd vs Coumarin-AXPs (μM) 
   
AMP 55 (12) 62 (15) 1450 (350) 
ADP 72 (14) 91 (25) 760 (200) 
ATP 120 (25) 85 (22) 1200 (300) 
Table 12 Nucleotide binding to phosphorylated SNF1 
Dissociation constants for the binding of each nucleotide to phosphorylated SNF1 were 
determined by competition against either NADH or Coumarin-ADP or Coumarin-ATP. 
These experiments were conducted in the presence of 100 mM NaCl at 20°C. The Kd values 
shown are the mean (±S.D.) of at least three independent measurements. These data were 
generated by S. Martin and E. Underwood. 
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Appendix 6 Neither ADP nor NADH allosterically activates SNF1 
SNF1 complexes were activated by incubation in the presence of CaMKKβ and its activity 
determined in the SAMS peptide assay in the presence or absence of a range of nucleotide 
concentrations.  
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Appendix 7 Affects of nucleotides on Sip2-containing SNF1 complexes 
Recombinant SNF1 complexes consisting of full length Snf1, a truncated N-terminus of the 
Sip2 subunit (Sip2154-415) and full length Snf4 were activated by incubation with CaMKKβ. 
Aliqouts were removed and incubated in the presence or absence of PP2C, and varying 
concentrations of either AMP or ADP (100, 300, 500, 800, 1000, 1500 μM) for 10 min at 
37°C. The reaction was terminated by dilution in ice-cold buffer supplemented with either 
AMP or ADP to bring all samples to a constant final nucleotide concentration. SNF1 activity 
was determined by the SAMS peptide assay and results shown are the average (±S.E.M. of 
≥3 independent experiments) and are plotted as a percentage of the positive control (in the 
absence of PP2C).  
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Appendix 8 Additional mutations in the Snf4 subunit of the SNF1 complex 
Following a lack of effect of mutation of conserved aspartic acid residues to disrupt 
nucleotide regulation of SNF1 space filling mutations were used to target the four potential 
binding sites. Residues known to point into the binding site (see Figure 5.5B) either from the 
same CBS domain (in-site) or from the opposite CBS domain (cross-site) were mutated in to 
tryptophan residues (summarised in Table 13)  
 
 ‘in site’ 
mutation 
‘cross site’ 
mutation 
Site 1 L78W S144W 
Site 2 V164W I62W 
Site 3 V235W V292W 
Site 4 V307W V220W 
 
 
 
 
Table 13 CBS domain mutations  
The effects of these mutations on SNF1 regulation by ADP was assessed by comparing the 
residual activity of complexes incubated with PP2C and in the presence or absence of 800 
μM ADP. Activity was judged by SAMS peptide assay. Results in A. and B. are for the ‘in-
site’ and ‘cross-site’ mutants respectively. Binding studies with NADH also showed no effect 
of these mutations (data not shown). 
A. B. 
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Appendix 9 Investigating ATP competition with ADP for SNF1 protection from dephos-
phorylation 
The unexpected additive effects of ATP in the SNF1 dephosphorylation assay with ADP 
were further investigated using a number of different approaches. The mammalian 
phosphatase used in this assay, PP2C, is a magnesium-dependent phosphatase and the 
presence of Mg2+ in this assay is essential for its activity. Nucleotides also associate with 
magnesium, which interacts with the phosphate groups, and consequently ATP has the 
highest affinity for magnesium of the three nucleotides, resulting in almost all cellular ATP 
being present as an Mg-ATP complex. Given this affinity of nucleotides, and particularly 
ATP, for magnesium it is possible that the presence of both ADP and ATP in the assay is 
sufficient to sequester all of the magnesium away from the phosphatase, preventing it from 
functioning fully. To investigate if the additive protection by ADP and ATP is in fact due to 
inhibition of the phosphatase this assay was repeated in the presence of excess magnesium, 
shown in Figure A7.1A. These data show very similar results to those seen at lower 
magnesium concentrations, indicating that the increased protection is not due to inhibition of 
the phosphatase as a result of insufficient magnesium in the assay. 
Another potential explanation for this additive affect could be due to hydrolysis of ATP into 
ADP during the assay and thus contributing to T210 protection, either through contaminating 
kinase carry-over or by autophosphorylation. In order to prevent any ATP hydrolysis in the 
assay a non-hydrolysable analogue, AMP-PNP, was investigated (Figure A7.1B). Repetition 
of the assay using this analogue showed that, as with ATP, there was no protection of P-T210 
alone but there was still increased protection from dephosphorylation in the presence of both 
nucleotides (Figure A7.1C).  
As this study was being conducted a crystal structure of AMPK with a more complete α-
subunit was determined, discussed in section 4.2.4 (Figure 4.4). This structure included the 
full length γ-subunit, the α-subunit with the exception of a disordered loop, and the C-
terminal of the β-subunit, and it had been crystallised in the presence of a kinase inhibitor. 
Staurosporine is a potent kinase inhibitor (Kd ~ 3nM) that binds tightly in the ATP-binding 
pocket of the kinase domain, inhibiting its activity (Ruegg and Burgess, 1989; Vulpetti and 
Bosotti, 2004). This structure indicated that when staurosporine was bound in the ATP pocket 
of AMPK the complex appeared to be in a conformation such that T172 was protected from 
dephosphorylation even in the absence of nucleotide. If the presence of substrate in the ATP-
208 
 
  
209 
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C. 
Figure A7.1 Investigating the effects of ATP on SNF1 dephosphorylation in the presence of
ADP with high concentrations of MgCl2 or non-hydrolysable ATP (AMP-PNP)  
The same set of experiments as described in Figure 5.6 were carried out (A) in the presence of
5mM MgCl2 (as opposed to 2.5mM MgCl2) or (B) using AMP-PNP (C), a non-hydrolysable ATP
analogue. B. Results shown are the mean ± S.E.M. for at least three independent experiments with
accompanying western blots. 
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 binding pocket is sufficient to reduce dephosphorylation of the complex it could be possible 
that the effects of ATP on SNF1 in the presence of ADP could be due to binding at the kinase 
domain rather than at the Snf4 subunit. The effects of staurosporine on dephosphorylation 
were investigated over a range of concentrations. As shown in Figure A7.2A, staurosporine 
potently prevented dephosphorylation of T210 on SNF1, an effect that was also seen in 
AMPK over the same concentration range (Figure A7.2B). This protection was not 
significantly altered by the addition of ADP to the assay. To characterise this effect of 
staurosporine further an autophosphorylation site on AMPK was also investigated. Figure 
A7.2C shows that the presence of the kinase inhibitor or ADP in the assay did not prevent 
dephosphorylation of S108 on the β subunit of AMPK. This indicates firstly that the 
phosphatase itself is not inhibited by these treatments but also that the mechanism/s 
responsible for protection of the T-loop threonine from dephosphorylation does not protect 
phosphorylation sites in other regions of the complex. Interestingly, comparison of these 
effects on the isolated AMPK kinase domain revealed that staurosporine did not protect T172 
in this truncated domain from dephosphorylation (Figure A7.2C). These data indicate that 
when staurosporine is bound in the ATP binding pocket of AMPK it maintains it in a 
conformation such that the T-loop is not available for dephosphorylation. However, the fact 
that the isolated kinase domain is not protected suggests that this effect is dependent on the 
wider complex rather than a localised conformation change. It would be interesting to see if a 
mutation in the ATP binding pocket of the kinase to prevent ATP binding would negate both 
the effects of staurosporine and the additive effects of ATP on SNF1. 
Taken together these results present a potential explanation for the additive effects of ADP 
and ATP in the dephosphorylation assay; when ADP is bound in the γ-subunit, T210 is 
further protected from dephosphorylation if ATP is bound in the active site and available to 
phosphorylate a downstream target. This phenomenon is not apparent in AMPK competition 
assays, potentially due to the significantly higher concentrations of nucleotide required in the 
SNF1 system or differences in the balance of binding constants between the ATP-binding site 
and the nucleotide binding sites in the γ-subunit. This is the first observation that substrate 
binding in the ATP-binding pocket of the catalytic domain is capable of stabilising an active 
conformation. It is not clear from these data if the stabilisation of the active conformation of 
the kinase domain is enhanced by nucleotide binding to the γ subunit but the fact that 
staurosporine is not capable of protecting the isolated kinase domain indicates that more than 
just this domain is required to maintain this conformation. It could be speculated that this is a 
210 
 
  
mechanism through which AMPK (or SNF1) phosphorylation of its targets is ensured even 
when ATP is limiting. 
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Figure A7.2 Staurosporine protects SNF1 T210 and AMPK T172 from dephosphorylation
Recombinant SNF1 (A. Snf1, Gal83, Snf4) or AMPK (B. α1β1γ1) complexes were activated
by CaMKKβ for 20 min at 37°C and aliquots were incubated in the presence or absence of
PP2C, staurosporine, ADP or a combination of 10 nM staurosporine and ADP as indicated for
either 20 min (AMPK) or 10 min (SNF1). The level of threonine phosphorylation was
determined by SDS/PAGE and western blot analysis. Results shown are quantitation of the
ratio of P-Thr: total-α (mean± S.E.M., n=4) and are plotted as a percentage of the control and
accompanied by a representative blot. C. Recombinant α1β1γ1 (AMPK) or kinase domain (α1
1-312) was activated and subjected to dephosphorylation in the presence or absence of
staurosporine or ADP. Western blot analysis was done using anti-P-T172, P-S108 and total β
antibodies and the total kinase domain loading was assessed via Simply Blue staining. The
results shown are a representative blot from three experiments.  
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Appendix 10 High concentrations of AMP or NADH in the dephosphorylation assay 
prevent dephosphorylation of the AMPK kinase domain 
Isolated active AMPK kinase domain (α1-312) was incubated in the presence of PP2C and a 
range of concentrations of AMP or NADH at 30ºC for 20 minutes. These reactions were 
diluted as previously described and the activity determined by SAMS peptide assay. This 
shows that high concentrations of these nucleotides have indirect effects in this assay as this 
regulation is not occurring via the Snf4 (γ) subunit.  
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